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Tuberculosis (TB) remains one of the deadliest infectious diseases worldwide. Although 
considered treatable and curable, control of this disease is threatened by an increase in 
antibiotic resistant strains of the causative pathogen, Mycobacterium tuberculosis (Mtb). One 
method to combat the rise in drug resistant TB is the development of therapeutics that act 
against novel pathways, such as biotin biosynthesis. Biotin (vitamin B7) is an essential 
vitamin for all forms of life and is utilized by biotin-dependent enzymes in important cellular 
processes such as energy metabolism and cell wall maintenance. While most organisms 
acquire biotin through a combination of transport and biosynthesis, Mtb relies solely on 
biosynthesis for biotin acquisition. The biotin biosynthesis pathway has been determined to 
be essential to both acute and latent stages of Mtb infection, signifying development of 
inhibitors against this pathway as a potential means for new anti-TB drug discovery efforts. 
The work in this thesis focuses on dethiobiotin synthetase (MtDTBS), the enzyme that 
catalyzes the penultimate step of biotin biosynthesis: the conversion of 7,8-
diaminopelargonic acid (DAPA) to dethiobiotin (DTB). Here, structural and biophysical 
investigation of MtDTBS ligand binding gleaned insight into its catalytic mechanism and 
guided the identification and development of alternate compounds that bind to the enzyme. 
During the structural characterisation of MtDTBS, an X-ray crystallographic technique was 
developed to aid the generation of ligand-complexed crystal structures. 
 
Preliminary attempts to analyze the ligand-binding activity of MtDTBS was prevented by the 
presence of crystallographic precipitants in the active site of the enzyme. Present at high 
concentrations in the crystallisation methodology, precipitants such as sulfate and citrate 
bound to the phosphate binding loop (P-loop) of MtDTBS, outcompeting ligands of interest 
from binding. Chapter 2 contains a manuscript published in Acta Crystallographica Section 
D, wherein a technique termed Precipitant Ligand Exchange was developed to overcome this 
issue. Here, pre-grown crystals of MtDTBS were taken out of the crystal growth liquor and 
transferred into a solution that contained the ligand of interest in place of the precipitant. A 
complex of ADP-MtDTBS was then solved, revealing an unexpected binding mode. 
Subsequently, multiple X-ray crystallographic models of MtDTBS in complex with a number 
of ligands were solved and are presented throughout this thesis. Given that crystallographic 
precipitants are commonly observed in structures deposited in the PDB, this problem is likely 
to be encountered frequently. Consequently, it is expected that this technique will be of use to 
researchers throughout the world. 
 
MtDTBS is unique in that it can utilize multiple nucleoside triphosphates (NTPs) to catalyze 
its reaction. Described as promiscuous binding, this ability was previously identified using 
biochemical means, and X-ray crystallography was performed with the substrate cytidine 
triphosphate (CTP). Despite this, the structural and biophysical mechanisms of MtDTBS 
promiscuity were unknown. Here, initial attempts at observing the promiscuous NTP binding 
characteristics of MtDTBS were inhibited by the presence of the aforementioned 
crystallographic precipitants. However, the use of Precipitant Ligand Exchange allowed the 
generation of investigative structural data. Chapter 3 contains a manuscript published in ACS 
Catalysis which details the use of X-ray crystallography and surface plasmon resonance 
(SPR) to determine that MtDTBS alternates between two NTP binding modes. CTP binds in a 
high affinity complex that exhibits slow dissociation as observed by SPR. Electron density 
pertaining to a single, stable CTP conformation involving specific hydrogen bonding to the 
enzyme was observed by X-ray crystallography. By contrast, other tested NTPs exhibited fast 
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association and dissociation kinetics, and much lower affinity. Electron density was only 
present for the triphosphates of these NTPs, while that pertaining to the nucleoside portion 
was absent. This lead to the hypothesis that promiscuity occurred primarily through high 
affinity binding solely between the triphosphates and the MtDTBS P-loop. This discovery 
highlighted the utility of Precipitant-Ligand Exchange, and raises the possibility that 
observation of this kind of promiscuity in other enzymes was previously inhibited by 
crystallographic precipitants. Promiscuity has not been demonstrated with DTBS from other 
species, however structural comparison revealed several similarities and differences. This 
encourages further exploration in order to determine the exact structural features required for 
promiscuity, and its occurrence throughout the wider proteome. 
 
Chapter 4 pertains to the identification and development of inhibitors against MtDTBS. 
Continuing on from a preliminary in silico screen of nucleoside analogues and fragments 
against MtDTBS, X-ray crystallography screening was used to investigate and confirm the 
binding mode of hits. Two alternate nucleoside scaffolds were identified to bind to MtDTBS, 
and it was determined that 2ʹ-deoxycytidine triphosphate exhibited higher affinity for 
MtDTBS than CTP. While this discovery had implications for the in vitro use of energy 
sources during MtDTBS catalysis, this constituted an improved probe for lead compound 
development. Additionally, a hit from a high concentration soak with a fragment yielded 
electron density within the DAPA binding pocket of MtDTBS. Interestingly, this compound 
was confirmed to be a degradation product of another fragment by NMR, LC/MS and small 
molecule X-ray crystallography. Chemical modification of this compound was guided by 
structural biology and led to a large increase in binding potency, however inhibition of the 
bacterium was not observed. It was hypothesized that both enzyme inhibition and bacterial 
cell entry should be simultaneously optimised in the future. As several compounds were 
identified to bind in adjacent positions in the enzyme active site, the possibility of generating 
a large, high affinity compound by linking smaller compounds together was investigated. 
Crystal structures with preliminary linked compounds indicated that the linking strategy was 
not optimised, providing future directions for the project. 
 
Altogether, this thesis represents a detailed investigation of the biophysical and structural 
characteristics of MtDTBS, with future prospects for the development of inhibitors against 
this promising anti-TB drug target. Having optimised screening techniques such as those for 
X-ray crystallography and SPR, this project is well suited for future fragment-based lead 
discovery endeavours. When considered in conjunction with the additional characterisation of 
the MtDTBS active site, the identification of new fragment scaffolds would significantly 
broaden the scope for inhibitor development. With the capability for rapid and accurate 
testing of inhibitors against both the MtDTBS enzyme and Mycobacterium tuberculosis, the 
results obtained from this project provide an excellent opportunity to pursue the development 
of anti-TB compounds. 
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1.1 Thesis description 
This thesis details the development and use of X-ray crystallography and surface plasmon 
resonance protocols to aid in the development of an antibiotic lead molecule. These 
techniques were used to investigate the structure and function of the anti-tuberculosis target 
enzyme: Mycobacterium tuberculosis dethiobiotin synthetase (MtDTBS). The insights gained 
here were then applied to lead molecule development, resulting in promising candidates for 
future antibiotic development. A central theme of this work is that the fragment-based lead 
discovery process is best guided by structural and functional information determined by a 
combination of orthogonal techniques.  
 
This thesis is presented as a combination of published manuscripts and traditional thesis 
chapters. Due to this format, each results chapter contains its own materials and methods 
section. Similarly, references for each manuscript are included within those chapters (1, 2 and 
3) and any remaining references (from chapters 1, 4 and 5) appear at the end of the thesis.  
 
The introduction chapter discusses multiple aspects of antibiotic drug development. Included 
is an invited review published in the Jiangsu Journal of Preventative Medicine as a result of 
collaboration with Yan Li, a visiting scholar in the Booker Laboratory. This review describes 
the global healthcare impact of tuberculosis and introduces biotin biology as a pathway for 
anti-mycobacterial drug development. Following this review, more specific background is 
included regarding MtDTBS. The chapter concludes with discussion of the methods of lead 
molecule identification and development, with a specific focus on fragment-based lead 
discovery (FBLD). 
 
Chapter 2 is a manuscript entitled “Precipitant-ligand exchange technique reveals ADP 
binding mode in MtDTBS” that has been published in Acta Crystallographica Section D. 
This manuscript details the development of a precipitant-ligand exchange crystallographic 
soaking technique. This technique allowed the generation of atomic resolution structures of 
proteins in complex with ligands that would otherwise be occluded by crystallographic 
reagents such as precipitants. The technique was validated by replicating a previous structure 
of MtDTBS with cytidine triphosphate. Subsequently, a novel binding site for adenosine 
diphosphate, an inhibitor and reaction by-product of MtDTBS was discovered. As 
crystallographic precipitants are commonly present in structures found in the Protein Data 
Bank, it is anticipated that this methodology will be useful to the wider crystallographic 
community.  
 
Chapter 3 is a manuscript entitled “Mycobacterium tuberculosis dethiobiotin synthetase 
facilitates nucleoside triphosphate promiscuity through alternate binding modes” that has 
been published in the American Chemical Society Journal Catalysis. In this work, 
precipitant-ligand exchange, as described in Chapter 2, was used to generate atomic 
resolution data that revealed the mechanism of promiscuous nucleoside triphosphate (NTP) 
utilization by MtDTBS. This phenomenon required careful analysis of crystallographic 
structural data and the accompanying biophysical data generated by surface plasmon 
resonance. Not only does this paper contribute to the overall understanding of substrate 
utilization by enzymes, but it also examines the MtDTBS binding site in great detail, which 
aided lead molecule design in the following chapter. 
 
Chapter 4 pertains to the identification of compounds that bind to MtDTBS, followed by their 
structure guided chemical modification towards high affinity binding. X-ray crystallography 
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screening was used to identify an optimised nucleoside ligand and a novel small molecule 
that bound to the active site. Interestingly, this small molecule was confirmed to be a 
degradation product of another fragment by NMR, LC/MS and small molecule X-ray 
crystallography. Chemical modification guided by structural biology led to a large increase in 
binding affinity. As several compounds were identified to bind in adjacent positions in the 
enzyme active site, the possibility of generating a high affinity compound by linking smaller 
compounds together was investigated. Crystal structures with preliminary linked molecules 
revealed strategies for future development. 
 
Chapter 5 features an overall discussion of the work presented in this thesis, as well as the 
future directions of this project. Advancements in the characterisation of MtDTBS are 
discussed in the context of the broader literature. This is then followed by an analysis of how 
this information guided and will continue to guide the development of the described 
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1.4 Dethiobiotin Synthetase 
 
As demonstrated in the published review, there is considerable evidence to support targeting 
biotin biosynthesis in anti-tubercular drug design efforts. Of particular interest is the 
demonstration that the biotin biosynthesis is essential for the acute and dormant phases of M. 
tuberculosis infection (Woong Park et al., 2011). The work presented in this thesis concerns 
Mycobacterium tuberculosis dethiobiotin synthetase (MtDTBS), the enzyme responsible for 
catalysing the penultimate step of biotin biosynthesis (Dey et al., 2010; Salaemae et al., 
2015). This enzyme was determined to be preferable to other enzymes in the pathway for 
drug discovery purposes. Firstly, there are two genes that produce differing isoforms of the 
initial enzyme in the pathway: 7-keto-8-aminopelargonic acid synthase (KAPAS), making 
this a challenging target for drug discovery as both forms would need to be simultaneously 
inhibited to arrest biotin biosynthesis activity (Salaemae et al., 2016). Secondly, the final 
enzyme in the pathway: biotin synthase, exhibits very low catalytic rates and is more 
functionally similar to a substrate than an enzyme (Salaemae et al., 2016). This suggests that 
high doses of inhibitor would be required to completely inhibit this step. Finally, it was 
previously found that 7,8-diaminopelargonic acid synthase (DAPAS) did not overexpress 
well using the facilities at the University of Adelaide. Consequently, MtDTBS was the 
deemed the best candidate for an inhibitor development project. 
 
MtDTBS catalyses energy dependent conversion of 7,8-diaminopelargonic acid (DAPA) to 
dethiobiotin (DTB; Scheme 1) (Huang et al., 1995; Käck et al., 1998). Unusually, and in 
contrast to homologues from other species, MtDTBS can utilize a broad range of nucleoside 
triphosphates (NTPs) to carry out its reaction, namely; adenosine, cytidine, guanosine, 
inosine, thymidine and uridine triphosphate (Salaemae et al., 2015). It was determined that 
MtDTBS exhibits a slight kcat preference for cytidine triphosphate (CTP kcat = 15.2 ± 0.3 × 
10-3 s-1, other NTPs kcat = 10.2 – 11.8 × 10-3 s-1), despite similar Km values (CTP Km = 25.2 ± 
1.7 µM, other NTPs Km = 17 – 30 µM) (Salaemae et al., 2015). While a crystal structure with 
CTP revealed how MtDTBS bound this substrate (PDB ID: 4WOP), the mechanism behind 
NTP promiscuity had eluded structural characterisation. The manuscript presented in Chapter 
3 contains insights into this phenomenon via X-ray crystallographic investigation. 
 
MtDTBS has previously been investigated by X-ray crystallography (Dey et al., 2010; 
Salaemae et al., 2015). The overall fold consists of alternating α-helices and β-sheets 
separated by interconnecting coil regions. The enzyme is only biologically active as a homo-
dimer and presents as a dimer of dimers in the crystallographic asymmetric unit (Salaemae et 
al., 2015). Crystal structures of MtDTBS in complex with several different ligands have been 
solved (Table 1), revealing that the active site contains adjacent CTP and DAPA binding 
pockets (Figure 1.1). While the overall fold is similar, the cytidine binding pocket differs 
from that in DTBS from other species, of which crystal structures have been solved in 
complex with multiple ligands (Table 1). The impact of these variations is discussed in the 





Scheme 1: The reaction catalysed by MtDTBS. After binding to MtDTBS, 7,8-diaminopelargonic acid (DAPA) 
is converted to DAPA-carbamate by reaction with a carbon dioxide molecule. A nucleoside triphosphate (NTP) 
catalyses phosphoryl transfer to DAPA, resulting in a mixed carbamic phosphoric acid DAPA anhydride (Käck 
et al., 1998). This molecule then collapses to close the ureido ring of dethiobiotin, releasing inorganic phosphate 
(Pi) in the process. Figure adapted from the manuscript in Chapter 3. 
 
Despite the previous structural characterisation of MtDTBS, there are no published examples 
of inhibitors developed against this enzyme, unlike its E. coli counterpart (Rendina et al., 
1999). Given the wealth of information demonstrating that biotin biosynthesis is an anti-
tubercular drug target, this project aimed to identify and develop small molecules that would 
bind with high affinity to MtDTBS. During development of the crystallographic technique 
(Chapter 2) and characterization of the MtDTBS NTP utilization mechanism (Chapter 3), 
several positions within the active site were identified as crucial binding regions for 
substrates. This information provided useful guidance for lead molecule development 
(Chapter 4). 
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Table 1: X-ray crystallographic structures of DTBS enzymes from the protein data bank (PDB). 
 
Organism Ligand bound PDB ID 
Mycobacterium tuberculosis Apo (unliganded) 3FGN (Dey et al., 2010)  
Dethiobiotin, Mg2+, PO42- 3FPA (Dey et al., 2010)  
DAPA-carbamate 3FMF (Dey et al., 2010)  
KAPA, SO42- 3FMI (Dey et al., 2010)  
CTP, SO42- 4WOP (Salaemae et al., 2015) 
Escherichia coli Apo 1BYI (Sandalova et al., 1999)  
Apo 1DTS (Huang et al., 1995)  
ATP, DAPA 1A82 (Käck et al., 1998a)  
ADP 1DAD (Huang et al., 1995)  
ADP, Mixed carbamic phosphoric acid anhydride of DAPA 1DAK (Käck et al., 1998a)  
ADP, 8-amino-7-carboxyamino-nonanoic acid (DAPA) with aluminium fluoride 1BS1 (Käck et al., 1998b)  
ADP, dethiobiotin, phosphate 1DAM (Käck et al., 1998b)  
ADP, 7-(carboxyamino)-8-amino-nonanoic acid (DAPA-carbamate) 1DAF (Huang et al., 1995)  
3-(1-aminoethyl)-nonanedioic acid 1DAE (Huang et al., 1995)  
DAPA-carbamate, 5’-adenosyl-methylene-triphosphate 1DAG (Huang et al., 1995)  
DAPA, 5’-adenosyl-methylene-triphosphate 1DAH (Huang et al., 1995)  
DAPA-carbamate 1DAI (Huang et al., 1995)  
Sulfate 1DBS (Alexeev et al., 1994) 
 Helicobacter pylori Apo 2QMO (Porebski et al., 2012)  
ATP 3QXC (Porebski et al., 2012)  
ATP, 8-aminocaprylic acid, phosphate 3MLE (Porebski et al., 2012)  
ADP, 8-aminocaprylic acid 3QXH (Porebski et al., 2012)  
ANP 3QXS (Porebski et al., 2012)  
GTP 3QXJ (Porebski et al., 2012)  
GDP 3QY0 (Porebski et al., 2012)  
GDP, 8-aminocaprylic acid 3QXX (Porebski et al., 2012) 






Figure 1.1: An overlay of CTP and DAPA-carbamate bound MtDTBS crystal structures (PDB IDs: 4WOP, 
3FMF, respectively). α-helices and 310 helices are coloured in blue, β-sheets in green, interconnecting coil in 
grey and the phosphate binding loop in magenta. A monomer is shown for clarity, the homo-dimerisation 
interface is formed by α3, α5 and α6. The cytosine moiety of CTP binds to a pocket formed by the coils 
connecting β6-α7 and β7-3102. The triphosphate moiety of CTP binds to the phosphate binding loop. DAPA-
carbamate binds adjacent to CTP in a deep pocket that is formed at the dimerization interface. Figure adapted 




1.5 Approaches to antibiotic drug discovery  
 
Resistance to current antibiotics poses a severe threat to global health. One method to combat 
resistance is the development of new antibiotics, a practice that has experienced a downturn 
in recent decades. This is the result of decreased investments, but also a failure in current 
drug discovery methods. A review from AstraZeneca extensively detailed their antibiotic 
high-throughput screening (HTS) programs from 2001–2010, from which no drugs were 
produced (Tommasi et al., 2015). HTS utilizes extremely high throughput assays to detect 
inhibition of a purified protein target using very large libraries (~106) of complex, drug like 
compounds. This review highlighted many issues with current antibiotic drug discovery 
strategies. Of particular note were the high rates of attrition when taking molecules with high 
protein target potency to bacterial cell-based assays. This was due to various medicinal 
chemistry issues, including poor chemical tractability of hits, resulting from the large, 
complex and drug-like molecules that comprised the compound library. It was also 
hypothesized that there was a lack of understanding of the biological systems involved, such 
as bacterial membrane permeability. Indeed, antibiotic drug discovery faces additional 
challenges when compared to drugs targeting human diseases, as both bacterial and human 
metabolism must be considered, as well as differing cell wall and membrane structures. M. 
tuberculosis, for example, possesses a unique cell wall structure made up of mycolic acids 
and persists within alveolar macrophages during chronic infection. Anti-mycobacterial 
therapeutics must therefore have the appropriate properties to not only gain entry into both 
cell types, but also retain function during macrophage and mycobacterial metabolism. New 
innovations are required to overcome the difficulties currently faced by antibiotic and anti-
mycobacterial drug discovery. 
 
Fragment-based lead discovery (FBLD) is considered a promising alternative to HTS 
(Erlanson et al., 2016; Mashalidis et al., 2013). In a FBLD campaign, a small library (~103) 
of relatively simple molecules is screened against protein targets to generate a number of low 
affinity hits (KD > 500 µM) (Baker, 2013; Joseph-McCarthy et al., 2014). Smaller compound 
libraries are easier to handle, making FBLD campaigns more attractive and accessible to a 
wide range of researchers, particularly academic groups (Erlanson et al., 2016). The small 
size of fragments results in more efficient sampling of chemical space than HTS, increasing 
the likelihood of success (Erlanson et al., 2016; Lamoree and Hubbard, 2018). Unlike HTS 
hits, which can be difficult to modify, fragment hits are highly tractable, and are routinely 
developed into larger and more complex molecules that are more potent inhibitors of the 
protein target. This process involves cyclical rounds of development and testing with 
structural, biophysical and biochemical methods. As this is an iterative process, this can 
coincide with observation and optimisation of the pharmacological properties of the 
compounds (Erlanson et al., 2016). It is hypothesized that this would be beneficial for 
antibiotic drug discovery, where properties such as bacterial metabolism and membrane 
permeability could be optimised during compound design. The work presented in Chapter 4 
entails the continuation of a FBLD campaign against MtDTBS; the validation of fragment 
binding and preliminary structurally guided compound elaboration.  
 
A central theme to this thesis is that structural, biophysical and biochemical characterisation 
of the target protein will greatly aid the process of fragment development. This is 
demonstrated again in the review by AstraZeneca (Tommasi et al., 2015). Here it was 
revealed that HTS against biotin ligase (BirA) uncovered no compounds with reproducible 
inhibitory activity in orthogonal assays. BirA has been shown to utilize an ordered catalytic 
mechanism initiated by binding biotin, which induces closure of the ‘biotin binding loop’ to 
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create the site to which adenosine triphosphate binds (Sternicki et al., 2017). It is likely that 
HTS was not able to identify compounds that inhibited BirA because this mechanism was not 
considered; these compounds did not outcompete biotin for binding to the highly specific 
biotin binding pocket, and in the absence of biotin, the adenosine triphosphate binding site 
would have been inaccessible. However, with consideration of the ordered catalytic 
mechanism of BirA, the Booker and Abell Laboratories at the University of Adelaide utilized 
a structural and biochemically guided approach that resulted in the generation of several lead 
compound series against the protein (Feng et al., 2016; Paparella et al., 2018a, 2018b; Soares 
da Costa et al., 2012; Tieu et al., 2015). These lead compounds mimicked the reaction 
intermediate, possessing a biotin moiety conjugated to alternative adenosine analogues. 
These compounds, designed with consideration of the structural and mechanistic properties 
of catalysis, inhibited the enzyme with high efficacy. This highlights that structural and 
mechanistic knowledge of enzyme catalysis can be crucial for ligand identification and 
design. 
As previously mentioned, the accessibility of FBLD can be taken advantage of by smaller 
and more focussed groups, such as academic labs that have expertise with particular 
enzymes. The Booker laboratory has researched biotin biology extensively, publishing over 
30 articles on the subject since 2008. In Chapters 2 and 3, these studies have been extended to 
investigations into the detailed ligand-binding characteristics of MtDTBS, revealing 
structural and biophysical details of interactions at the cytidine binding site, phosphate 
binding loop, and DAPA pocket. The resulting information guided the preliminary compound 
identification and design presented in Chapter 4 and will continue to guide future inhibitor 
development. Altogether, the work presented in this thesis extends our knowledge of 
MtDTBS structure and function and represents a crucial progression towards the development 
of inhibitors of MtDTBS, and ultimately Mycobacterium tuberculosis, in order to provide 
new avenues of treatment for antibiotic-resistant tuberculosis. 
 
1.5 Project Aims 
 
This study aimed to continue the investigation of MtDTBS, an enzyme that has been 
identified as a promising target for the development of anti-tuberculosis therapies.  
 
The first aim was to develop and optimize protocols for the structural and biophysical of 
MtDTBS. With protocols for the expression and purification of MtDTBS, as well as a 
biochemical activity assay available to the Booker Lab, additional protocols would allow for 
comprehensive study of this enzyme. 
 
The second aim was to utilize the developed protocols to structurally and biophysically 
characterize MtDTBS promiscuous NTP utilization during catalysis. As this is an unusual 
phenomenon, uncovering further insight into this capability would be of interest to the 
scientific community. 
 
The third aim of this study was to assist in the development of compounds which would bind 
to MtDTBS with high affinity, with the ultimate aim of inhibiting the activity of this enzyme. 
This aim was influenced by the results of the first two aims, requiring the development of 
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Dethiobiotin synthetase from Mycobacterium tuberculosis (MtDTBS) is a
promising antituberculosis drug target. Small-molecule inhibitors that target
MtDTBS provide a route towards new therapeutics for the treatment of
antibiotic-resistant tuberculosis. Adenosine diphosphate (ADP) is an inhibitor
of MtDTBS; however, structural studies into its mechanism of inhibition have
been unsuccessful owing to competitive binding to the enzyme by crystallo-
graphic precipitants such as citrate and sulfate. Here, a crystallographic
technique termed precipitant–ligand exchange has been developed to exchange
protein-bound precipitants with ligands of interest. Proof of concept for the
exchange method was demonstrated using cytidine triphosphate (CTP), which
adopted the same binding mechanism as that obtained with traditional crystal-
soaking techniques. Precipitant–ligand exchange also yielded the previously
intractable structure of MtDTBS in complex with ADP solved to 2.4 Å
resolution. This result demonstrates the utility of precipitant–ligand exchange,
which may be widely applicable to protein crystallography.
1. Introduction
Biotin biosynthesis has been identified as a promising pathway
for the development of new antituberculosis chemotherapies
required to combat the rise of multidrug-resistant infections
(Salaemae et al., 2011, 2016; Thompson et al., 2016; Dai et al.,
2014, 2015; Dey et al., 2010; Woong Park et al., 2011). The
penultimate reaction in the pathway is the energy-dependent
conversion of 7,8-diaminopelargonic acid (DAPA) to dethio-
biotin (DTB), catalysed by dethiobiotin synthetase (DTBS).
Small molecules that target DTBS represent valuable starting
points for antitubercular drug discovery. We have previously
demonstrated that ADP is an inhibitor of Mycobacterium
tuberculosis DTBS (MtDTBS; Ki = 0.14 mM with respect to
ATP) and binds with comparable affinity to ATP (ADP IC50 =
248 mM, ATP IC50 = 349 mM) in a competitive displacement
assay (Salaemae, 2015). Thus, ADP provides a potential
starting point for the chemical development of nucleoside
analogues to treat antibiotic-resistant tuberculosis. The crystal
structure of MtDTBS in complex with cytidine triphosphate
(CTP; PDB entry 4wop) revealed the binding mode for this
ligand (Salaemae et al., 2015). The cytosine moiety bound in a
pocket formed by the coils connecting !7 to 3102 and !6 to "7
(Figs. 1 and 2), and the polyphosphate group bound at the
phosphate-binding loop (P-loop, Walker A motif; depicted in
Fig. 1). However, efforts to crystallize MtDTBS in complex
with other nucleosides such as ADP have been unsuccessful
ISSN 2059-7983
# 2018 International Union of Crystallography
(Salaemae et al., 2015; Dey et al., 2010) despite similar struc-
tures having been obtained with homologues from other
bacteria (Huang et al., 1995; Käck et al., 1998). In our repeated
attempts to solve the ADP–MtDTBS crystal structure, elec-
tron density consistent with a sulfate ion bound at the P-loop
was observed, resulting from the high concentrations of
ammonium sulfate in the crystallization condition (1.2–1.7 M
ammonium sulfate, 0.1 M Tris pH 8, 10–15% glycerol; adapted
from Salaemae et al., 2015). Concordant with this, a sulfate ion
was observed instead of CTP in one active site of the CTP–
MtDTBS crystal structure (Salaemae et al., 2015). We propose
that precipitants that are present at high concentrations in
the crystallization condition directly compete with ADP for
binding to the P-loop. Consequently, we sought to overcome
precipitant occupation of the active site in order to investigate
MtDTBS in complex with ADP.
Crystallographic reagents commonly bind to distinct
regions of protein molecules. Table 1 depicts the prevalence of
common crystallographic reagents modelled in structures
deposited as Protein Data Bank (PDB) entries. Of the total
submissions in the PDB (139 357 at the time of writing),
sulfate is present in 12.4% of submissions and glycerol (a
common cryoprotectant) is present in 10.5%. These two
molecules are the most commonly modelled free ligands in the
PDB, indicating that this is a common occurrence in protein
crystallography. Efforts to avoid crystallographic reagents may
require either a new crystallization condition or the use of a
homologous protein. Alternatively, techniques to remove
these compounds by crystal manipulation and soaking have
also been reported. Examples of such approaches in the
literature include crystal washing to remove dioxane, back-
soaking to remove substrates and soaking with homologous
precipitants (for example, replacing citrate with malonate)
(reviewed in Öster et al., 2015). Ligand-exchange methods
have previously been utilized to substitute co-crystallized
peptides (Kontopidis et al., 2003) and degraded substrates
(Ciccone et al., 2015) with ligands. In the current study, this
principle was applied to exchange active-site-bound crystallo-
graphic precipitants with ligands. This alternate methodology
was required to ensure the stability of MtDTBS crystals, which
was reliant upon a high concentration of a suitable compound
(either precipitant or ligand) being bound within the P-loop.
Here, we describe a soaking methodology to overcome the
occlusion of ligands of interest by crystallographic precipitant
molecules in the active site. Having ascertained that alternate
crystal-growth conditions also resulted in precipitants bound
to the P-loop, we assessed the crystal integrity in varying
concentrations of the precipitants sulfate and citrate, and
ultimately replaced the precipitant with high concentrations of
the ligand of interest. As proof of concept, two structures of
MtDTBS in complex with CTP were solved using precipitant–
ligand exchange with crystals from two independent growth
conditions. In both structures, CTP adopted the same binding
pose as demonstrated by our previous crystal structure (PDB
entry 4wop). Subsequently, a crystal structure of the
previously intractable complex with the inhibitor ADP was
obtained. We suggest that our precipitant–ligand exchange
technique may be broadly applicable to crystallography of
protein–ligand complexes and may be especially important for
obtaining crystals of weak-affinity complexes such as those
studied in fragment-based drug discovery.
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Figure 2
Superposition of CTP in our previously published structure (white sticks;
PDB entry 4wop) and those solved by precipitant–ligand exchange (pink,
sulfate-grown crystal; blue, citrate-grown crystal).
Table 1
The prevalence of selected crystallographic reagents modelled as free







Sulfate ion 17338 12.4
Glycerol 14594 10.5
Ethane-1,2-diol (EDO) 8370 6.0
Phosphate ion 5046 3.6
Acetate ion 4334 3.1
Di(hydroxyethyl)ether (nonpolymer PEG) 2444 1.8
Citrate 409 0.3
Figure 1
The ADP-bound monomer of MtDTBS (chain A; PDB entry 6czd).
Secondary structure is depicted as ribbons: helices are coloured red,
!-sheets blue and interconnecting coils yellow. ADP (grey sticks) bound
distal to the cytidine-binding site (coils connecting !7 to 3102 and !6 to
"7). The !-phosphate bound at the P-loop (cyan) coordinated to a
magnesium ion (green sphere).
2. Materials and methods
2.1. Protein expression and purification
MtDTBS was expressed and purified as described
previously (Salaemae et al., 2015), except that a HiPrep 26/60
Sephacryl S-300 HR column (GE Healthcare) was used as an
additional purification step following IMAC chromatography.
MtDTBS was concentrated to 10 mg ml"1 and stored in the
following solution: 25 mM Tris pH 7.5, 30 mM NaCl, 1 mM
EDTA, 1 mM dithiothreitol (DTT), 5%(v/v) glycerol.
2.2. Nucleoside polyphosphate preparation
Nucleoside polyphosphates (NpPs) were purchased as
analytical grade powders (Sigma–Aldrich) and solubilized to
100–500 mM in Milli-Q H2O followed by adjustment to pH 7
with NaOH.
2.3. General crystallographic methods
All MtDTBS crystals were grown via the hanging-drop
method with a well volume of 500 ml and a drop ratio of 1:1
protein:well solution at 16#C unless otherwise stated. Sulfate
ion-bound MtDTBS crystals were grown in an ammonium
sulfate crystallization condition consisting of 1.2–1.7 M
ammonium sulfate, 0.1 M Tris pH 8, 10–15% glycerol. Citrate-
bound MtDTBS crystals were grown in a citrate crystallization
solution consisting of 0.7 M sodium citrate, 0.1 M imidazole
pH 7.0 with 20% glycerol.
2.4. Serial dilutions and ligand-exchange solutions
Serial Dilution Solution 1: a twofold serial dilution of citrate
(0.35–0.011 M) was produced by mixing the citrate crystal-
lization condition with an equal volume of precipitant-free
solution (0.1 M imidazole pH 7.0 with 20% glycerol).
Serial Dilution Solution 2: a twofold serial dilution of citrate
(0.35–0.011 M) in the presence of 5 mM ATP was produced by
mixing the citrate crystallization condition with a solution
containing ATP in place of citrate (10 mM ATP, 1 mM MgCl2,
0.1 M imidazole pH 7.0, 20% glycerol).
Exchange Solution 1 consisted of 300 mM ATP, 60 mM
MgCl2, 0.022 M sodium citrate, 0.1 M imidazole pH 7.0, 20%
glycerol.
Exchange Solution 2 consisted of 300 mM ATP, 30 mM
MgCl2, 0.1 M Tris pH 8, 10–20% glycerol. The well solution
consisted of 0.1 M Tris pH 8, 10–20% glycerol.
Exchange Solution 3 consisted of 100 mM CTP, 10 mM
MgCl2, 0.1 M imidazole pH 7, 20% glycerol.
Exchange Solution 4 consisted of 100 mM CTP, 10 mM
MgCl2, 0.1 M Tris pH 8, 25% glycerol.
Exchange Solution 5 consisted of 70 mM ADP, 30 mM
MgCl2, 0.1 M Tris pH 8, 10–20% glycerol. The well solution
consisted of 0.1 M Tris pH 8, 10–20% glycerol.
2.5. Data collection and processing
All crystals were flash-cooled in liquid nitrogen and
subjected to X-ray diffraction on the MX1 beamline at the
Australian Synchrotron, which is part of ANSTO (McPhillips
et al., 2002). 360 images were collected with 1# oscillation at
100 K and at a wavelength of 0.9537 Å. Data were indexed,
scaled and merged using iMosflm (Battye et al., 2011) and
AIMLESS (CCP4; Winn et al., 2011). Resolution truncation
was performed in accordance with previously described CC1/2
cutoff values (Karplus & Diederichs, 2012, 2015). Phasing was
performed with Phaser-MR (McCoy et al., 2007) using an in-
house search model. The structure was iteratively refined with
manual modelling in Coot (Emsley & Cowtan, 2004) and
refinement with phenix.refine (Adams et al., 2010) until the R
factors converged and significant difference density was
accounted for. The structure was validated using MolProbity
as part of the PHENIX package. Structure figures were
generated with the UCSF Chimera package (Pettersen et al.,
2004) and MacPyMOL (Schrödinger). Coordinates and
structure factors were deposited in the Protein Data Bank for
ADP–MtDTBS (PDB entry 6czd), CTP–MtDTBS from crys-
tals grown in ammonium sulfate (PDB entry 6e05) and in
sodium citrate (PDB entry 6e06).
3. Results
3.1. Alternate crystal conditions consistently contained
precipitants bound at the P-loop
In order to obtain crystals of nucleoside polyphosphates
(NpPs) bound to MtDTBS without a competing precipitant,
alternate crystallization conditions were explored. To avoid
the use of ammonium sulfate, MtDTBS crystals were grown in
a citrate crystallization solution adapted from Dey et al. (2010)
(see x2). However, no NpP-complexed crystal structures were
obtained via either co-crystallization or soaking. Instead,
electron density resembling citrate was observed bound to the
P-loop in all solved crystal structures (data not shown).
Further crystallographic screening yielded hits in conditions
containing high concentrations of sulfate, citrate or organic
acid mixtures (Tacsimate), all of which are likely to bind at the
same location. Therefore, a technique was developed to
replace the precipitants with an NpP.
3.2. Reducing the precipitant concentration caused crystal
instability
The stability of MtDTBS crystals in decreasing concentra-
tions of precipitant was assessed. MtDTBS crystals were
grown in the citrate crystallization condition before being
transferred directly into each solution of a twofold serial
dilution of citrate (0.35–0.011 M sodium citrate; Serial Dilu-
tion Solution 1; x2). As expected, crystal stability correlated
with the precipitant concentration (Fig. 3). Crystals trans-
ferred into solutions containing less than 0.044 M citrate
dissolved rapidly (<30 min), those in 0.088 M citrate dissolved
overnight and those in 0.175 M citrate cracked severely. It was
therefore hypothesized that crystal integrity was dependent on
the presence of a suitable molecule, in this case the precipi-
tant, bound to the P-loop of MtDTBS.
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3.3. The addition of ligand
increased the stability of crystals
As NpP molecules also bind to
the P-loop, it was proposed that
these molecules would rescue
crystal stability in the absence of
precipitant. To test this, crystal
stability was assessed in a twofold
serial dilution series of citrate
containing a constant concentra-
tion of 5 mM ATP (Serial Dilu-
tion Solution 2; x2). There was no
appreciable improvement in
crystal stability using this
concentration of ligand (Table 2).
It was hypothesized that the
percentage of MtDTBS mole-
cules in the crystal bound to a
ligand (precipitant or NpP) was
not high enough to retain crystal
integrity. Therefore, much higher
concentrations of NpP were
trialled, analogous to the high
concentrations of precipitant
required for crystal growth
described previously. Crystals
were transferred into a solution
of 0.022 M citrate that was
supplemented with 300 mM ATP
(Exchange Solution 1; x2). The
crystals of MtDTBS showed
improved stability, as they did not
degrade overnight. Similarly,
crystals grown in sulfate were
stable when supplemented with
ATP. This was consistent with the
hypothesis that crystal integrity
was dependent on the presence of
a suitable ligand to occupy the P-
loop.
To ensure that the ligand of
interest would be unobscured by
precipitant density in the
resulting crystal structure, efforts
were made to completely remove
the protein-bound precipitant.
MtDTBS crystals were grown in
the ammonium sulfate crystal-
lization condition before being
transferred into an 8 ml drop of
Exchange Solution 2 containing
300 mM ATP. An 8 ml drop size
was used to minimize dilution by
any of the original buffer
components in the transfer
process. This resulted in crystals
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Table 2
Data-collection and processing statistics for MtDTBS crystal structures.














Wavelength (Å) 0.9537 0.9537 0.9537
Temperature (K) 100 100 100
Space group P212121 P212121 P212121
a, b, c (Å) 55.33, 105.29, 153.76 56.680, 105.70, 153.26 54.77, 105.75, 155.20
", !, # (#) 90, 90, 90 90, 90, 90 90, 90, 90






Total No. of reflections 394104 (39657) 428391 (46135) 367683 (33793)
No. of unique reflections 31792 (3444) 32594 (3577) 33558 (2787)
Completeness (%) 99.500 (97.500) 99.700 (98.700) 93.400 (78.800)
Multiplicity 12.400 (11.500) 13.100 (12.900) 10.900 (11.600)
hI/$(I)i 7.100 (1.4) 7.100 (0.9) 18.500 (7.7)
Rr.i.m. 0.367 (2.293) 0.449 (3.796) 0.101 (0.291)
Rp.i.m. 0.102 (0.653) 0.122 (1.041) 0.029 (0.079)




$ Cutoff F > 0.310$(F ) F > 0.320$(F ) F > 0.310$(F )
No. of reflections, working set 30053 (2584) 30798 (2470) 31802 (2194)
No. of reflections, test set 1603 (154) 1639 (140) 1742 (130)
Final Rcryst 0.210 (0.2852) 0.217 (0.3519) 0.189 (0.1956)
Final Rfree 0.285 (0.3614) 0.288 (0.4109) 0.259 (0.3263)
No. of non-H atoms
Protein 6351 6351 6306
Ligand 120 120 112
Solvent 377 319 596
Total 6848 6790 7014
R.m.s. deviations
Bonds (Å) 0.009 0.009 0.007
Angles (#) 1.248 1.301 0.999
Average B factors (Å2)
Protein 41.28 54.56 31.23
Ligand 35.13 30.84 33.86
Ramachandran plot
Most favoured (%) 98.22 97.78 97.56
Allowed (%) 1.44 1.89 1.89
† Anomalies in the Wilson plot arose owing to ice rings.
Figure 3
Qualitative crystal stability after transfer into solutions containing varying concentrations of citrate
precipitant and ATP or ADP. Crystal stability is denoted from highest to lowest from green to brown.
that were stable in solution for more than 2 d, depending upon
the ligand used. This method served as a template for
obtaining previously intractable co-complexes involving
MtDTBS.
3.4. Proof of concept: precipitant–ligand exchange with CTP
reveals the expected binding mode
To demonstrate that structures obtained using precipitant–
ligand exchange are biologically relevant, crystals of MtDTBS
were grown in either the sodium citrate or ammonium sulfate
crystallization conditions and then transferred into an
exchange solution containing 100 mM CTP in place of the
precipitant (Exchange Solutions 3 and 4, respectively; x2).
Photographs of crystals in the transfer process are provided in
Supplementary Fig. S1. After a short exchange (10–30 min),
the MtDTBS crystals were flash-cooled and subjected to X-ray
data collection at the Australian Synchrotron. Both data sets
were solved to 2.5 Å resolution by molecular replacement
(PDB entries 6e05 and 6e06; crystallographic data are listed in
Table 2). Consistent with previous reports, MtDTBS was
solved in space group P212121, with four monomers in the
asymmetric unit corresponding to two biological dimers. The
monomer possessed the same "-helical/!-sheet fold as
previously reported, with the P-loop present between !1 and
"1 and the cytidine binding site formed by the coils connecting
!7 to 3102 and !6 to "7 (Fig. 1). In both structures, CTP was
modelled into well defined electron density present in the
active site (Supplementary Figs. S2a and S2b), adopting an
identical binding pose to our previous structure (PDB entry
4wop; Fig. 2). These data demonstrate that the complexes
acquired by precipitant–ligand exchange were consistent with
those obtained by conventional X-ray crystallographic tech-
niques such as co-crystallization.
3.5. A crystal structure of ADP–MtDTBS revealed an
unexpected binding mode
Attempts to obtain a structure of MtDTBS in complex with
the inhibitor ADP using traditional crystal soaking were
unsuccessful. We therefore turned to the precipitant–ligand
exchange method, whereby MtDTBS crystals were first grown
in the ammonium sulfate condition and then transferred into
Exchange Solution 5 containing 70 mM ADP in place of the
ammonium sulfate. Under these conditions crystals were
stable for several hours but dissolved overnight, encouraging
the use of shorter soak times. The crystals were subjected to an
hour-long exchange before flash-cooling and X-ray data
collection at the Australian Synchrotron. The resulting data
set was solved to a resolution of 2.4 Å by means of molecular
replacement (PDB entry 6czd; crystallographic data are given
in Table 2). Consistent with previous reports, MtDTBS was
solved in the same space group P212121, with the overall fold
and asymmetric unit as described above.
ADP was modelled into well defined electron density
present in the active site (Figs. 4a and 4b; Supplementary Figs.
S2c and S2d). In validation of the technique, no precipitant
molecules were observed in the P-loop. Instead, the poly-
phosphate moiety of ADP was bound at this site. ADP bound
in two alternate conformations, both of which extended in the
reverse direction compared with the prototypical CTP
conformation. These two conformations were differentiated
by the adenosine moiety binding ‘within’ (anti conformation,
present in chains A, B and D; Figs. 4a and 5a) or ‘adjacent’ to
(syn conformation, present in chain C; Figs. 4b and 5b) the
DAPA binding site. In both conformations the ADP
!-phosphate bound at the same position as that observed for
CTP (Salaemae et al., 2015), in a highly coordinated network
of hydrogen bonds and electrostatic interactions with the
P-loop, involving the backbone amides of Val13 (3.2–3.42 Å),
Gly14 (2.67–3.15 Å), Lys15 (2.47–3.05 Å) and Thr16 (3.04–
3.1 Å), as well as the side chains of Lys15 (2.55–2.65 Å) and
Thr16 (2.91–3.07 Å) (Figs. 5a and 5b). The ADP "-phosphate
bound at the CTP #-phosphate position in both conforma-
tions; however, the protein interactions differed slightly. In the
‘within’ conformation, the "-phosphate formed hydrogen-
bonding and electrostatic interactions with the backbone of
Gly111 (2.89–3.02 Å) and the side chain of Lys15 (2.39–
2.48 Å) (Fig. 5a). In the ‘adjacent’ conformation, the "-
phosphate also interacted with the backbone of Gly111
(3.28 Å) but formed an interaction with the side chain of
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Figure 4
Alternate ADP binding modes. ADP (grey sticks) and a magnesium ion
(green sphere) were modelled into well defined electron density (white;
polder map 3$; Liebschner et al., 2017) in the active site of MtDTBS (light
blue surface). Superposition with CTP (yellow lines; PDB entry 4wop)
and DAPA carbamate (black lines; PDB entry 3fmf; Dey et al., 2010)
revealed that ADP clearly bound in the reverse direction to CTP;
however, the !-phosphates for ADP and CTP bound in the same location
at the P-loop (salmon surface). ADP exhibited two different conforma-
tions, (a) within and (b) adjacent to the DAPA pocket, with the latter
accompanied by rearrangement of the P-loop.
Lys37 (3.15 Å) (Fig. 4b). Both of the phosphates also bound to
a magnesium present in the active site, which coordinated to
the side chains of Thr16, Asp49 and Glu108, as well as a water
molecule (all 1.83–2.44 Å; Figs. 5a and 5b). The ribose ring was
hydrogen bonded to the side chain of Arg45 in both confor-
mations; however, the ‘within’ conformation interacted
through the 20- and 30-hydroxyl groups (2.55–3.06 Å; Fig. 5a),
whereas it was flipped in the ‘adjacent’ conformation, inter-
acting through O40 (3.06 Å; Fig. 5b). When bound within the
DAPA pocket, the adenine did not make polar contacts with
the enzyme (Fig. 4a). Instead, the adenine was bound to water
molecules and encased by hydrophobic contacts with Thr11,
Met72, Ala73, Ala110, Val115 and Leu143. In this conforma-
tion, the adenine did not extend as deep into the binding site
as the native substrate DAPA (Fig. 4a). When the adenine
moiety bound adjacent to the DAPA pocket, rearrangement
of the P-loop saw Thr11 move away from the ADP, allowing
two hydrogen bonds to be made between the adenine N6 and
the carbonyl backbone atoms of Gly10 (3.19 Å) and Leu143
(3.29 Å) (Fig. 5b).
4. Discussion
In this report, we name and describe precipitant–ligand
exchange, a methodology to obtain structural data when
crystallographic precipitants compete for binding with a
ligand. This technique was validated by obtaining two crystal
structures of MtDTBS in complex with CTP. Precipitant–
ligand exchange revealed the same binding mode for CTP as
that obtained from other crystallographic techniques. We then
demonstrated the practical utilization of this technique by
obtaining crystallographic data for the previously intractable
complex between ADP and MtDTBS. We anticipate that
this precipitant–ligand exchange approach may be widely
applicable to ligand–protein interaction
crystallography. However, several key
points should be considered. This tech-
nique requires crystals that are amen-
able to soaking, a ligand of appropriate
size for diffusion through solvent chan-
nels, and solvent-accessibility of the
protein binding pocket. Under these
conditions, ligand occupation may be
affected by the following factors: the
concentration and solubility of the
ligand, the duration of interaction and,
as observed here, the properties of
competing precipitants. The affinity of
the protein–ligand interaction is also an
important consideration in the experi-
mental design. For higher affinity
protein–ligand interactions, such as
CTP–MtDTBS (IC50 = 54.4 mM;
Salaemae et al., 2015), precipitant
occupation was easily overcome with a
moderate concentration of ligand (CTP
was co-crystallized at 1 mM; Salaemae
et al., 2015). However, the weaker affinity ADP interaction
(IC50 = 248 mM; Salaemae, 2015) was outcompeted by the
precipitant. Thus, the aim of this methodology was to achieve
the optimal concentrations of both precipitant and ligand to
result in distinct and observable electron density solely for the
ligand after the exchange. Furthermore, ligand concentration
and soaking duration were optimized such that crystal
degradation was minimal, whilst still allowing high-occupancy
ligand binding to occur. In order to aid other researchers
attempting this technique, we have provided a flow diagram
for decision making (Fig. 6).
To ensure that ligand density was unobscured, the precipi-
tant was completely replaced with the ligand of interest. While
crystal degradation did occur, shorter soak times were found
to be sufficient for both diffraction quality and ligand density
(e.g. 30–60 min). Some protein crystals may be less stable, and
optimization of the ratio of ligand to precipitant may be
required. This should be performed by solving several data
sets at different ratios and soak times and optimizing each
based on both diffraction quality and ligand electron density.
In such cases, avoiding crystal transfer may also be preferred,
and dilution of the precipitant can be performed directly in the
drop. For example, adding 6 ml of a precipitant-free high
ligand-concentration solution to a 2 ml drop would reduce the
precipitant concentration by 75%. However, care must be
taken to delineate between the electron density of the preci-
pitant and ligand during interpretation.
ADP was observed to bind in two alternate conformations
in the vicinity of the DAPA pocket, a mode distinct from that
of CTP. We have previously shown that ADP (IC50 = 248 mM;
Salaemae, 2015) and ATP (IC50 = 349 mM; Salaemae et al.,
2015) displace a competitive ATP fluorophore with compar-
able affinities. A modest increase in affinity could be attrib-
uted to the dual binding mode of ADP; however, comparative
research papers
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Figure 5
Polar intermolecular interactions between ADP (grey sticks) and MtDTBS (blue surface, grey
sticks). A highly coordinated network of hydrogen bonds and electrostatic interactions forms
between the P-loop (salmon surface), the "- and !-phosphate groups of ADP and the magnesium
ion (green sphere). The magnesium ion exhibits six-coordination with the ADP phosphates, Thr16,
Asp49, Glu108 and a water molecule (water molecules are not shown for clarity). Intermolecular
interactions differ dependent on the adenosine conformation. (a) When bound within the DAPA
pocket, the adenine moiety did not form polar interactions. (b) When bound adjacent to the DAPA
pocket, Thr11 moved away from ADP, allowing polar contacts between the adenosine moiety and
the carbonyl backbones of Gly10 and Leu143.
structural investigation into the binding mode of ATP is
ongoing. Interestingly, the !-phosphate of ADP in both
conformations shared the same binding site as the !-phos-
phate of CTP within the P-loop. This was also the same site as
observed for the sulfate precipitant, suggesting that this is a
high-affinity binding site for anionic compounds. These
structural data provide the first evidence for a molecule other
than DAPA carbamate, or the closely related molecule 7-keto-
8-aminopelargonic acid (KAPA), bound within the DAPA
pocket. This revealed that the DAPA pocket can also
accommodate larger and more varied compounds than the
simple elongated acyl chains of DAPA and KAPA, a finding
that will aid drug discovery. Finally, this structure indicates
that inhibition by ADP may occur through competition with
either substrate, a finding that invites further experimental
investigation. The value of this structure lies in its contribution
to mapping the binding characteristics of the active site of
MtDTBS. This will inform future antitubercular drug-
discovery efforts targeting MtDTBS activity and biotin
biosynthesis, assisting in the design of inhibitors that bind with
high specificity to the enzyme.
This technique may be of use in fragment-based drug
discovery, where hits generally have weak affinity (Kd >
500 mM; Baker, 2013). If a fragment has been shown to bind to
a protein using affinity and/or competitive inhibition assays,
but only precipitant electron density is observed in the active
site of the crystal structure, this technique can be used to
exchange the precipitant, leading to fragment electron density.
With weak ligands, it may not be possible to reduce the
precipitant concentration to the required levels while main-
taining crystal stability. This may lead to a scenario in which a
certain proportion of protein molecules in the crystal are
bound to precipitant, with the remainder bound to ligand. In
this case, both precipitant- and ligand-bound states could be
modelled (Pearce, Krojer & von Delft, 2017), or it may be
useful to combine this technique with a program such as
PanDDA (Pearce, Krojer, Bradley et al., 2017) or polder maps
(Liebschner et al., 2017) to aid in discerning fragment density.
5. Conclusions
Here, we describe a crystallographic method for simulta-
neously removing and replacing active-site-bound precipitant
molecules with a ligand of interest: a process that we have
termed precipitant–ligand exchange. This technique was used
to solve two CTP–MtDTBS structures from independent
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Figure 6
Flow diagram of the decision-making process during precipitant–ligand exchange.
crystal-growth conditions. In validation of precipitant–ligand
exchange, the results were consistent with the published
literature. Subsequently, we solved a previously intractable
structure of ADP bound to MtDTBS. This structure revealed
an alternate binding mode to that previously reported for CTP,
providing new insight into the biology of the enzyme, as well
as informing antitubercular inhibitor-design efforts. Given the
prevalence of crystallographic reagents modelled in entries in
the PDB, we believe that this method will be broadly applic-
able and will benefit structure-based interaction-analysis
projects that utilize crystallography.
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Dethiobiotin synthetase from Mycobacterium tuberculosis (MtDTBS) is a
promising antituberculosis drug target. Small-molecule inhibitors that target
MtDTBS provide a route towards new therapeutics for the treatment of
antibiotic-resistant tuberculosis. Adenosine diphosphate (ADP) is an inhibitor
of MtDTBS; however, structural studies into its mechanism of inhibition have
been unsuccessful owing to competitive binding to the enzyme by crystallo-
graphic precipitants such as citrate and sulfate. Here, a crystallographic
technique termed precipitant–ligand exchange has been developed to exchange
protein-bound precipitants with ligands of interest. Proof of concept for the
exchange method was demonstrated using cytidine triphosphate (CTP), which
adopted the same binding mechanism as that obtained with traditional crystal-
soaking techniques. Precipitant–ligand exchange also yielded the previously
intractable structure of MtDTBS in complex with ADP solved to 2.4 Å
resolution. This result demonstrates the utility of precipitant–ligand exchange,
which may be widely applicable to protein crystallography.
1. Introduction
Biotin biosynthesis has been identified as a promising pathway
for the development of new antituberculosis chemotherapies
required to combat the rise of multidrug-resistant infections
(Salaemae et al., 2011, 2016; Thompson et al., 2016; Dai et al.,
2014, 2015; Dey et al., 2010; Woong Park et al., 2011). The
penultimate reaction in the pathway is the energy-dependent
conversion of 7,8-diaminopelargonic acid (DAPA) to dethio-
biotin (DTB), catalysed by dethiobiotin synthetase (DTBS).
Small molecules that target DTBS represent valuable starting
points for antitubercular drug discovery. We have previously
demonstrated that ADP is an inhibitor of Mycobacterium
tuberculosis DTBS (MtDTBS; Ki = 0.14 mM with respect to
ATP) and binds with comparable affinity to ATP (ADP IC50 =
248 mM, ATP IC50 = 349 mM) in a competitive displacement
assay (Salaemae, 2015). Thus, ADP provides a potential
starting point for the chemical development of nucleoside
analogues to treat antibiotic-resistant tuberculosis. The crystal
structure of MtDTBS in complex with cytidine triphosphate
(CTP; PDB entry 4wop) revealed the binding mode for this
ligand (Salaemae et al., 2015). The cytosine moiety bound in a
pocket formed by the coils connecting !7 to 3102 and !6 to "7
(Figs. 1 and 2), and the polyphosphate group bound at the
phosphate-binding loop (P-loop, Walker A motif; depicted in
Fig. 1). However, efforts to crystallize MtDTBS in complex
with other nucleosides such as ADP have been unsuccessful
ISSN 2059-7983
# 2018 International Union of Crystallography
(Salaemae et al., 2015; Dey et al., 2010) despite similar struc-
tures having been obtained with homologues from other
bacteria (Huang et al., 1995; Käck et al., 1998). In our repeated
attempts to solve the ADP–MtDTBS crystal structure, elec-
tron density consistent with a sulfate ion bound at the P-loop
was observed, resulting from the high concentrations of
ammonium sulfate in the crystallization condition (1.2–1.7 M
ammonium sulfate, 0.1 M Tris pH 8, 10–15% glycerol; adapted
from Salaemae et al., 2015). Concordant with this, a sulfate ion
was observed instead of CTP in one active site of the CTP–
MtDTBS crystal structure (Salaemae et al., 2015). We propose
that precipitants that are present at high concentrations in
the crystallization condition directly compete with ADP for
binding to the P-loop. Consequently, we sought to overcome
precipitant occupation of the active site in order to investigate
MtDTBS in complex with ADP.
Crystallographic reagents commonly bind to distinct
regions of protein molecules. Table 1 depicts the prevalence of
common crystallographic reagents modelled in structures
deposited as Protein Data Bank (PDB) entries. Of the total
submissions in the PDB (139 357 at the time of writing),
sulfate is present in 12.4% of submissions and glycerol (a
common cryoprotectant) is present in 10.5%. These two
molecules are the most commonly modelled free ligands in the
PDB, indicating that this is a common occurrence in protein
crystallography. Efforts to avoid crystallographic reagents may
require either a new crystallization condition or the use of a
homologous protein. Alternatively, techniques to remove
these compounds by crystal manipulation and soaking have
also been reported. Examples of such approaches in the
literature include crystal washing to remove dioxane, back-
soaking to remove substrates and soaking with homologous
precipitants (for example, replacing citrate with malonate)
(reviewed in Öster et al., 2015). Ligand-exchange methods
have previously been utilized to substitute co-crystallized
peptides (Kontopidis et al., 2003) and degraded substrates
(Ciccone et al., 2015) with ligands. In the current study, this
principle was applied to exchange active-site-bound crystallo-
graphic precipitants with ligands. This alternate methodology
was required to ensure the stability of MtDTBS crystals, which
was reliant upon a high concentration of a suitable compound
(either precipitant or ligand) being bound within the P-loop.
Here, we describe a soaking methodology to overcome the
occlusion of ligands of interest by crystallographic precipitant
molecules in the active site. Having ascertained that alternate
crystal-growth conditions also resulted in precipitants bound
to the P-loop, we assessed the crystal integrity in varying
concentrations of the precipitants sulfate and citrate, and
ultimately replaced the precipitant with high concentrations of
the ligand of interest. As proof of concept, two structures of
MtDTBS in complex with CTP were solved using precipitant–
ligand exchange with crystals from two independent growth
conditions. In both structures, CTP adopted the same binding
pose as demonstrated by our previous crystal structure (PDB
entry 4wop). Subsequently, a crystal structure of the
previously intractable complex with the inhibitor ADP was
obtained. We suggest that our precipitant–ligand exchange
technique may be broadly applicable to crystallography of
protein–ligand complexes and may be especially important for
obtaining crystals of weak-affinity complexes such as those
studied in fragment-based drug discovery.
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Figure 2
Superposition of CTP in our previously published structure (white sticks;
PDB entry 4wop) and those solved by precipitant–ligand exchange (pink,
sulfate-grown crystal; blue, citrate-grown crystal).
Table 1
The prevalence of selected crystallographic reagents modelled as free







Sulfate ion 17338 12.4
Glycerol 14594 10.5
Ethane-1,2-diol (EDO) 8370 6.0
Phosphate ion 5046 3.6
Acetate ion 4334 3.1
Di(hydroxyethyl)ether (nonpolymer PEG) 2444 1.8
Citrate 409 0.3
Figure 1
The ADP-bound monomer of MtDTBS (chain A; PDB entry 6czd).
Secondary structure is depicted as ribbons: helices are coloured red,
!-sheets blue and interconnecting coils yellow. ADP (grey sticks) bound
distal to the cytidine-binding site (coils connecting !7 to 3102 and !6 to
"7). The !-phosphate bound at the P-loop (cyan) coordinated to a
magnesium ion (green sphere).
2. Materials and methods
2.1. Protein expression and purification
MtDTBS was expressed and purified as described
previously (Salaemae et al., 2015), except that a HiPrep 26/60
Sephacryl S-300 HR column (GE Healthcare) was used as an
additional purification step following IMAC chromatography.
MtDTBS was concentrated to 10 mg ml"1 and stored in the
following solution: 25 mM Tris pH 7.5, 30 mM NaCl, 1 mM
EDTA, 1 mM dithiothreitol (DTT), 5%(v/v) glycerol.
2.2. Nucleoside polyphosphate preparation
Nucleoside polyphosphates (NpPs) were purchased as
analytical grade powders (Sigma–Aldrich) and solubilized to
100–500 mM in Milli-Q H2O followed by adjustment to pH 7
with NaOH.
2.3. General crystallographic methods
All MtDTBS crystals were grown via the hanging-drop
method with a well volume of 500 ml and a drop ratio of 1:1
protein:well solution at 16#C unless otherwise stated. Sulfate
ion-bound MtDTBS crystals were grown in an ammonium
sulfate crystallization condition consisting of 1.2–1.7 M
ammonium sulfate, 0.1 M Tris pH 8, 10–15% glycerol. Citrate-
bound MtDTBS crystals were grown in a citrate crystallization
solution consisting of 0.7 M sodium citrate, 0.1 M imidazole
pH 7.0 with 20% glycerol.
2.4. Serial dilutions and ligand-exchange solutions
Serial Dilution Solution 1: a twofold serial dilution of citrate
(0.35–0.011 M) was produced by mixing the citrate crystal-
lization condition with an equal volume of precipitant-free
solution (0.1 M imidazole pH 7.0 with 20% glycerol).
Serial Dilution Solution 2: a twofold serial dilution of citrate
(0.35–0.011 M) in the presence of 5 mM ATP was produced by
mixing the citrate crystallization condition with a solution
containing ATP in place of citrate (10 mM ATP, 1 mM MgCl2,
0.1 M imidazole pH 7.0, 20% glycerol).
Exchange Solution 1 consisted of 300 mM ATP, 60 mM
MgCl2, 0.022 M sodium citrate, 0.1 M imidazole pH 7.0, 20%
glycerol.
Exchange Solution 2 consisted of 300 mM ATP, 30 mM
MgCl2, 0.1 M Tris pH 8, 10–20% glycerol. The well solution
consisted of 0.1 M Tris pH 8, 10–20% glycerol.
Exchange Solution 3 consisted of 100 mM CTP, 10 mM
MgCl2, 0.1 M imidazole pH 7, 20% glycerol.
Exchange Solution 4 consisted of 100 mM CTP, 10 mM
MgCl2, 0.1 M Tris pH 8, 25% glycerol.
Exchange Solution 5 consisted of 70 mM ADP, 30 mM
MgCl2, 0.1 M Tris pH 8, 10–20% glycerol. The well solution
consisted of 0.1 M Tris pH 8, 10–20% glycerol.
2.5. Data collection and processing
All crystals were flash-cooled in liquid nitrogen and
subjected to X-ray diffraction on the MX1 beamline at the
Australian Synchrotron, which is part of ANSTO (McPhillips
et al., 2002). 360 images were collected with 1# oscillation at
100 K and at a wavelength of 0.9537 Å. Data were indexed,
scaled and merged using iMosflm (Battye et al., 2011) and
AIMLESS (CCP4; Winn et al., 2011). Resolution truncation
was performed in accordance with previously described CC1/2
cutoff values (Karplus & Diederichs, 2012, 2015). Phasing was
performed with Phaser-MR (McCoy et al., 2007) using an in-
house search model. The structure was iteratively refined with
manual modelling in Coot (Emsley & Cowtan, 2004) and
refinement with phenix.refine (Adams et al., 2010) until the R
factors converged and significant difference density was
accounted for. The structure was validated using MolProbity
as part of the PHENIX package. Structure figures were
generated with the UCSF Chimera package (Pettersen et al.,
2004) and MacPyMOL (Schrödinger). Coordinates and
structure factors were deposited in the Protein Data Bank for
ADP–MtDTBS (PDB entry 6czd), CTP–MtDTBS from crys-
tals grown in ammonium sulfate (PDB entry 6e05) and in
sodium citrate (PDB entry 6e06).
3. Results
3.1. Alternate crystal conditions consistently contained
precipitants bound at the P-loop
In order to obtain crystals of nucleoside polyphosphates
(NpPs) bound to MtDTBS without a competing precipitant,
alternate crystallization conditions were explored. To avoid
the use of ammonium sulfate, MtDTBS crystals were grown in
a citrate crystallization solution adapted from Dey et al. (2010)
(see x2). However, no NpP-complexed crystal structures were
obtained via either co-crystallization or soaking. Instead,
electron density resembling citrate was observed bound to the
P-loop in all solved crystal structures (data not shown).
Further crystallographic screening yielded hits in conditions
containing high concentrations of sulfate, citrate or organic
acid mixtures (Tacsimate), all of which are likely to bind at the
same location. Therefore, a technique was developed to
replace the precipitants with an NpP.
3.2. Reducing the precipitant concentration caused crystal
instability
The stability of MtDTBS crystals in decreasing concentra-
tions of precipitant was assessed. MtDTBS crystals were
grown in the citrate crystallization condition before being
transferred directly into each solution of a twofold serial
dilution of citrate (0.35–0.011 M sodium citrate; Serial Dilu-
tion Solution 1; x2). As expected, crystal stability correlated
with the precipitant concentration (Fig. 3). Crystals trans-
ferred into solutions containing less than 0.044 M citrate
dissolved rapidly (<30 min), those in 0.088 M citrate dissolved
overnight and those in 0.175 M citrate cracked severely. It was
therefore hypothesized that crystal integrity was dependent on
the presence of a suitable molecule, in this case the precipi-
tant, bound to the P-loop of MtDTBS.
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3.3. The addition of ligand
increased the stability of crystals
As NpP molecules also bind to
the P-loop, it was proposed that
these molecules would rescue
crystal stability in the absence of
precipitant. To test this, crystal
stability was assessed in a twofold
serial dilution series of citrate
containing a constant concentra-
tion of 5 mM ATP (Serial Dilu-
tion Solution 2; x2). There was no
appreciable improvement in
crystal stability using this
concentration of ligand (Table 2).
It was hypothesized that the
percentage of MtDTBS mole-
cules in the crystal bound to a
ligand (precipitant or NpP) was
not high enough to retain crystal
integrity. Therefore, much higher
concentrations of NpP were
trialled, analogous to the high
concentrations of precipitant
required for crystal growth
described previously. Crystals
were transferred into a solution
of 0.022 M citrate that was
supplemented with 300 mM ATP
(Exchange Solution 1; x2). The
crystals of MtDTBS showed
improved stability, as they did not
degrade overnight. Similarly,
crystals grown in sulfate were
stable when supplemented with
ATP. This was consistent with the
hypothesis that crystal integrity
was dependent on the presence of
a suitable ligand to occupy the P-
loop.
To ensure that the ligand of
interest would be unobscured by
precipitant density in the
resulting crystal structure, efforts
were made to completely remove
the protein-bound precipitant.
MtDTBS crystals were grown in
the ammonium sulfate crystal-
lization condition before being
transferred into an 8 ml drop of
Exchange Solution 2 containing
300 mM ATP. An 8 ml drop size
was used to minimize dilution by
any of the original buffer
components in the transfer
process. This resulted in crystals
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Table 2
Data-collection and processing statistics for MtDTBS crystal structures.














Wavelength (Å) 0.9537 0.9537 0.9537
Temperature (K) 100 100 100
Space group P212121 P212121 P212121
a, b, c (Å) 55.33, 105.29, 153.76 56.680, 105.70, 153.26 54.77, 105.75, 155.20
", !, # (#) 90, 90, 90 90, 90, 90 90, 90, 90






Total No. of reflections 394104 (39657) 428391 (46135) 367683 (33793)
No. of unique reflections 31792 (3444) 32594 (3577) 33558 (2787)
Completeness (%) 99.500 (97.500) 99.700 (98.700) 93.400 (78.800)
Multiplicity 12.400 (11.500) 13.100 (12.900) 10.900 (11.600)
hI/$(I)i 7.100 (1.4) 7.100 (0.9) 18.500 (7.7)
Rr.i.m. 0.367 (2.293) 0.449 (3.796) 0.101 (0.291)
Rp.i.m. 0.102 (0.653) 0.122 (1.041) 0.029 (0.079)




$ Cutoff F > 0.310$(F ) F > 0.320$(F ) F > 0.310$(F )
No. of reflections, working set 30053 (2584) 30798 (2470) 31802 (2194)
No. of reflections, test set 1603 (154) 1639 (140) 1742 (130)
Final Rcryst 0.210 (0.2852) 0.217 (0.3519) 0.189 (0.1956)
Final Rfree 0.285 (0.3614) 0.288 (0.4109) 0.259 (0.3263)
No. of non-H atoms
Protein 6351 6351 6306
Ligand 120 120 112
Solvent 377 319 596
Total 6848 6790 7014
R.m.s. deviations
Bonds (Å) 0.009 0.009 0.007
Angles (#) 1.248 1.301 0.999
Average B factors (Å2)
Protein 41.28 54.56 31.23
Ligand 35.13 30.84 33.86
Ramachandran plot
Most favoured (%) 98.22 97.78 97.56
Allowed (%) 1.44 1.89 1.89
† Anomalies in the Wilson plot arose owing to ice rings.
Figure 3
Qualitative crystal stability after transfer into solutions containing varying concentrations of citrate
precipitant and ATP or ADP. Crystal stability is denoted from highest to lowest from green to brown.
that were stable in solution for more than 2 d, depending upon
the ligand used. This method served as a template for
obtaining previously intractable co-complexes involving
MtDTBS.
3.4. Proof of concept: precipitant–ligand exchange with CTP
reveals the expected binding mode
To demonstrate that structures obtained using precipitant–
ligand exchange are biologically relevant, crystals of MtDTBS
were grown in either the sodium citrate or ammonium sulfate
crystallization conditions and then transferred into an
exchange solution containing 100 mM CTP in place of the
precipitant (Exchange Solutions 3 and 4, respectively; x2).
Photographs of crystals in the transfer process are provided in
Supplementary Fig. S1. After a short exchange (10–30 min),
the MtDTBS crystals were flash-cooled and subjected to X-ray
data collection at the Australian Synchrotron. Both data sets
were solved to 2.5 Å resolution by molecular replacement
(PDB entries 6e05 and 6e06; crystallographic data are listed in
Table 2). Consistent with previous reports, MtDTBS was
solved in space group P212121, with four monomers in the
asymmetric unit corresponding to two biological dimers. The
monomer possessed the same "-helical/!-sheet fold as
previously reported, with the P-loop present between !1 and
"1 and the cytidine binding site formed by the coils connecting
!7 to 3102 and !6 to "7 (Fig. 1). In both structures, CTP was
modelled into well defined electron density present in the
active site (Supplementary Figs. S2a and S2b), adopting an
identical binding pose to our previous structure (PDB entry
4wop; Fig. 2). These data demonstrate that the complexes
acquired by precipitant–ligand exchange were consistent with
those obtained by conventional X-ray crystallographic tech-
niques such as co-crystallization.
3.5. A crystal structure of ADP–MtDTBS revealed an
unexpected binding mode
Attempts to obtain a structure of MtDTBS in complex with
the inhibitor ADP using traditional crystal soaking were
unsuccessful. We therefore turned to the precipitant–ligand
exchange method, whereby MtDTBS crystals were first grown
in the ammonium sulfate condition and then transferred into
Exchange Solution 5 containing 70 mM ADP in place of the
ammonium sulfate. Under these conditions crystals were
stable for several hours but dissolved overnight, encouraging
the use of shorter soak times. The crystals were subjected to an
hour-long exchange before flash-cooling and X-ray data
collection at the Australian Synchrotron. The resulting data
set was solved to a resolution of 2.4 Å by means of molecular
replacement (PDB entry 6czd; crystallographic data are given
in Table 2). Consistent with previous reports, MtDTBS was
solved in the same space group P212121, with the overall fold
and asymmetric unit as described above.
ADP was modelled into well defined electron density
present in the active site (Figs. 4a and 4b; Supplementary Figs.
S2c and S2d). In validation of the technique, no precipitant
molecules were observed in the P-loop. Instead, the poly-
phosphate moiety of ADP was bound at this site. ADP bound
in two alternate conformations, both of which extended in the
reverse direction compared with the prototypical CTP
conformation. These two conformations were differentiated
by the adenosine moiety binding ‘within’ (anti conformation,
present in chains A, B and D; Figs. 4a and 5a) or ‘adjacent’ to
(syn conformation, present in chain C; Figs. 4b and 5b) the
DAPA binding site. In both conformations the ADP
!-phosphate bound at the same position as that observed for
CTP (Salaemae et al., 2015), in a highly coordinated network
of hydrogen bonds and electrostatic interactions with the
P-loop, involving the backbone amides of Val13 (3.2–3.42 Å),
Gly14 (2.67–3.15 Å), Lys15 (2.47–3.05 Å) and Thr16 (3.04–
3.1 Å), as well as the side chains of Lys15 (2.55–2.65 Å) and
Thr16 (2.91–3.07 Å) (Figs. 5a and 5b). The ADP "-phosphate
bound at the CTP #-phosphate position in both conforma-
tions; however, the protein interactions differed slightly. In the
‘within’ conformation, the "-phosphate formed hydrogen-
bonding and electrostatic interactions with the backbone of
Gly111 (2.89–3.02 Å) and the side chain of Lys15 (2.39–
2.48 Å) (Fig. 5a). In the ‘adjacent’ conformation, the "-
phosphate also interacted with the backbone of Gly111
(3.28 Å) but formed an interaction with the side chain of
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Figure 4
Alternate ADP binding modes. ADP (grey sticks) and a magnesium ion
(green sphere) were modelled into well defined electron density (white;
polder map 3$; Liebschner et al., 2017) in the active site of MtDTBS (light
blue surface). Superposition with CTP (yellow lines; PDB entry 4wop)
and DAPA carbamate (black lines; PDB entry 3fmf; Dey et al., 2010)
revealed that ADP clearly bound in the reverse direction to CTP;
however, the !-phosphates for ADP and CTP bound in the same location
at the P-loop (salmon surface). ADP exhibited two different conforma-
tions, (a) within and (b) adjacent to the DAPA pocket, with the latter
accompanied by rearrangement of the P-loop.
Lys37 (3.15 Å) (Fig. 4b). Both of the phosphates also bound to
a magnesium present in the active site, which coordinated to
the side chains of Thr16, Asp49 and Glu108, as well as a water
molecule (all 1.83–2.44 Å; Figs. 5a and 5b). The ribose ring was
hydrogen bonded to the side chain of Arg45 in both confor-
mations; however, the ‘within’ conformation interacted
through the 20- and 30-hydroxyl groups (2.55–3.06 Å; Fig. 5a),
whereas it was flipped in the ‘adjacent’ conformation, inter-
acting through O40 (3.06 Å; Fig. 5b). When bound within the
DAPA pocket, the adenine did not make polar contacts with
the enzyme (Fig. 4a). Instead, the adenine was bound to water
molecules and encased by hydrophobic contacts with Thr11,
Met72, Ala73, Ala110, Val115 and Leu143. In this conforma-
tion, the adenine did not extend as deep into the binding site
as the native substrate DAPA (Fig. 4a). When the adenine
moiety bound adjacent to the DAPA pocket, rearrangement
of the P-loop saw Thr11 move away from the ADP, allowing
two hydrogen bonds to be made between the adenine N6 and
the carbonyl backbone atoms of Gly10 (3.19 Å) and Leu143
(3.29 Å) (Fig. 5b).
4. Discussion
In this report, we name and describe precipitant–ligand
exchange, a methodology to obtain structural data when
crystallographic precipitants compete for binding with a
ligand. This technique was validated by obtaining two crystal
structures of MtDTBS in complex with CTP. Precipitant–
ligand exchange revealed the same binding mode for CTP as
that obtained from other crystallographic techniques. We then
demonstrated the practical utilization of this technique by
obtaining crystallographic data for the previously intractable
complex between ADP and MtDTBS. We anticipate that
this precipitant–ligand exchange approach may be widely
applicable to ligand–protein interaction
crystallography. However, several key
points should be considered. This tech-
nique requires crystals that are amen-
able to soaking, a ligand of appropriate
size for diffusion through solvent chan-
nels, and solvent-accessibility of the
protein binding pocket. Under these
conditions, ligand occupation may be
affected by the following factors: the
concentration and solubility of the
ligand, the duration of interaction and,
as observed here, the properties of
competing precipitants. The affinity of
the protein–ligand interaction is also an
important consideration in the experi-
mental design. For higher affinity
protein–ligand interactions, such as
CTP–MtDTBS (IC50 = 54.4 mM;
Salaemae et al., 2015), precipitant
occupation was easily overcome with a
moderate concentration of ligand (CTP
was co-crystallized at 1 mM; Salaemae
et al., 2015). However, the weaker affinity ADP interaction
(IC50 = 248 mM; Salaemae, 2015) was outcompeted by the
precipitant. Thus, the aim of this methodology was to achieve
the optimal concentrations of both precipitant and ligand to
result in distinct and observable electron density solely for the
ligand after the exchange. Furthermore, ligand concentration
and soaking duration were optimized such that crystal
degradation was minimal, whilst still allowing high-occupancy
ligand binding to occur. In order to aid other researchers
attempting this technique, we have provided a flow diagram
for decision making (Fig. 6).
To ensure that ligand density was unobscured, the precipi-
tant was completely replaced with the ligand of interest. While
crystal degradation did occur, shorter soak times were found
to be sufficient for both diffraction quality and ligand density
(e.g. 30–60 min). Some protein crystals may be less stable, and
optimization of the ratio of ligand to precipitant may be
required. This should be performed by solving several data
sets at different ratios and soak times and optimizing each
based on both diffraction quality and ligand electron density.
In such cases, avoiding crystal transfer may also be preferred,
and dilution of the precipitant can be performed directly in the
drop. For example, adding 6 ml of a precipitant-free high
ligand-concentration solution to a 2 ml drop would reduce the
precipitant concentration by 75%. However, care must be
taken to delineate between the electron density of the preci-
pitant and ligand during interpretation.
ADP was observed to bind in two alternate conformations
in the vicinity of the DAPA pocket, a mode distinct from that
of CTP. We have previously shown that ADP (IC50 = 248 mM;
Salaemae, 2015) and ATP (IC50 = 349 mM; Salaemae et al.,
2015) displace a competitive ATP fluorophore with compar-
able affinities. A modest increase in affinity could be attrib-
uted to the dual binding mode of ADP; however, comparative
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Figure 5
Polar intermolecular interactions between ADP (grey sticks) and MtDTBS (blue surface, grey
sticks). A highly coordinated network of hydrogen bonds and electrostatic interactions forms
between the P-loop (salmon surface), the "- and !-phosphate groups of ADP and the magnesium
ion (green sphere). The magnesium ion exhibits six-coordination with the ADP phosphates, Thr16,
Asp49, Glu108 and a water molecule (water molecules are not shown for clarity). Intermolecular
interactions differ dependent on the adenosine conformation. (a) When bound within the DAPA
pocket, the adenine moiety did not form polar interactions. (b) When bound adjacent to the DAPA
pocket, Thr11 moved away from ADP, allowing polar contacts between the adenosine moiety and
the carbonyl backbones of Gly10 and Leu143.
structural investigation into the binding mode of ATP is
ongoing. Interestingly, the !-phosphate of ADP in both
conformations shared the same binding site as the !-phos-
phate of CTP within the P-loop. This was also the same site as
observed for the sulfate precipitant, suggesting that this is a
high-affinity binding site for anionic compounds. These
structural data provide the first evidence for a molecule other
than DAPA carbamate, or the closely related molecule 7-keto-
8-aminopelargonic acid (KAPA), bound within the DAPA
pocket. This revealed that the DAPA pocket can also
accommodate larger and more varied compounds than the
simple elongated acyl chains of DAPA and KAPA, a finding
that will aid drug discovery. Finally, this structure indicates
that inhibition by ADP may occur through competition with
either substrate, a finding that invites further experimental
investigation. The value of this structure lies in its contribution
to mapping the binding characteristics of the active site of
MtDTBS. This will inform future antitubercular drug-
discovery efforts targeting MtDTBS activity and biotin
biosynthesis, assisting in the design of inhibitors that bind with
high specificity to the enzyme.
This technique may be of use in fragment-based drug
discovery, where hits generally have weak affinity (Kd >
500 mM; Baker, 2013). If a fragment has been shown to bind to
a protein using affinity and/or competitive inhibition assays,
but only precipitant electron density is observed in the active
site of the crystal structure, this technique can be used to
exchange the precipitant, leading to fragment electron density.
With weak ligands, it may not be possible to reduce the
precipitant concentration to the required levels while main-
taining crystal stability. This may lead to a scenario in which a
certain proportion of protein molecules in the crystal are
bound to precipitant, with the remainder bound to ligand. In
this case, both precipitant- and ligand-bound states could be
modelled (Pearce, Krojer & von Delft, 2017), or it may be
useful to combine this technique with a program such as
PanDDA (Pearce, Krojer, Bradley et al., 2017) or polder maps
(Liebschner et al., 2017) to aid in discerning fragment density.
5. Conclusions
Here, we describe a crystallographic method for simulta-
neously removing and replacing active-site-bound precipitant
molecules with a ligand of interest: a process that we have
termed precipitant–ligand exchange. This technique was used
to solve two CTP–MtDTBS structures from independent
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Figure 6
Flow diagram of the decision-making process during precipitant–ligand exchange.
crystal-growth conditions. In validation of precipitant–ligand
exchange, the results were consistent with the published
literature. Subsequently, we solved a previously intractable
structure of ADP bound to MtDTBS. This structure revealed
an alternate binding mode to that previously reported for CTP,
providing new insight into the biology of the enzyme, as well
as informing antitubercular inhibitor-design efforts. Given the
prevalence of crystallographic reagents modelled in entries in
the PDB, we believe that this method will be broadly applic-
able and will benefit structure-based interaction-analysis
projects that utilize crystallography.
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Chapter 4:  
The identification and development of compounds 




This chapter focuses on the discovery and development of compounds that bind to MtDTBS, 
with a future goal of producing an inhibitor of both the enzyme and the pathogen M. 
tuberculosis. This work continues a previously established screening campaign against the 
MtDTBS active site, where in silico screening with 57 cytidine analogues (Sigma Aldrich) 
and 93,904 commercially available and rule of three compliant fragments (UCSF ZINC 
library) generated a number of predicted hits (Wanisa Salaemae and Prof. Grant Booker, 
University of Adelaide) (Salaemae, 2015). In this screen, in silico hits were ranked according 
to predicted binding energy and 26 hits with more favourable predicted energy than CTP 
were purchased for further testing (11 cytidine analogues and 15 ZINC fragments). 
Preliminary surface plasmon resonance (SPR) binding experiments with 4 cytidine analogues 
and 7 fragment hits indicated weak affinity binding, while docking results predicted the hits 
bound to the active site. This chapter describes the use of X-ray crystallography to confirm 
specific ligand binding and provide detailed binding pose information. This technique, in 
combination with further SPR, was then used to guide chemical development of hits towards 
higher affinity MtDTBS binding. The chemical development of hits presented in this chapter 
utilized the principles of fragment-based lead discovery (FBLD). 
 
As discussed in the introduction (Chapter 1), FBLD is a promising strategy for the 
development of novel antibiotics. After the identification of hits, there are several different 
structure-guided methods for compound optimisation in FBLD, including growing, merging 
or linking compounds together (Lamoree and Hubbard, 2018). Growing involves the addition 
of functional groups to a hit in order to create additional contacts to the protein target. 
Alternatively, two or more compounds with overlapping or adjacent binding poses can be 
merged or linked together in order to generate higher affinity interactions. Progress in 
fragment development is often measured using the ligand efficiency (LE) metric. LE is 
defined as the ratio of the free energy of binding to the heavy atom count (HAC) of the 
molecule (∆G/HAC), with ‘good’ values considered to be equal to or greater than 0.4 
(Hopkins et al., 2014). The first successful cases of FBLD involved fragment linking (Shuker 
et al., 1996), and gave a practical example of how this method of compound development can 
generate super-additive affinity improvements (Jencks, 1981). However, the composition of 
the linker moiety is crucial to achieving high affinity, and must be designed to not only 
interact favourably with the protein, but also to retain the binding poses of the original 
fragments (Ichihara et al., 2011). Furthermore, linkers should have appropriate rigidity to 
minimise entropic penalties upon binding. This can be problematic in practice and 
consequently fragment growing is more commonly reported (Erlanson et al., 2016). In this 
chapter, FBLD principles were used to grow a promising hit based on previous structural 
investigation of the MtDTBS active site. Additionally, ligands bound to distal regions of the 
active site were identified, encouraging the use of linking to conjugate these ligands.  
 
Previous biophysical and high-resolution structural characterisation of MtDTBS generated in 
Chapter 2 and 3, as well as previous literature, provided useful information for optimisation 
and development of fragment hits and linked compounds. Investigation into the ligand 
binding characteristics of the cytidine binding site, the phosphate binding loop (P-loop) and 
the DAPA pocket (Figure 4.1) revealed interactions that could be exploited during compound 
development to attain high affinity for MtDTBS. In Chapter 3, the high affinity nucleoside 
triphosphate (NTP) binding mode was described. The cytosine moiety binds in a shallow 
binding pocket, making four hydrogen bonds with MtDTBS residues. This highly efficient 
and specific interaction could be exploited during drug discovery. During the development of 
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the precipitant-ligand exchange technique presented in Chapter 2, it became apparent that the 
MtDTBS P-loop was a high affinity binding site for anionic compounds. This was further 
investigated in Chapter 3, where it was found that the LRLR nest in particular exhibits 
extremely high affinity for phosphates, such as those present in nucleoside polyphosphates. 
This information suggested anionic interactions in this vicinity could also be exploited for 
drug discovery. Finally, structures of MtDTBS in complex with DAPA-carbamate (PDB IDs: 
3FMF, 6CVE) and ADP (Chapter 2) provided insights for the growing or merging of 




Figure 4.1: The active site of MtDTBS in complex with CTP and DAPA-carbamate (PDB ID: 6CVE; Chapter 
3). The surface of MtDTBS (grey) is depicted with the following ligand-binding regions highlighted: the 
cytidine binding pocket (yellow), the P-loop (salmon) and the DAPA pocket (blue). CTP (yellow sticks) and 
DAPA-carbamate (black sticks) are displayed bound to the active site. 
 
This chapter describes X-ray crystallographic binding confirmation of two cytidine analogues 
and one fragment that bound to the DAPA pocket, which were identified as promising 
starting points for compound growing and linking. The cytidine analogues were found to bind 
to the nucleoside binding pocket, and while the cytosine base appeared to be optimal, 
modifications at the 2ʹ ribose site were observed to bind, with one such modification resulting 
in improved affinity over cytidine. The structure solved from a fragment soak with MtDTBS 
suggested that a degradation product of the original fragment was bound to the DAPA pocket 
of MtDTBS. The chemical structure of this compound was confirmed through several 
orthogonal methods. Serendipitously, this compound constituted a convenient scaffold for 
structure guided fragment growing, enabling the development of a compound with greatly 
improved binding affinity for MtDTBS. Finally, having identified ligands that bound to the 
cytidine binding site and the DAPA pocket, these compounds were linked and the binding 
affinity and mode analysed. Although these linked compounds did not improve binding over 
their substituents, X-ray crystallographic data revealed strategies that could be implemented 





4.2 Materials and Methods 
 
4.2.1 General X-ray crystallographic data collection and processing 
 
Purified MtDTBS protein was obtained as indicated in Chapters 2 and 3. Generally, ligands 
were soaked at as high concentration possible with consideration of the stock concentration. 
DMSO dissolved ligands were generally soaked such that a maximum concentration of 10% 
DMSO was allowed. Ligand treated MtDTBS crystals were flash cooled in liquid nitrogen 
and subjected to X-ray diffraction on the MX-1 Beamline at the Australian Synchrotron, part 
of ANSTO (McPhillips et al., 2002). Data were collected at 100K and at a wavelength of 
0.9537 Å. Diffraction data for 1-CTN-MtDTBS were collected at the Braggs Facility 
(University of Adelaide) using a Rigaku R-AXIS IV++ detector at a wavelength of 1.54 Å 
and at 100K. Datasets were indexed, scaled and merged in either iMosflm (Battye et al., 
2011) or XDS (Kabsch, 2010) and AIMLESS (CCP4) (Winn et al., 2011) in accordance with 
CC1/2 cut-off values (Karplus and Diederichs, 2012, 2015). The phase problem was solved via 
molecular replacement (PhaserMR (McCoy et al., 2007) or DIMPLE) using in-house 
MtDTBS search models. Structures were modelled through iterative rounds of building in 
Coot (Emsley and Cowtan, 2004) and refinement in Phenix.refine (Adams et al., 2010).  
 
4.2.2 Crystallographic screening of in silico hits 
 
Select in silico hits were subjected to crystallographic screening against MtDTBS (ligand 
purchasing and formulation details in (Salaemae, 2015)). Cytidine analogue hits and alternate 
nucleosides (Table 4.1) were screened via crystal soaking using the methodology provided in 
4.2.1, however, in the screening pipeline, each dataset for the cytidine analogue screen was 
solved using AIMLESS and DIMPLE to the maximum resolution which resulted in CC1/2 and 
completeness values above 0.9 and 90% respectively. Each model was then subjected to 
PanDDAs refinement (Pearce et al., 2017) and hits were manually inspected for ligand 




Table 4.1:  Lab denotation, name, structure and concentration used in the crystallographic 
screening of cytidine analogue hits and select nucleosides. The bolded compounds indicate 









































































































































Fragment hits (Table 4.2) were tested via a combination of co-crystallography (incubating the 
ligand with the protein prior to crystal growth via vapour diffusion), and traditional soaking 
(adding ligand directly to drops containing pre-grown crystals). Several fragment hit datasets 
were solved in accordance with the methodology provided in 4.2.1 before examination of the 
structure for electron density pertaining to the ligand. More detailed soaking methodology 
involving compound 1 is provided in Table 4.4. Compound 1 was purchased from Specs. 
 
Table 4.2: Lab book denotation, ZINC ID, name, structure and details of the attempts to 
generate a complex by crystallography for three of the previously determined in silico hits. 
The bolded crystallographic attempt indicates that the crystal structure contained ligand 
electron density. 
 
*Crystallography described in more detail in table 4.4  
Lab book 








at 10 mM 
 








at ~2 mM 
 
Soaked at ~5 
mM 
B9  





at 10 mM 
 















4.2.3 Confirmed hits and their analogues 
 
Following X-ray crystallographic determination of the binding mode of cytidine analogues 
and fragment hits, analogues were identified and synthesized for structure activity 
relationship (SAR) studies. Table 4.3 provides a list of all chemical structures referred to in 
this chapter. Details of their use in MtDTBS crystallography studies are provided in Table 
4.4. Cytidine, its analogues, and compound 1 are listed again for ease of structural 
comparison.  
 
Table 4.3: Abbreviations, names and structures of crystallographic hits, analogues of hits, 
synthesized compounds and other compounds referred to in Chapter 4. 
 












































































































































4.2.4 Preparation of compounds found in Table 4.3  
 
Gemcitabine, 2ʹ-deoxycytidine, 2ʹ-deoxycytidine diphosphate and cytidine were purchased as 
analytical grade powders from Sigma Aldrich and solubilised in water. The stock 
concentration was determined according to Beer’s Law, using literature wavelength and 
extinction coefficient values (Sambrook et al., 1989) and UV absorption (Nanodrop 2000, 
Thermo Scientific).  
 
Compounds 2 (subsequent to initial discovery) and 4 were synthesized by Birgit Gaiser 
(Department of Chemistry, University of Adelaide). Compounds 3, 5-9 were synthesized by 
Kwang Jun Lee (Department of Chemistry, University of Adelaide). Concentrated stock 
solutions of synthesized compounds were prepared in 100% DMSO (Sigma Aldrich) (100-
330 mM). 
 
4.2.5 Crystallography methodology for new structures 
 
All MtDTBS crystals were grown via the hanging drop method (1:1 drop:well ratio, 2-4 uL 
total volume) with a 500 µL well solution in either of the following conditions: (1) 1.2 – 1.7 
M ammonium sulfate, 0.1 M Tris pH 8, 10-15% glycerol (2) 0.7 M sodium citrate, 0.1 M 
Tris pH 7 and 20% glycerol. Co-crystallisation involved growing crystals in the presence of 
the ligand. Soaking was performed by adding the desired ligand directly to the crystallization 
condition containing a pre-grown crystal. Precipitant ligand exchange involved transferring 
crystals into a solution where ligand replaced the precipitant (highlighted above in bold). 



































Table 4.4: Crystallisation and ligand complexing methodology for all new structures.  
 
Ligand Condition Concentration Other Method Time Cryoprotection 
dCTN 1 56 mM - Soaking 8 days - 
dCDP 2 20 mM 2 mM MgCl2 Co-crystallisation - Paratone-N 
dCTP 2 10 mM 1 mM MgCl2 Soaking Overnight  
dFdC 1 ~50 mM (slurry) - Soaking 2 days - 
2 (1*) 1 30 mM 10% DMSO Soaking 8 days - 
Synthesized-2 1 20 mM 10% DMSO Soaking 2 days - 
2 + CTN 1 30 mM (1) 60 mM (CTN) 5% DMSO Soaking Overnight - 
3a 2 10 mM 10% DMSO Precipitant ligand exchange 2 days - 
4 1 30 mM 10% DMSO Soaking 2 days - 
5 1 10 mM 10 % DMSO Soaking Overnight - 
6 1 10 mM 10 % DMSO Soaking Overnight - 
7 1 10 mM 10 % DMSO Soaking Overnight - 
8 1 10 mM 10 % DMSO Soaking Overnight - 
9 1 10 mM 10% DMSO Precipitant ligand exchange < 30 min - 
10 2 10 mM 10% DMSO Soaking 2 days - 
 
*NB: 2-MtDTBS crystal structure was obtained by soaking with compound 1. 
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4.2.6 Surface plasmon resonance binding experiments 
 
SPR binding analysis was performed using a Biacore S200 instrument (GE Healthcare). 
Biotinylated-MtDTBS was immobilized via streptavidin mediated coupling as described in 
Chapter 3. Streptavidin alone was used in the reference cell, for reference subtraction in all 
analyses. Immediately before analysis, compounds were diluted into 50 mM Tris pH 7.4, 150 
mM NaCl, 0.05% Tween20 to a final concentration of 5% DMSO. Compounds were then 
further diluted to the maximum test concentrations and serially diluted in running buffer (50 
mM Tris pH 7.4, 150 mM NaCl, 0.05% Tween20, 5% DMSO). 8-point solvent correction 
curves were obtained using 50 mM Tris pH 7.4, 150 mM NaCl, 0.05% Tween20 with DMSO 
ranges of 4.2% – 5.7%. Solvent correction curves were used as the secondary correction for 
all binding analyses for compounds that were dissolved in DMSO. SPR results and example 
sensorgrams for binding measurements with compounds 2-10, dCDP and dCTP are provided 





4.3.1 General description of MtDTBS crystal structures 
 
Crystallographic methodology for all new structures discussed in this chapter is provided in 
Materials and Methods 4.2.1, 4.2.2 and 4.2.5 (Table 4.4) and crystallographic data tables for 
all new datasets are provided in Appendix 1. All MtDTBS crystal structures described in this 
chapter were solved in the P212121 space group, with identical overall fold to previous 
structures (Dey et al., 2010; Salaemae et al., 2015; Thompson et al., 2018b, 2018a). The 
asymmetric unit contained a dimer of the catalytic MtDTBS homodimer, which was 
comprised of coil regions that connected alternating α-helices and β-sheets (Figure 4.2). 
Notable structural features of the active site include the cytidine binding site (formed by the 
coils connecting β7-3102 and β6-α7), the phosphate binding loop (P-loop; between α1 and β1) 
and the DAPA pocket (a pocket formed at the homo-dimerisation interface) (compare to 
Figure 4.1 for surface representation).  
 
 
Figure 4.2: Representative overall fold of the catalytic MtDTBS homodimer in crystal structures. Each 
monomer contains α-helices (blue) and β-sheets (green). Dimerization occurs along an interfaced formed by α3, 




4.3.2 Investigation into in silico cytidine analogue hits 
 
In order to investigate the hits from the in silico screening described in section 4.1, the 8 
available cytidine analogues were subjected to crystallographic soaking experiments with 
MtDTBS (Table 4.1). To further probe the active site, guanosine, adenine and uridine were 
also included. From this experiment, 11 datasets were solved according to the 
crystallographic methodology detailed in 4.2.1; 4.2.2; 4.2.5. Of these 11 datasets, ligand 
electron density was only observed in the cytidine binding site for MtDTBS crystals soaked 
with 2ʹ-deoxycytidine (dCTN) and 2ʹ,2ʹ-difluoro-2ʹ-dexoycytidine (aka gemcitabine, denoted 
dFdC). These molecules differ from cytidine by the substituents present at the 2ʹ position on 
the ribose ring, where cytidine contains a 2ʹ-OH, dCTN contains two protons, and dFdC 
contains two fluorine atoms (Table 4.1, 4.3; Figure 4.3B, C). The hydrogen bonding 
arrangement between MtDTBS and the cytosine bases were identical to that previously 
described in Chapter 3 for CTN. These interactions involved cytosine 4NH2 and the 
backbone carbonyl of Pro197 and Gly169, cytosine 3N and the backbone amide of Ala200, 
and hydrophobic interactions between cytosine 4C and 5C, and the side chain of Val17 
(Figure 4.3). Compounds that varied at the cytosine moiety were not observed by 
crystallography, consistent with the notion that the cytosine interactions are highly optimized 
for binding to this pocket. The absence of alternate nucleoside interactions is also consistent 
with the promiscuous ligand binding model (Chapter 3). Adenine was not observed in the 
DAPA pocket, as found in the ADP-MtDTBS structure in Chapter 2. This was likely because 




Figure 4.3:  The MtDTBS active site (blue surface; interacting residues represented by grey sticks) bound to 
cytidine and analogues (yellow sticks). A. cytidine (CTN) B. 2ʹ-deoxycytidine (dCTN), C. gemcitabine (2ʹ,2ʹ-
difluoro-2ʹ-dexoycytidine, dFdC). Both cytidine analogues adopt similar poses, and interact with the residues 
Gly169, Pro197, Ala200 and Ala201 as previously demonstrated for CTN. The substituents present at the 2ʹ 
position on the ribose ring of the analogues (circled) are proximal to the hydrophobic sidechains of residues 




The cytidine binding site was able to accommodate chemical variation at the 2ʹ ribose 
position of cytidine. This site is adjacent to the hydrophobic residues Ala201 and Val17. 
Therefore, it was hypothesized that the 2ʹ protons of dCTN or fluorines of dFdC may interact 
more favourably with MtDTBS than the more hydrophilic 2ʹOH of cytidine (Figure 4.3). SPR 
binding experiments were unable to distinguish the affinities for dCTN and dFdC, due to 
their weak binding (KD > 1 mM). However, 2ʹ-deoxycytidine diphosphate (dCDP; KD = 120 ± 
30 nM, n = 3) bound approximately 3-fold tighter than CDP (KD = 450 nM ± 50, n = 4), and 
2ʹ-deoxycytidine triphosphate (dCTP; KD = 47 nM, n = 3) likewise bound with ~3-fold higher 
affinity than CTP (KD = 160 ± 10 nM, n = 5) (Figure 4.4A, B; SPR data tables presented in 
Appendix 2). X-ray crystallographic investigation of the dCDP and dCTP binding modes 
revealed an identical binding pose to that observed for CDP and CTP (Figure 4.4C), 
demonstrating these molecular composition changes don’t alter binding mode. SPR data were 
fit using kinetic binding analysis (Biacore S200) to determine dCDP association and 
dissociation rates (ka = 1.2 ± 0.4×106 M-1s-1; kd = 1.2 ± 0.3×10-1 s-1). Comparison to CTP (ka 
= 3.2 ± 0.3×105 M-1s-1, kd = 5.3 ± 0.4×10-2 s-1) revealed that dCDP associated approximately 
4-fold faster than CTP, but also dissociated 2-fold faster, explaining the similarity in KD 
values. While dCTP exhibited association rates between those of dCDP and CTP, it 
dissociated the slowest out of all cytidine or deoxycytidine polyphosphates (ka = 7.13 ± 
0.05×105 M-1s-1; kd = 3.4 ± 0.02×10-2 s-1). A graphical representation of binding kinetics 
values for CTP, CDP, dCDP and dCTP is provided in Figure 4.4B. These data demonstrate 
that the 2ʹ hydroxy group leads to a slower association rate and faster dissociation rate, 
culminating in the observation that dCTP is the preferred NTP when measured by binding 
affinity. For the purposes of linked inhibitor design, dCTN currently constitutes the highest 
affinity ligand for the cytidine binding site. Further investigation is required to determine the 
effect that the 2ʹ-difluoro group has on the binding of dFdC, as well as to explore other 
chemical variations at this position. 








Figure 4.4: A. Examples of SPR sensorgrams for dCDP and dCTP binding to MtDTBS. Both ligands exhibited 
slow association and dissociation rates and were accordingly fit with the kinetic binding model (Biacore S200 
Evaluation Software). B. Comparison of association and dissociation rates for CDP (green circle), CTP (blue 
triangle), dCDP (orange square) and dCTP (black triangle). Error bars represent standard error of the mean. 
dCDP associated and dissociated faster than CTP, resulting in similar KD values (diagonal lines). dCTP had the 
slowest dissociation of all polyphosphates, contributing to its high affinity. NB: error bars were smaller than the 
size of the symbol for dCTP C. Overlays of the binding poses of CDP (green sticks) and dCDP (orange sticks), 






















KD= 1x10-8 MKD= 1x10-9 M
dCTP
B. Kinetic Comparison Between Cytidine & Deoxycytidine Polyphosphates
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4.3.3 Investigation into in silico fragment hits  
 
X-ray crystallography reveals an unexpected molecule bound to the DAPA pocket 
Three fragment hits were available for binding mode investigation via X-ray crystallography; 
data were collected for several soaking experiments with MtDTBS crystals (Methodology in 
4.2.1 – 4.2.5). Electron density corresponding to a ligand bound to the active site was only 
observed for one structure, which will be the sole focus of this section. Ligand electron 
density was observed in the DAPA pocket, for a structure solved from crystals soaked with 
9b-hydroxy-6b,7,8,9,9a,9b-hexahydrocyclopenta[3,4]cyclobuta[1,2-c]chromen-6(6aH)-one 
(1; 30 mM final concentration; X-ray crystallographic data in Appendix 1). Interestingly, this 
electron density was not consistent with that expected for compound 1 (Figure 4.5A), and 
low density fit scores (Coot; 0.5-0.7) and real-space correlation coefficients (PHENIX; 
0.565-0.814) were determined for this ligand after modelling and refinement. The observed 
density was also inconsistent with other crystallographic reagents present, i.e. sulfate, 
glycerol or DMSO, implying it may instead correspond to a degradation product of 1.  
 
The presence of a phenolic lactone, fused to a strained cyclobutane ring, suggested that 
compound 1 may be susceptible to hydrolysis and subsequent ring opening to form 2-(2-(2-
hydroxybenzoyl)cyclopentyl)acetic acid (2; Figure 4.5B). Compound 2 clearly exhibited 
higher visual coherence with the observed electron density than molecule 1 (Figure 4.5C, D), 
as well as high density fit scores (Coot; > 1.09) and real-space correlation coefficients 
(PHENIX; > 0.938). Predicted compound 2 contained two stereocenters, of which the 
stereochemistry was unknown. While compound 1 was provided as a racemic mixture of the 
cis,cis,cis-isomer (Specs, Netherlands), racemisation of 2 was likely to occur during 
hydrolysis due to the relatively acidic nature of the protons adjacent to the ketone. Although 
trans stereochemistry at the cyclopentane ring was hypothesized to be more 
thermodynamically stable, each of the four possible diastereomers (RS/SR/RR/SS) were 
simultaneously modelled into the crystal structure to see which most closely matched the 
observed electron density (Figure 4.5C, D). Trans diastereomer RS-2 exhibited the highest 
occupancy after refinement (RS: 0.51, SR: 0.13, RR: 0.32, SS: 0.34) and the most preferable 
real-space refinement statistics. However, due to the minimal structural differences observed 
between diastereomers (Figure 4.5C, D), it was not possible to distinguish the 
stereochemistry of 2 with confidence. Thus, the crystallographic modelling was consistent 
with a stereoisomer of 2 bound to MtDTBS, and most likely the RS form, although 






Figure 4.5: A. Walleye view of 1 (black sticks) within Polder electron density (3σ) observed within the active 
site of MtDTBS. This molecule fits poorly into the density, and does not appear to be compatible with its 
structure. B. Proposed mechanism for the degradation of lactone 1 to carboxylic acid 2. Degradation was 
hypothesized to occur via hydrolysis of the lactone and collapse of the four-membered ring. This degradation 
was accompanied by the generation of two new stereocentres (red circles). C, D. Two walleye perspectives of 
each diastereomer of 2 (RR: light blue, SS: dark blue, SR: pink, RS: orange) fit into Polder electron density (3σ) 
observed in the MtDTBS active site.  Each of these molecules is visually consistent with the electron density. 
Minimal structural differences between diastereomers were observed, and the preferred molecule could not be 
definitively identified solely by crystallography.  
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Experimental confirmation of the molecular structure of 2  
The DMSO stock solution of compound 1 was analysed for the presence of degradation 
product 2 by a combination of small molecule X-ray crystallography, NMR and MS analysis 
(performed by Birgit Gaiser, University of Adelaide, Appendix 3) and LC/MS (Adelaide 
Proteomics Centre, Appendix 4). The vial with the stock of 1 contained a crystal, as well as 
an amorphous solid. This crystal was analysed by small molecule X-ray crystallography and 
was shown to be cis-cis-cis-1 (Appendix 3). NMR analysis of the amorphous residue 
revealed that this sample consisted largely of 1, but that resonances consistent with 2 were 
also present (Appendix 1). The ratio of compounds was estimated to be 3:1 in favour of 1 
after accounting for the removal of the crystal prior to NMR analysis. Resonances from 2 
indicated the presence of two different stereoisomers, and NOESY experiments revealed the 
major component was the trans-isomer, with only small amounts of the cis-isomer present 
(~75% trans-2; Appendix 3). Finally, LC/MS analysis of the stock of 1 indicated main ions, 
with m/z 231 (C14H15O3) corresponding to 1, 249 (C14H17O4) corresponding to 2. An 
additional ion with m/z 213 (C14H13O2) was observed, consistent with an unknown compound 
similar to 1 with a loss of H2O (Appendix 4). This compound was also observed in MS of a 
freshly reconstituted stock of 1, indicating that it is a by-product from compound synthesis. 
Together these results suggested that moisture present in the sample had induced partial 
degradation of 1 to 2. 
 
An independent sample of compound 2 was then intentionally produced by treatment of 
freshly purchased 1 with aq. LiOH (Birgit Gaiser, University of Adelaide). The NMR 
resonances of this compound were consistent with 2 and matched peaks in the spectrum of 
the original DMSO stock of 1 (Appendix 3). MS similarly confirmed the presence of 2 
(Appendix 3). Compound 2 was found to be in the trans-conformation only, leading to the 
conclusion that the cis-isomer of 2 is indeed unstable and conversion to the trans-isomer 
occurs rapidly. Attempts to separate the trans isomers through the use of a chiral auxiliary 
proved unsuccessful, and separation of the trans-2 isomers for affinity comparison remains a 
future goal of this project. X-ray crystallographic data from MtDTBS crystals soaked with 
hydrolysis product 2 revealed essentially identical active site electron density to that in the 
original crystal structure. Together, these data confirmed the identity of the original ligand as 
2, and that it was present in the original stock solution, most likely as the result of hydrolysis 
by trace amounts of water.  
 
The MtDTBS crystallisation condition causes degradation from 1 to 2  
Soaking with 1 was originally carried out for 8 days in crystallisation condition 1, which is 
basic (pH 8, Section 4.2.3 Crystallography). As the solution used to deliberately hydrolyse 1 
into 2 was also basic, it was hypothesized that further degradation to 2 could result from the 
crystallisation condition itself. A small amount of 1 was added to this solution and monitored 
by TLC over the course of a week. The first traces of 2 were detected after 2 days and 
complete conversion occurred after 6 days (Appendix 3). Therefore, even though some 2 may 
have been present in the stock solution, complete degradation of 1 likely occurred during the 






Figure 4.6: MtDTBS (blue/pink surface) binding to 2 (green sticks) exhibits similar interactions to natural 
substrates. A. Overlay with CTP (yellow sticks) and DAPA (black sticks) (PDB ID: 6CVE). The carboxyl group 
of 2 occupies a similar region to the γ-phosphate of CTP bound at the P-loop (pink surface). Specific polar 
contacts to Thr11, Lys15 and Gly111 are depicted. The remainder of 2 binds in the DAPA pocket, however 
DAPA extends further into this binding pocket with its carboxyl group. B. Overlay with ADP (pink sticks) and 
the mixed carbamic phosphoric acid anhydride of DAPA (black sticks) (EcDTBS; PDB ID: 1DAK). The 
carboxyl group of 2 overlays well with the phosphoryl group, which also exhibits polar interactions with Thr11, 
Lys15 and Gly118 (the EcDTBS equivalent residue of Gly111). This indicates that inhibitors developed from 2 
could function as mimics of the reaction intermediate. C. Binding of 2 is favoured by hydrogen bonds from the 
carboxyl group of 2 to the side chains of the P-loop residues Thr11 and Lys15, as well as an additional 
interaction to the amide backbone of Gly111.  
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2 mimics the phosphorylated reaction intermediate  
Compound 2 was observed bound to the MtDTBS DAPA pocket. Superposition with the 
structure of MtDTBS in complex with CTP and DAPA-carbamate (PDB ID: 6CVE) revealed 
that 2 replicates interactions exhibited by the biological substrates and the enzyme (Figure 
4.6A, B). The 2 carboxy group occupied a similar region to the γ-phosphate of CTP, 
replicating hydrogen bonding interactions to the side chain of Thr11 (2.36 – 2.71Å), Lys15 
(2.96 – 3.45Å), amide backbone of Gly111 (3.02 – 3.21Å), and several water molecules (side 
chain interactions depicted in Figure 4.6C). However, comparison to the structure of E. coli 
DTBS bound to a trapped reaction intermediate, revealed that the 2 carboxyl group more 
closely mimics the phosphate of the mixed carbamic phosphoric acid anhydride of DAPA, 
formed by phosphoryl transfer from ATP to DAPA-carbamate (Figure 4.6B; PDB ID: 
1DAK). The remainder of 2 binds to the hydrophobic DAPA pocket, with the pentane and 
aryl rings occupying the same region as the DAPA 8-amino group and alkyl chain 
respectively (Figure 4.6A, B). SPR measurements with 2 revealed it binds with weak affinity 
(KD = 3.4 ± 0.4 mM; Table 1; Appendix 2). This was also reflected by the requirement for 
high concentrations for the crystal soaking, as electron density for 2 was not observed in 
soaks using concentrations below 10 mM.  
 
2-series: chemical elaboration of 2  
Compound 2 contains several sites that were identified for manipulation in structure-activity 
relationship (SAR) studies (R1-4, Table 4.5). Initially, 3 was synthesized (Kwang Jun Lee, 
University of Adelaide), in which the phenol was replaced with a methoxy group at position 
R1. This did not noticeably affect affinity (KD = 3.4 ± 1.3 mM; Table 4.5), and in fact the 
increase in molecular mass resulted in a minor decrease in ligand efficiency (0.18 
kcal/mol/heavy atom). Accordingly, removal of this moiety completely (4) led to increased 
ligand efficiency (0.20 kcal/mol/heavy atom; molecule synthesized by Birgit Gaiser, 
University of Adelaide) despite a negligible affinity difference (KD = 3.5 ± 1.4 mM; Table 
4.5). A crystal structure of compound 4 in complex with MtDTBS revealed a similar binding 
pose to 2, with slight variation in one chain of the crystal structure (both poses in Figure 
4.7A). In Chain D, the electron density indicated that the ketone of 4 (R4) was rotated 
compared to 2, suggesting that this group has more conformational freedom in the absence of 
the R1 phenol group. It is therefore possible that intramolecular hydrogen bonding between 
these groups may rigidify the structure of 2. Whether or not this has an effect on the entropy 
of binding remains a future direction of this project; investigation of the optimal substituent 
here will require additional studies using higher affinity starting compounds.  
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2 OH CCOOH H C=O 3400 ± 400 4 0.19 
3  OMe CCOOH H C=O 3400 ± 1300 2 0.18 
3a  OMe C(COOH)2 H C=O 46 ± 2 3 0.27 
4  H CCOOH H C=O 3500 ± 1400 3 0.20 
5 H CCOOH COOH C=O 19 ± 5 3 0.32 
6 H CCOOH CCOOH C=O 17 ± 1 4 0.31 
7 H CCOOH COOH H 39 ± 2 4 0.29 




Compound 3a, an intermediate from the synthesis of 3, was also tested for its affinity to 
MtDTBS. This compound contained an additional carboxyl group at position R2, affording it 
a 74-fold improved affinity over 3 (KD = 46 ± 2 µM), and an improved ligand efficiency 
(0.27 kcal/mol/heavy atom; Table 4.5). Crystallographic investigation of the 3a-MtDTBS 
interaction revealed it adopted an analogous binding pose to 2, but with the additional 
carboxyl group hydrogen bonding with the side chains of Lys37 and Asn40, providing an 
explanation for the increase in affinity (3.0 – 3.3Å; Figure 4.7B). Lys37, in particular, is a 
residue involved in stabilizing the phosphorylated DAPA-carbamate, indicating that this 
substituent also mimics the reaction intermediate. However, the additional carboxyl was also 
proximal to the side chain of Asp49 (2.6 – 3.5Å), a residue known to coordinate Mg2+ during 
NTP binding (Thompson et al., 2018a) (Chapters 2, 3). This was an unexpected result as two 
negatively charged carboxyl groups would have been predicted to repel each other, and polar 
contacts were not predicted by MacPyMOL (Schrödinger). It was therefore hypothesized that 
these groups would coordinate Mg2+, which was present in the SPR running buffer during 
affinity measurement. However, when Mg2+ was included in the soaking experiment, this ion 
was not seen to coordinate 3a. While this result demonstrates that growing 2 towards the P-
loop region is a viable strategy to increase potency, the crystallographic data suggest that 
more optimal substituents at the R2 position may be employed to favourably interact with the 
side chain of Asp49. 
 
The R3 position on the aromatic ring of 2 and 3 superimposes well with C3 of the DAPA 
alkyl chain (Figure 4.6A, B, Figure 4.7C). This suggested that addition of a carboxyl group at 
R3 would mimic the interactions made between the DAPA carboxyl and residues Gly144, 
Leu146 and Asn147 on α6 of the adjacent MtDTBS subunit (2.7 – 3.0 Å; Figure 4.7C). The 
importance of this interaction site in MtDTBS is supported by the observation that SO42- 
bound to this region in the 2-MtDTBS structure, suggesting a propensity for binding to 
anions. Gratifyingly, incorporation of a carboxy (5; KD = 19 ± 5 µM) or carboxymethyl (6; 
KD = 17 ± 1 µM) group at the R3 position of 3 afforded a 184-fold increase in affinity for 
MtDTBS, and significantly improved ligand efficiency (Table 4.5). Minimal affinity 
difference was observed between a one or two carbon carboxyl substituent, however the 
smaller chain had marginally higher ligand efficiency (0.32 vs 0.31, Table 4.5). Crystal 
structures of MtDTBS bound to 5 or 6 each confirmed that these carboxy substituents 
mimicked the aforementioned DAPA interactions (2.7 – 3.4 Å; Figure 4.7D). Minimal 
structural differences were observed between 5 and 6, with the latter compound shifting 
slightly in its pose to accommodate the longer carboxymethyl moiety (Figure 4.7E).  
 
Another pair of carboxy (7; KD = 39 ± 1 µM) and carboxymethyl (8; KD = 56 ± 8 µM) 
analogues was produced, this time lacking the R4 ketone functionality. These compounds 
demonstrated that the ketone functional group provides at least a 2-fold increase in affinity 
for MtDTBS, while also providing additional confirmation that the R3 carboxy substitutions 
are important for binding. Crystal structures of 7 and 8 bound to MtDTBS reveal that the 
absence of the ketone does not alter the binding pose compared to molecules 5 and 6 (5 and 7 
shown in Figure 4.7F). In the crystal structure of 5 bound to MtDTBS, this ketone group 
forms a hydrogen bond to a water molecule (3.28 Å; chain A) that in turn hydrogen bonds to 
the R2 carboxy group of the compound (2.51 Å), as well as other ordered water molecules 
within the active site. It is possible that this interaction contributes to the increase in affinity 
observed in the presence of the ketone moiety. Altogether, these compounds constitute the 
successful replication of the interactions formed by DAPA within the binding pocket, as well 





Figure 4.7: X-ray crystallography during development of the 2-series. A. Overlay of 2 and 3 (green and blue 
sticks, respectively) reveals similar binding poses (top), except for chain D (bottom), where the ketone of 3 is 
rotated compared to 2. B. Binding pose of 3a (cyan sticks) overlaid with 2 (green sticks) in the MtDTBS active 
site (blue surface). 3a binds to the same P-loop residues (salmon surface, grey sticks) as 2, but the additional 
carboxyl group faces towards Asp49. The two carboxyl groups are arranged perpendicularly. C. The benzyl 
group of 2 (green sticks) overlays well with C3 of DAPA (black sticks) within the binding pocket (blue surface). 
DAPA forms hydrogen bonds to residues Gly144, Leu146 and Asn147 on α6 the adjacent subunit (α-helices 
depicted in Figure 4.2). D. Compound 5 (yellow sticks) mimics the DAPA binding pocket interactions 
previously described. E. Compounds 5 (yellow sticks) and 6 (pink sticks) have analogous binding poses, 
however the carboxymethyl group of 6 induces a slight conformational change compared to 5. F. Compound 7 
(orange sticks) does not contain the R4 ketone moiety, however it still adopts an essentially identical binding 
pose to 5 (yellow sticks). NB: in all cases, only the RS stereochemistry is shown for ease of interpretation. At 
the time of writing, the preferred stereochemistry of these compounds is unknown. 
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Testing 2-series compounds for inhibition of Mycobacterial growth  
Select compounds from the 2-series were tested for antibiotic activity against a 
Mycobacterium tuberculosis cell culture (Figure 4.8; performed by Gayathri Nagalingam, 
Laboratory of A/Prof Jamie Triccas, Department of Infectious Diseases and Immunology, 
University of Sydney). Here, Mtb growth in a biotin depleted media was measured in the 
presence of a range of compound concentrations. Despite the low-micromolar affinity of 
compounds 3a and 5-8 for MtDTBS, none inhibited the growth of M.tb strain H37Rv at 
concentrations up to 100 µM. It is unknown whether the compounds were able to enter the 
bacterium. However, it is likely that compounds with higher MtDTBS affinity will be 
required to inhibit Mtb. Considering the R2 carboxyl group of 2-series compounds occupies a 
similar region to the γ-phosphate of CTP, these ligands would likely compete with nucleoside 
triphosphates for binding to MtDTBS. As CTP exhibits a 100-fold higher affinity over the 
highest affinity compound in the 2-series (CTP KD = 160 nM), this ligand would likely 
outcompete any current 2-series compound bound to MtDTBS. This could be confirmed in 
the future, by determining enzyme inhibition by this compound series using the previously 




Figure 4.8: Testing the antibiotic effect of the 2-series against Mycobacterium tuberculosis strain H37Rv. 
Experimental work performed by Gayathri Nagalingam, Laboratory of A/Prof Jamie Triccas, Department of 
Infectious Diseases and Immunology, University of Sydney. A. Compounds 5-8 and 3a did not significantly 
inhibit the growth of the bacterium. An undisclosed synthetic intermediate of 2 was included as a negative 
control. B, C. Positive controls with the antitubercular drugs rifampicin and isoniazid (INH) demonstrated 
inhibition of Mtb.  
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4.3.4 Linked molecule development and optimisation 
 
MtDTBS is able to simultaneously bind both cytidine and 2  
Having identified optimised ligands for the cytidine and DAPA binding pockets, compound 
development efforts turned to the generation of linked molecules. Initially, as proof of 
concept, a crystal structure of MtDTBS in complex with both cytidine (CTN) and 2 was 
solved to 2.46Å. Both molecules retained their previously determined binding poses, and 
SO42- was bound to the LRLR nest within the P-loop, as found in previous structures (Figure 
4.10). This structure demonstrates that the MtDTBS active site is capable of simultaneously 
accommodating these compounds, suggesting that it may also be able to bind a compound 
consisting of CTN and 2 linked together. Consequently, efforts turned towards the 
development of an appropriate linker moiety for the conjugation of deoxycytidine and an 




Figure 4.10: A soak with both CTN (yellow sticks) and 2 (green sticks) yielded a crystal structure with these 
compounds bound in identical poses to those previously determined (CTN: grey sticks; 2: magenta sticks). This 
revealed that the MtDTBS binding site (blue surface) is able to accommodate both of these ligands 
simultaneously. SO42- was observed bound to the P-loop (salmon surface), as previously shown (PDB ID: 
4WOP; Chapters 3, 4). 
 
First and second generation linked molecules did not bind to the P-loop 
A first generation linked compound was synthesized using Cu-catalysed azide-alkyne click 
chemistry: an azide derivative of dCTN and an alkyne containing analogue of 2 were reacted 
to produce triazole-linked compound 9 (synthesized by Kwang Jun Lee, University of 
Adelaide; structure in Table 4.3). While SPR binding assays with this compound suggested 
higher affinity than the original substituents, a projection of the KD beyond the range of 
concentrations used in the assay was required due to solubility issues with the compound (KD 
= 600 ± 200 µM, n = 2, sensorgram in appendix 2; Compare to dCTN KD = >1 mM, 2 KD = 
3.4 mM). Consequently, this value could be subject to larger error than indicated, and 
conclusions from this should be cautious. This compound exhibited poor ligand efficiency, 
presumably owing to its high heavy atom count compared to its substituent compounds (39 
heavy atoms; LE = 0.11 kcal/mol/heavy atom). Conventional X-ray crystallographic 
techniques were unsuccessful in generating ligand complexed crystal structures, however, 
precipitant-ligand exchange with molecule 9 (crystallographic details in Materials and 
Methods) yielded a structure that contained reduced biased electron density in the active site 
(Polder, 3σ) that closely resembled the ligand (Figure 4.11A, B; 0.75 occupancy; 0.87 
PHENIX real-space correlation coefficient). Compound 9 was modelled using RS-2 
stereochemistry at the cyclopentane ring. While the dCTN moiety of this molecule bound in 
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the same pose observed previously, the 2-moiety differed slightly, presumably due to 
conversion of the R4 carboxyl group to an amide, abrogating several interactions with the 
MtDTBS active site and allowing accommodation of the linker moiety (Figure 4.11C, D; 
compare to Figure 4.6C). Interestingly, the triazole linker moiety did not bind to the P-loop, 
and instead was located away from the protein surface, around a SO42- ion bound at this 
position (Figure 4.11A). The carbonyl from the amide linkage was proximal to the side chain 
of Thr11 (2.72Å) and the SO42- (2.97Å), suggestive of intermolecular hydrogen bonding or 
electrostatic interactions. However, the electron density representing the linker moiety is less 
defined than that of the dCTN and 2 moieties (Figure 4.11B), suggesting that this region 
bound more dynamically. Consequently, it is possible that these observed hydrogen bonds are 
more transient. Nevertheless, the SPR and crystallography results suggest that the triazole 
linker moiety does not favourably interact with the P-loop. This could be a result of several 
structural features of the ligand, including but not limited to the length and chemical 
properties of the linker region.  
 
 
Figure 4.11: The binding mode of linked compound 9 to MtDTBS. A. 9 (grey sticks) binds to the MtDTBS 
active site (blue surface) above a sulfate ion (yellow sticks) that is bound to the P-loop (salmon surface). B. 
Compound 9 modelled into polder map electron density at 3σ. C. The dCTN moiety of 9 (grey sticks) overlays 
well with CTN (yellow sticks). D. The 2-moiety of 9 exhibits conformational differences from the original 2 
binding pose (green sticks), presumably due to the replacement of the R2 carboxyl group to form the amide bond 
to the linker. In compound 2, this carboxyl group formed hydrogen bonds with residues Thr11, Lys15 and 
Gly111 in the MtDTBS active site.  
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The SPR and X-ray diffraction data suggest that the neutral triazole moiety did not interact 
with the LRLR nest within the P-loop, which has been shown to have a binding preference 
for anionic compounds (Chapters 2, 3). A second generation linked compound 10 was 
synthesized containing a glutamic acid linker moiety (Kwang Jun Lee, University of 
Adelaide; structure in Table 4.3). This compound contained dCTN conjugated to the glutamic 
acid side-chain, and 6 conjugated to its amine group via an amide bond. The free carboxyl 
moiety of the glutamic acid linker was hypothesised to bind to the LRLR nest within the P-
loop. When combined with the presence of a carboxymethyl group at the R4 position of 6, 
this compound was expected to have higher affinity for MtDTBS than triazole linked 
compound 9. However, SPR binding experiments with 10 revealed the binding affinity and 
ligand efficiency of the two compounds were similarly low (KD = 700 ± 200 µM vs 600 ± 
200 µM for 9; LE = 0.10 kcal/mol/heavy atom vs 0.11 kcal/mol/heavy atom for 9). The 
affinity of 10 was ~40-fold weaker than 6 itself. X-ray crystallographic investigation by 
traditional soaking methods revealed electron density that displayed a similar binding pose to 
9, wherein the dCTN and 6 moieties adopted poses similar to those previously observed, but 
the linker moiety bound adjacent to the crystallographic precipitant, citrate (Figure 4.12A-D; 
0.69 occupancy; 0.862 PHENIX real-space correlation coefficient). Here, electron density for 
the glutamic acid linker moiety was weaker than that for the dCTN and 6 substituents, 
indicating that it did not possess a single, stable conformation but was instead disordered 
(Figure 4.12B). The SPR and X-ray crystallographic data show that using glutamic acid as 
the anionic linker moiety to conjugate dCTN and 6 did not improve binding over the triazole 
linked compounds. Considering that both of these linked molecules are able to bind adjacent 
to the crystallographic precipitant at the P-loop, the length of the linker moiety may need to 






Figure 4.12: The binding pose of 10 (grey sticks) in the MtDTBS active site (blue and salmon surface). A. Like 
9, 10 exhibits a binding pose adjacent to the crystallographic precipitant, in this case citrate (yellow sticks), but 
the dCTN and 6 moieties bind to the cytidine and DAPA binding pockets respectively. B. Polder electron 
density for 10 is strong (3σ; grey mesh) for dCTN and 6 but weak (1σ; cyan mesh) for the glutamic acid linker 
moiety, suggesting it has a less stable conformation, and may bind in a more disordered manner. C. Overlay of 
10 with crystal structures of dCTN (cyan sticks) and 6 (magenta sticks) individually. The dCTN and 6 
substituents of 10 bind to similar regions to these individual compounds. Similar to compound 9, the 6 
substituent on 10 differs in its pose, presumably due to the modification of the R2 carboxyl group during 




4.4  Discussion and Future Directions 
 
4.4.1 Investigation into the cytidine binding pocket 
 
The crystallographic screening of the cytidine analogues revealed several key points 
regarding the nature of the cytidine binding site. Firstly, the absence of structures of MtDTBS 
bound to alternate nucleosides and nucleoside analogues containing varied base moieties 
provides additional confirmation that the cytidine binding site has evolved to be highly 
specific for the cytosine base. However, the use of crystal soaking and X-ray crystallography 
in this circumstance could bias these observations towards the energy minimized states of the 
protein structures that form the cytidine binding site. It is possible that, in solution, the 
cytidine binding site is more flexible and could undergo conformational changes which 
would allow it to accommodate alternate scaffolds. Experiments to investigate this could 
include solution-based ligand-protein interaction detection techniques such as heteronuclear 
single quantum coherence nuclear magnetic resonance (HSQC NMR). Here, MtDTBS would 
be labelled with 15N, allowing for the observation of the chemical environment of each 
nitrogen atom within the enzyme. Spectra would be recorded in the absence and presence of 
cytidine, generating a pattern of residues that it interacts with in the binding site. By 
comparing these spectra to those determined in the presence of alternate nucleosides and 
nucleoside analogues, it would be possible to ascertain whether or not such compounds bind 
to the cytidine binding site residues. A concern with the use of HSQC NMR is that spectrum 
quality is generally inversely proportional to protein molecular weight. The MtDTBS 
homodimer has a molecular weight of 47 kDa in solution, which could prove problematic for 
this technique. Initial attempts to obtain HSQC NMR spectra did reveal observable and 
distinguishable peaks (data not shown). However, optimisation efforts were focussed on SPR 
and X-ray crystallography in the current project. Nevertheless, this does indicate that 
optimisation of HSQC NMR to study MtDTBS in future projects is feasible. 
 
Crystallographic screening also determined that the cytidine binding pocket is able to 
accommodate structural differences at the 2ʹ position on the ribose ring of cytosine containing 
nucleosides. Crystal structures were determined with dCTN and dFdC, containing 
unsubstituted 2ʹ and 2ʹ-difluoro moieties respectively, compared to the 2ʹ-hydroxy group of 
CTN. The ability to accommodate variations at the ribose ring may be due to the relatively 
solvent exposed nature of the MtDTBS cytidine binding site, as discussed in Chapter 3. The 
2ʹ ribose position is located adjacent to hydrophobic residues, which may interact 
unfavourably with the hydrophilic 2ʹ-hydroxy moiety. This provides a possible explanation 
for the decreased association rate and lower affinity observed for 2ʹ-hydroxy containing 
nucleotides. While the effect of the 2ʹ-difluoro substitution was not determined, it could be 
investigated in the future through SPR binding affinity assays with the pharmacologically 
active triphosphate form (dFdCTP) (Alvarellos et al., 2014). It is hypothesized that, due to 
the hydrophobic nature of C-F bonds, the 2ʹ-difluoro substituent may also interact favourably 
with the hydrophobic residues. Comparison to dCTP and CTP would be useful for future 
inhibitor development. Further exploration of the 2ʹ ribose site, as well as the ribose binding 
site as a whole, may reveal alternate functional groups that result in even higher binding 
affinity. A final consideration is that incorporation of fluorines in therapeutics has a number 
of pharmacological benefits such as improved metabolic stability and membrane permeability 




By assaying the di- and triphosphate counterparts of dCTN with SPR, it was determined that 
proton substituents at the 2ʹ site were preferred by MtDTBS over the hydroxy group. This 
finding invites further investigation into MtDTBS NTP utilization in a biological setting, as it 
is possible that dCTP is the catalytically preferred substrate in vivo. The likelihood of this 
depends on the concentrations of the nucleoside triphosphate pools available to MtDTBS at 
varying stages of the Mtb lifecycle, a factor that is currently unknown, as well as 
confirmation of the presumed utility of dCTP in the enzyme reaction. The latter could be 
determined using the previously established MtDTBS enzyme activity assay (Salaemae et al., 
2015). Performing this assay in the presence of a mixture of NTPs at biologically relevant 
relative concentrations and observing the relative rates of substrate utilization (e.g. by LC/MS 
and or NMR) would reveal valuable insight into the in vivo substrate promiscuity of 
MtDTBS. 
 
4.4.2 In silico fragment hit investigation: discovery and SAR of compound 2 
 
The discovery of degradation product 2 as a ligand of MtDTBS was an improbable and 
serendipitous circumstance. It highlights the utility of the model provided by X-ray 
crystallography in the drug discovery process, as it is likely that 2 would not have been 
discovered without use of this technique to investigate the in silico hits. This discovery also 
highlights the importance of using orthogonal techniques in screening processes; not only to 
investigate preliminary hits, but also to confirm their molecular structures, a sentiment that is 
echoed in the literature (Davis and Erlanson, 2013). However, this compound constitutes a 
single confirmed hit from a screening campaign and its importance should not be 
overemphasized. Given the ability of the largely hydrophobic MtDTBS DAPA pocket to also 
accommodate the adenosine moiety of ADP (Chapter 2), the DAPA binding site, and indeed 
the whole of the active site, should be probed with additional fragment screening campaigns, 
using techniques such as SPR, thermal shift assay (TSA) or saturation transfer difference 
NMR (STD-NMR). Identifying alternate chemical scaffolds that bind to various regions of 
the MtDTBS active site would increase the capacity to merge, grow or link fragments 
towards efficient, high affinity inhibitors of the enzyme and M. tuberculosis.   
 
The utility of 2 lies in the possibility for chemical modification to probe the MtDTBS active 
site. Initial SAR concerned position R1, where little affinity difference was observed by SPR 
between proton, hydroxyl and methoxy substituents, primarily due to the weak affinity 
observed for these compounds. While a proton substituent in this position was utilized for the 
development studies outlined in this chapter, affinity differentiation between substituents at 
this position is still required. This could be achieved by assaying the affinity of R1 variants on 
a higher affinity scaffold, such as 5 or 6, akin to the SAR carried out at the R4 position. It is 
hypothesized that the hydroxyl R1 substituent may stabilize the compound through 
intramolecular hydrogen bonding with the R4 ketone, increasing the affinity by reducing the 
entropic penalty upon binding (Andrews et al., 1984; Chang et al., 2007). Similarly, the 
preferred stereochemistry of the 2-series ligands remains unknown. This could be determined 
by SPR binding assays with each stereoisomer (SS/RR/SR/RS) using higher affinity 
analogues that are able to be physically separated. When assaying higher affinity compounds 
the results become more precise, leading to an increased ability to confidently distinguish 
affinities. In doing so, SAR of the 2-series compounds can be performed more rigorously in 
order to determine the optimal substituents at positions R1-4. 
 
The binding mode of 2 was compared to the biological substrates of MtDTBS to guide further 
compound development. The addition of carboxy and carboxymethyl substituents to position 
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R3 to form 5 and 6 successfully replicated interactions that DAPA makes within its binding 
site, greatly increasing the affinity of these compounds. This was a highly promising result, 
and definitively demonstrates the potential for structure-guided compound development 
against the MtDTBS target. This also implies that replication of interactions between anionic 
species and the LRLR nest is feasible and is likewise predicted to substantially improve 
binding affinity. As shown in chapters 2 and 3, this region within the P-loop exhibits 
extremely high affinity for anionic species and replicating such interactions would likely 
result in a significant increase in the affinity of potential inhibitors. Indeed, the carboxy at 
position R2 of compound 2 bound to some P-loop residues, as well as those that are involved 
in the stabilization of the phosphorylated DAPA-carbamate reaction intermediate (observed 
in PDB ID: 1DAK)(Käck et al., 1998). Compound 3a, with a dicarboxy substituent at R2, was 
thought to bind to additional P-loop residues but instead exhibited hydrogen bonding with 
additional residues that stabilized the reaction intermediate. This was another promising 
result, leading to a large increase in affinity for 3a over 3. Mimicking enzyme transition 
states has been documented as a successful method of drug discovery (Schramm, 2018) and 
is a method of compound progression that should be considered for the development of 
inhibitors from the 2-series.  
 
There are clear opportunities for increasing the affinity of 2-series molecules to MtDTBS. 
Firstly, combining the dicarboxy substituent of 3a (~70-fold improvement over 3) with the 
carboxy or carboxymethyl substituents present in 5 and 6 (~200-fold improvement over 2) 
could greatly increase affinity for MtDTBS. It is hypothesized that this could result in as 
large as a 14,000-fold improvement in affinity, leading to a predicted KD of ~200 nM. 
Precipitant-ligand exchange revealed that the additional carboxyl group of 3a was most 
proximal to the side chain of Asp49 (2.6 – 3.5Å compared to 3.0 – 3.5Å for Lys37 and 
Asn40). Replacing this carboxyl group with a positively charged substituent such as an 
amidine or guanidine (Greenhill and Lue, 1993) could possibly increase the affinity of 3a as a 
result of interaction to the negatively charged Asp49 side chain, even if interactions to the 
Lys37 and Asn40 were lost. However, the charged nature of amidine and guanidine groups 
may lead to undesirable pharmacological properties, and aspartate-binding groups used in 
BACE1 inhibitors such as aminohydantoin, aminooxazoline, or aminothiazoline may be 
preferable (Coimbra et al., 2018). Ideally, a functional group that is capable of binding to the 
Asp49 in addition to the Lys37 and Asn40 would be used, resulting in a highly efficient 
compound. Finally, further fragment growing into the P-loop to interact with the LRLR nest 
should be considered, as it could potentially lead to extremely large increases in affinity. 
Currently, chemical modification of 2 has resulted in a ~180-fold increase in affinity, which 
is a highly promising start to the hit to lead development process and provides a solid 
foundation for further compound development endeavours.  
 
4.4.3 M. tuberculosis inhibition 
 
There are several possible explanations for the failure of 2-series compounds to inhibit Mtb 
growth in a culture based assay. The Mtb cell wall consists largely of mycolic acids, a 
component which is thought to contribute to virulence and to impede cell penetration by 
drugs, especially those that are hydrophilic (Lambert, 2002; Takayama et al., 2005). 
Rifampicin, a clinically used antibiotic for the treatment of TB and a positive control in the 
reported assay, is relatively hydrophobic, enabling it to cross the mycolic acid barrier and 
inhibit the bacterium. Smaller and more hydrophilic TB drugs such as isoniazid (INH in the 
Mtb assay), pyrazinamide and ethambutol are thought to traverse the mycobacterial cell wall 
through membrane bound porin proteins, which exhibit low rates of uptake (Lambert, 2002; 
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Masi et al., 2017). The most potent compounds from the 2-series each contain 2 anionic 
carboxylic acid groups, increasing the polarity and hydrophilicity of these compounds and 
making traversal of the cell wall barrier most likely to occur through similar porin structures. 
Considering that the maximum concentration used in the Mtb inhibition assay was 100 µM, it 
is likely that the concentration of 2-series compound within the cell would be even less. 
Furthermore, given that the affinity difference between the substrates CTP or dCTP and 6, 
the highest affinity 2-series molecule, is >100-fold, it is possible that these compounds would 
have been outcompeted for binding to MtDTBS. In order to determine if this is the case, the 
efficacy of MtDTBS inhibition by 2-series compounds should be tested in an enzyme activity 
assay. While providing a possible explanation for the lack of inhibition observed, this also 
indicates that higher affinity MtDTBS binding compounds will be required in order to 
achieve successful inhibition of the mycobacterium.  
 
The pharmacological properties of 2-series compounds should also be modified in order to 
increase permeability through the mycobacterial cell wall and result in a higher concentration 
within the cell. This may include increasing lipophilicity in order to allow diffusion through 
the mycolic acid barrier, as observed with rifampicin. However, factors such as solubility, 
size, bioavailability as well as other pharmacokinetic parameters should be taken into 
consideration. One such improvement on the current 2-series molecules could be to replace 
existing carboxylic acid groups with more drug-like moieties such as the tetrazole. Tetrazoles 
have similar pKa values to carboxylic acids but exhibit higher lipophilicity due to the 
delocalization of electrons around the ring (Myznikov et al., 2007). Consequently, tetrazole 
containing compounds could retain interactions to the positively charged residue backbones 
such as those seen between 2-series molecules and the P-loop or the DAPA pocket, while 
potentially resulting in an increased ability to traverse the mycobacterial cell wall. Indeed, 
tetrazole containing compounds have been reported in antifungal compounds (Lockhart et al., 
2016; Warrilow et al., 2014). Ideally, tetrazole substitution would retain the binding affinity 
of 2-series compounds, whilst increasing their drug-like nature, however, it is possible that 
interactions will not be fully retained and affinity for MtDTBS may decrease. Future studies 
hoping to simultaneously optimise affinity and pharmacological through the use of 
substitutions such as the tetrazole should monitor the affinity and inhibition of both enzyme 
and mycobacterium for each compound.  
 
4.4.4 Linked molecule development  
 
The identification of ligands bound to each pocket of the MtDTBS active site encouraged the 
development of a linked compound with potentially super-additive affinity. The two 
synthesized linked compounds 9 and 10 showed the potential of this approach, as the dCTN 
and 2-series substituents were found to bind to MtDTBS by X-ray crystallography, adopting 
similar poses to those previously determined. Given this, it was expected that the compounds 
would bind with higher affinity than their substituent molecules. While this appeared to be 
the case for 9, it was not for 10. This could be because X-ray crystallography provides a static 
model, which can be different from what occurs in solution (Davis and Erlanson, 2013). This 
is particularly pronounced when observing dynamic phenomena. Consequently, the structures 
with 9 and 10 may not be fully representative of the protein-ligand interaction that is 
observed in solution by SPR. For example, it may be that low affinity was determined by 
SPR because the dCTN and 2-series moieties of the linked compounds do not simultaneously 
bind to the MtDTBS active site in solution. Additionally, precipitants were observed bound to 
the P-loop in the crystal structures, but were not present in the SPR experiments to determine 
affinity. In the crystallography, it is possible that the precipitant molecules aided in providing 
 86 
order to the MtDTBS active site by binding to the P-loop, or interacted with the linker itself 
and stabilized the observed binding mode. To test this hypothesis in solution, SPR ligand 
binding was attempted with precipitants present, however these compounds appeared to bind 
non-specifically to the sensor surface, presumably due to their charged nature (data not 
shown). This hindered analysis of the effect that precipitants have on linked compound 
binding in solution, inviting further investigation by orthogonal methods such as HSQC 
NMR. Nevertheless, the current crystallographic and SPR results together reveal several 
options for future development of linked compounds. 
 
Despite occupying a similar region at the DAPA pocket, the binding mode of the 2-series 
substituent of the linked molecules differed slightly compared to that observed for 
compounds 2-8. This was most likely a consequence of abrogation of the hydrogen bonds 
between the R2 carboxyl group and residues Thr11, Lys15 and Gly111; the interactions that 
mimic the reaction intermediate demonstrated previously (PDB ID: 1DAK)(Käck et al., 
1998). In both linked compounds, this group was converted to an amide during conjugation 
to the linker moiety, and subsequent geometric rearrangement of this region prevented the 
same hydrogen bonds from being retained. In the future, linkers should aim to retain these 
hydrogen bonds, possibly by conjugating through one of the two carboxyl groups at position 
R2 in compound 3a. This may be difficult due to their structural similarity, and care must be 
taken to singly protect one carboxyl to ensure that this is done selectively. In order to ensure 
that linked compounds are highly efficient, the investigation of additional and alternative 
means to conjugate the linker to the 2-series compounds will be required. 
 
The composition of the linker moiety is a crucial component to future compound 
development. The similar affinities observed between compounds 9 and 10 indicate that the 
triazole linker may in fact be preferable to the glutamic acid linker. Compound 10 was 
expected to have higher affinity not only due to the linker moiety, but also because of the 
inclusion of 6, which exhibited the highest affinity for MtDTBS owing to the presence of the 
R3 carboxymethyl. By comparison, 9 contained the original compound 2 that does not 
possess a R3 carboxyl substituent, yet bound with comparable affinity to 10. This suggests 
that the glutamic acid linker may negatively affect binding, possibly owing to factors such as 
geometry, flexibility and strain of the linker (Chung et al., 2009). Indeed, the linker moiety of 
10 contains multiple rotatable bonds, affording it more conformational flexibility than the 
more rigid and planar triazole linker of 9. Thus, there is likely to be a smaller entropic penalty 
upon binding for 9, whereas 10 may encounter a large penalty for the loss of rotational and 
translational entropy (Andrews et al., 1984). These factors can be difficult to distinguish 
using the static crystallographic model, however it is clear that the electron density 
representing the glutamic acid linker was very weak compared to the rest of the molecule, 
suggesting that it did not adopt a stable binding pose. This was also reflected in the high B-
factors for the glutamic acid linker moiety compared to the rest of 10 and also MtDTBS 
residues (B-factors: 10-linker = ~40-55, 10 average = 37, MtDTBS average = 39). In order to 
determine whether the triazole exhibits more preferable characteristics as a linking moiety, a 
compound consisting of dCTN linked to 6 by a triazole moiety should be synthesized and 
tested for binding. However, the neutral triazole linker is not expected to interact with the P-
loop. Given that LRLR nest in particular is known to exhibit extremely high affinity for 
anionic compounds, other linker moieties should be investigated to replicate these 
interactions. One such example would be the use of an aspartic acid linker, which would 
reduce the linker by one carbon compared to glutamic acid. This may exhibit different 
geometry, possibly constraining the linker towards the P-loop, encouraging interactions with 
the LRLR nest. If successful, this would be expected to result in a large increase in affinity. 
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Finally, as with the development of the 2-series, the pharmacological and pharmacokinetic 
properties of future linked molecules should also be carefully observed and optimised, such 
that permeability of the Mtb cell wall is possible. 
 
4.4.5 Concluding remarks 
 
There are countless options for future development of compounds to bind MtDTBS with high 
affinity. The work presented here constitutes the beginning of the optimisation process, and it 
is intended that the reported data will be used to guide future compound development. The 
most useful information provided is the optimisation and use of the methodologies for 
biophysical and structural investigation of MtDTBS ligand binding. Using this information, 
synthesized compounds can be rapidly and accurately assessed by orthogonal assays in future 
studies. This will be an iterative and collaborative process that shows promise for the 
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5.1 Antibiotic development through new pathways and techniques 
 
It is clear that significant investment and development is required to combat the rise in 
antibiotic resistance, as this phenomenon has the potential to become a global human health 
crisis. In the current project, the biotin biosynthesis enzyme MtDTBS was identified as a 
promising target for the development of antibiotics to treat drug resistant Tuberculosis. This 
is a notoriously difficult process, spurring the adoption of innovative methods of drug 
discovery, as discussed in the introduction (Lamoree and Hubbard, 2018; Tommasi et al., 
2015). Here, the emerging technique fragment-based lead discovery (FBLD) was employed 
to identify and develop compounds that bind to MtDTBS with high affinity. In accordance 
with the ethos that a fundamental understanding of the characteristics of a drug target will aid 
inhibitor development, the Booker laboratory had already begun to investigate the 
biochemical nature of MtDTBS catalysis. It was determined that, uniquely, MtDTBS was 
able to utilize multiple nucleoside triphosphates (NTPs) to catalyze its reaction (Salaemae et 
al., 2015). However, the biophysical and structural mechanisms by which MtDTBS was able 
to promiscuously bind NTPs were unknown. Consequently, structural and biophysical 
investigation of these mechanisms constituted a major part of this thesis. Throughout the 
investigation of this mechanism it was observed that X-ray crystallography of MtDTBS in 
complex with ligands was hindered by the presence of crystallographic precipitants within 
the active site. Precipitant-ligand exchange was developed to overcome this issue, and was 
deemed of use to the crystallographic community (published in Acta Crystallographica 
Section D). Using this technique to determine structures of MtDTBS in complex with NTPs 
revealed insight into the promiscuity mechanism that was of interest to the catalysis field 
(published in ACS Catalysis). Together, these articles contributed to understanding the ligand 
binding characteristics of MtDTBS, and aided the decision-making process in regard to the 
FBLD compound identification and development presented in Chapter 4. It is hypothesized 
that this information, particularly that regarding the characteristics of the phosphate binding 
loop (P-loop) will be useful in the future development of inhibitors against MtDTBS. In this 
discussion, precipitant-ligand exchange will be discussed initially, as it was an enabling 
technique for many of the results in this thesis. Following this, the structural and biophysical 
characterisation of MtDTBS ligand binding will be summarised and discussed with regard to 
the literature, followed by discussion regarding the use of this information for guiding 
compound development.  
 
5.2  Precipitant-ligand exchange is an enabling technology 
 
During the structural investigation of MtDTBS, it became apparent that the P-loop was 
binding to the anionic crystallographic precipitants sulfate and citrate. This issue was 
exacerbated by the high precipitant concentration used in the crystallization condition (1.0 - 
1.5 M sulfate; 0.7 M citrate). By transferring crystals into a solution that contained the ligand 
of interest in place of the precipitant, several key ligand-complexed crystal structures of 
MtDTBS were solved. The development of this technique was crucial to many of the results 
presented in this thesis. It is hypothesized that this technique will also be of use to the wider 
crystallography community. X-ray crystallography is the most widely used structural biology 
technique, contributing 130,743 of the 146,093 (89%) structures deposited in the Protein Data 
Bank (PDB) at the time of writing (November 2018). Of the X-ray crystallography structures 
deposited in the PDB, 18,089 (14%) contain a sulfate ion, constituting the most commonly 
modelled free ligand in the PDB. Incidentally, the P-loop, which bound the sulfate ion, was a 
major focal point for both the investigation of the MtDTBS NTP binding characteristics, as 
well as for the future of compound development. It is therefore possible that crystallographic 
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precipitants have prevented the atomic resolution investigation of other important interactions 
observed in proteins throughout the proteome. Consequently, precipitant-ligand exchange is 
intended to be of use to crystallographic researchers throughout the world. 
 
5.3  Structural and biophysical characterisation of MtDTBS natural ligand binding 
 
5.3.1 MtDTBS exhibits a unique mechanism of NTP promiscuity in catalysis 
 
Here, MtDTBS NTP promiscuity will be briefly summarised, followed by a discussion of this 
finding in regard to the wider literature. Prior to the work presented in this thesis, MtDTBS 
was known to promiscuously utilize nucleoside triphosphates (NTPs) for catalysis. However, 
the mechanism was unknown. In Chapter 3, surface plasmon resonance (SPR) and X-ray 
crystallography were used to determine that MtDTBS alternates between two NTP binding 
modes. Cytidine triphosphate (CTP) binds in a high affinity binding mode, forming a 
complex that dissociates slowly as observed by SPR. X-ray crystallographic structural data 
for this interaction revealed strong electron density representing the entirety of the ligand, 
and hydrogen bonding was observed between the cytosine moiety and the enzyme. All other 
NTPs tested against MtDTBS by SPR revealed fast association and dissociation rates, with 
similar affinities regardless of the varying nucleoside. X-ray crystallographic investigation of 
these NTPs exhibited significantly stronger electron density for the triphosphate moiety than 
the nucleoside. This lead to the conclusion that ligands binding in the promiscuous binding 
mode were predominantly ‘anchored’ to MtDTBS through the interaction between the P-loop 
and the triphosphate, while the nucleoside moiety was less ordered. This binding mode was 
visualized through the use of molecular dynamics simulations. Finally, the binding affinity 
contribution of the triphosphate moiety was quantified, with the interaction between the β-
phosphate and a moiety within the P-loop known as the LRLR-nest exhibiting extremely high 
affinity. Together, these results demonstrate that MtDTBS can promiscuously utilize NTPs 
through dual binding modes, both of which are governed by similar, high affinity interactions 
between the P-loop and triphosphate tail. 
 
The mechanism of NTP promiscuity observed for MtDTBS has not been observed in 
homologous enzymes from other bacteria. In structurally characterized DTBS enzymes, 
differences in the nucleoside binding pockets and P-loops may provide possible explanations 
as to the unique nature of the MtDTBS catalytic mechanism. These were briefly summarised 
in chapter 3, and will be discussed in more detail and with regard to available biophysical and 
biochemical data. We have previously demonstrated that Escherichia coli DTBS (EcDTBS) 
has a more than 100-fold catalytic preference for ATP over CTP and GTP, and cannot use 
ITP, UTP or TTP to carry out its reaction (Salaemae et al., 2015). Structures of EcDTBS 
bound to ATP reveal electron density corresponding to the entire ATP molecule (PDB ID: 
1A82), implying a single, stable conformation akin to CTP-MtDTBS. This conformation 
involved hydrogen bonding between adenine and the sidechain of Asn175. The spatially 
equivalent amino acid in MtDTBS is a glycine, which is unable to support the same side 
chain interaction. Crystal structures have also been determined for the Helicobacter pylori 
DTBS (HpDTBS) in complex with both ATP (PDB ID: 3QXC) and GTP (PDB ID: 3QXX), 
although binding affinities for these ligands were not reported (Porebski et al., 2012). The 
HpDTBS structures also reveal interactions between the nucleoside and Asn175, but different 
contacts are made between the two purines and HpDTBS. This method of promiscuity is 
clearly distinct from the mechanism described for MtDTBS, where interactions between 
promiscuous nucleosides and the enzyme were not observed. Furthermore, the nucleoside 
electron density in these other DTBS structures was well-defined, indicating that binding 
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occurs in a single conformation. The absence of a hydrogen bonding partner in MtDTBS 
equivalent to Asn175 is a plausible explanation as to why MtDTBS was not observed to bind 
the nucleoside of ATP or other NTPs. An alternative explanation arises from the observation 
that EcDTBS also binds the ATP ribose through hydrogen bonding with residue Glu211, 
another residue that is not present in MtDTBS. The absence of hydrogen bonding between 
DTBS and the nucleoside ribose sugar may allow for the nucleoside conformational 
flexibility that was observed in the ensemble refinement of ATP-MtDTBS (chapter 3). 
Interestingly, an equivalent of the hydrogen bond between EcDTBS Glu211 and the 
nucleotide ribose is not present in HpDTBS. Assessment of HpDTBS nucleotide specificity 
would therefore be useful for clarifying the role of this interaction. An additional feature that 
may contribute to the promiscuity mechanism of MtDTBS is sequence variation in the P-
loop. The MtDTBS (Gly-Thr-Gly-Thr-Gly-Val-Gly-Lys-Thr), EcDTBS (Gly-Thr-Asp-Thr-
Glu-Val-Gly-Lys-Thr), HpDTBS (Ala-Thr-Asn-Thr-Asn-Ala-Gly-Lys-Thr) and Francisella 
tularensa DTBS (Gly-Thr-Asp-Thr-Glu-Val-Gly-Lys-Thr) all share a Gly-Lys-Thr motif 
(bold text) (Porebski et al., 2012). MtDTBS possesses a Gly12, but the equivalent residues 
(Glu, Asn; underlined text above) from other DTBS are larger and more charged. It is 
hypothesized that these residues may sterically prevent the promiscuous binding mechanism 
observed with MtDTBS.  
 
Examples of non-homologous enzymes that exhibited NTP promiscuity identified in the 
literature differed from MtDTBS, suggesting the mechanism described in chapter 3 is unique. 
Nucleoside diphosphate kinase (NDK), a phosphotransferase, can bind ADP and TTP (PDB 
IDs: 1KDN and 1NDC respectively)(Xu et al., 1997). Inspection of these crystal structures 
revealed that NDK binds the aromatic purine and pyrimidine heterocycles through π-π 
stacking interactions with the side chain of a phenylalanine. Here, the defined interactions 
between enzyme and nucleoside differentiate NDK promiscuity from that of MtDTBS. The 
helicase domain from the bacteriophage T7 replicative helicase-primase is able to hydrolyze 
several NTPs, however, only dTTP  and dATP confer helicase activity (Satapathy et al., 
2009; Sawaya et al., 1999). In crystal structures with these ligands, dTTP was modelled into 
minimal electron density compared to dATP (PDB ID: 1CR1 and 1CR2 respectively). This is 
similar to the differences between the high affinity and promiscuous binding modes of 
MtDTBS; CTP was modelled into complete electron density, while only electron density for 
the triphosphate was observed for the remaining NTPs. Interestingly, the P-loop in the 
bacteriophage T7 replicative helicase-primase is structurally similar to MtDTBS, and is 
bound to a sulfate ion in the structure devoid of NTP (PDB ID: 1CR0). Unlike MtDTBS, 
however, amino acid residues bind to the nucleoside moiety to govern specificity (Satapathy 
et al., 2009). Nucleoside triphosphate diphosphohydrolase isoforms NTPDase1 and 
NTPDase3 from Toxoplasma gondii also differentiate between ATP and ADP substrates 
through altered binding modes (Krug et al., 2013). Structures of NTPDase1 in complex with 
non-hydrolysable analogues of ATP (AMPPNP; PDB ID: 4KH4) and ADP (AMPNP; PDB 
ID: 4KH5) revealed some structural data similar to that observed for the promiscuous 
MtDTBS binding mode, indicated by ligand density solely for the ligand polyphosphate 
(present in chain A). However, unlike MtDTBS, the alternate subunit (chain B) contained 
electron density pertaining to the full ligand in both structures, suggesting that this may be 
due to the other factors, such as the accessibility of chain A due to the crystal packing. 
Interestingly, NTPDase1 does not bind the triphosphate moiety with a P-loop structure. 
Finally, protein kinase PKR is activated by RNA containing a 5ʹ-triphosphate moiety, 
irrespective of the RNA sequence (Toroney et al., 2012). This ability appears similar to the 
promiscuous binding mode for MtDTBS, where NTPs are bound by the 5ʹ-triphosphate, 
irrespective of the structure of the nucleoside. Therefore, atomic investigation into the 
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mechanism of RNA triphosphate binding may reveal further comparative insight to the 
MtDTBS NTP promiscuity mechanism. These select examples detail several similarities to 
the biophysical capabilities and observed structural data for MtDTBS, including NTP 
promiscuity, alternate binding modes, the observation of weak nucleoside density in the 
crystallography data and promiscuity enabled by the binding of a common triphosphate 
moiety. However, the stark contrast between the alternating binding modes and the nature of 
crystallographic data observed for the promiscuous binding mode appear to be unique to 
MtDTBS.  
 
5.3.2 Future directions for the investigation MtDTBS promiscuity 
 
Further investigation into the nature of MtDTBS promiscuity would benefit from the use of a 
technique that observes dynamic phenomena. As mentioned in chapter 4, X-ray 
crystallographic models are a static snapshot which can differ from what occurs in solution 
(Davis and Erlanson, 2013). While this technique was crucial to the investigation of MtDTBS 
promiscuity, there may be further insights that were not observed. X-ray crystallography 
requires the formation of ordered protein crystals, which is governed by intermolecular 
interactions between proteins. This is known as crystal packing, and can prevent 
conformational changes and also result in conformations distinct from those in solution 
(Davis and Erlanson, 2013). It is possible that the MtDTBS active site is more dynamic in 
solution and crystal packing restricted this conformational freedom, preventing the 
observation of specific nucleoside-protein contacts for NTPs binding in the promiscuous 
binding mode. The SPR data determined that these NTPs exhibited similar affinities despite 
structural differences, supporting that binding occurred predominantly through the 
triphosphate tail that is common to all NTPs. However, the affinities of promiscuous NTPs 
did vary (KD 16.5 – 93 µM; Chapter 3), suggesting that there were further protein-ligand 
interactions which contributed to binding but were unobserved. One possible method to test 
this would be to employ heteronuclear single quantum coherence NMR (HSQC-NMR), as 
discussed in Chapter 4. Briefly, proteins can be labelled with 15N, enabling the observation of 
each nitrogen atom present, including the peptide backbone and certain side chains. Upon 
ligand binding, the chemical environment of surrounding nitrogens is changed, producing a 
measurable effect. Therefore, by comparing HSQC-NMR spectra of MtDTBS in the absence 
and presence of a ligand, it is possible to determine which residues the ligand interacts with. 
Subsequently, one could compare the difference between spectra of MtDTBS in the presence 
of CTP and adenosine triphosphate (ATP), for example, to determine if these ligands interact 
with similar residues. Consequently, interactions additional to those between the triphosphate 
tail of ATP and the P-loop could be observed, revealing whether there are specific 
nucleoside-protein interactions that were unable to be observed by crystallography.  
 
An alternate method to further investigate MtDTBS NTP promiscuity would be to identify 
alternate crystallization conditions that resulted in crystals with different packing. These 
would most likely require precipitants other than SO42- or citrate. It is hypothesized that, upon 
binding to the P-loop of MtDTBS, these precipitants structurally stabilise this region, which 
either encourages or allows the formation of the crystal packing interactions. This is based on 
the observation that MtDTBS crystals rapidly degraded when transferred from a precipitant-
containing solution to one devoid of a ligand that could bind at the P-loop, suggesting that 
loss of precipitant leads to a loss of crystal stability, possibly as a result of abrogated crystal 
contacts (chapter 2). Although MtDTBS crystals were only observed in crystallization 
conditions containing anionic precipitants in chapter 2, alternate crystallographic methods 
such as crystal seeding were not employed. Seeding has been identified as a useful tool for 
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the optimisation of crystal growth conditions (Bergfors, 2007). This involves the use of 
crushed, pre-grown crystal fragments to bypass the nucleation stage, allowing crystal growth 
to occur in alternate conditions. As MtDTBS readily crystallizes in a number of conditions, 
this would be a promising avenue to identify alternate crystal forms. Ideally, new 
crystallization conditions would be free from anionic precipitants such as SO42-, citrate or 
other organic acids, and result in an unbound P-loop. While a crystal structure of MtDTBS 
with no ligands modelled at the P-loop has been previously reported (PDB ID: 3FGN), this 
was not able to be replicated using the same conditions. It is hypothesized that investigation 
into alternate conditions may reveal novel structural information regarding conformational 
flexibility of MtDTBS. Furthermore, co-crystallization or soaking with NTPs using an 
alternate crystal form of MtDTBS may reveal previously unobserved intermolecular 
interactions, providing further insight into the structural mechanism of NTP promiscuity. 
 
Given that P-loops are commonly observed in ATP and GTP binding proteins throughout the 
proteome, it is possible that this mechanism of promiscuity will be observed in other proteins. 
Initial structural and biophysical investigations into NTP promiscuity in other enzymes 
should be performed on DTBS from other species, in particular that from Helicobacter 
pylori. As described previously, the active site of HpDTBS bears similarities to that of 
MtDTBS; a highly positively charged area at the P-loop and a lack of hydrogen bonding to 
the ribose ring of its bound NTP. Investigation of HpDTBS NTP binding would determine if 
these specific structural features contribute to the unique mechanism of MtDTBS NTP 
promiscuity. Subsequently, studying other P-loop containing proteins from throughout the 
proteome may provide further insight into the occurrence of this phenomenon and the 
structural features that cause it. Examples of ligand promiscuity in the literature may be 
difficult to find due to the use of different identifying terms; other researchers may have 
discovered similar phenomena but not referred to it as promiscuity. Therefore, a more 
thorough method of identifying other potential proteins that bind NTPs promiscuously would 
be to search protein databases (e.g. NCBI, RCSB PDB, Phyre2) for similar sequences or 
structures to the MtDTBS P-loop. After identifying several proteins, their genes could be 
transformed into bacteria for expression and purification, followed by biophysical and 
structural investigation as performed in chapters 2 and 3. To conclude, investigation into NTP 
utilization in DTBS from other species will aid the determination of the structural features 
required for promiscuity. Comparison of the activities of enzymes that bind ligands 
promiscuously may also provide insight into the biological purpose of this phenomenon. As 
was hypothesized for MtDTBS, this may be a method to retain enzyme activity at all times, 
regardless of nutrient availability. A practical use of identifying the minimal structural 
requirements of NTP promiscuity would be to engineer other enzymes to utilize a range of 
energy sources, which may be beneficial for industrial purposes where it is important to 
utilize cheaper reagents. 
 
5.3.3 In vivo implications of NTP promiscuity 
 
Despite biochemical, biophysical and structural characterization of NTP promiscuity, the 
effect of this phenomenon within the mycobacterium remains unclear. In chapter 3, it was 
determined that the MtDTBS exhibited significantly higher affinity for CTP than other NTPs. 
Subsequently in chapter 4, it was determined that 2ʹ-deoxycytidine triphosphate (dCTP) also 
binds to MtDTBS in the same high affinity binding mode exhibited by CTP, but with 
approximately 3-fold higher affinity. This encourages the use of the available MtDTBS 
enzyme activity assay to determine the extent to which dCTP is able to be used as an energy 
source during catalysis. However, despite the high affinity preference for CTP, previous 
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enzyme kinetic data revealed similar Km values (CTP Km = 25.2 ± 1.7 µM, other NTPs Km = 
17 – 30 µM) and a slight kcat preference for CTP (CTP kcat = 15.2 ± 0.3 µM, other NTPs Kcat 
= 10.2 – 11.8 µM) (Salaemae et al., 2015). The similarity in these values can be explained by 
the relatively high affinity of CDP, which could slow the binding of new substrates after each 
round of catalysis, resulting in an overall rate comparable to the other, lower affinity NTPs. 
However, it appears that there is little catalytic difference between the high affinity and 
promiscuous NTPs. Consequently, it is unclear as to what degree NTP promiscuity affects 
energy source use by MtDTBS during catalysis within the mycobacterium. We have 
previously hypothesized that NTP promiscuity allows MtDTBS to remain active at all stages 
of the Mtb lifecycle, owing to the fact that the gene is essential for survival (Salaemae et al., 
2015) (Chapter 3). However, given the vast affinity differences between NTP binding modes 
(~2,000-fold) and an appreciable amount of CTP or dCTP, MtDTBS would be most likely 
bound to these substrates rather than any of the promiscuous NTPs. Indeed, it may be that the 
levels of cytosine-containing nucleoside triphosphates available to MtDTBS depreciates 
significantly throughout the lifecycle, causing it to rely on other substrates. Although it is 
known that the concentrations of NTP vary throughout the lifecycle of bacteria (Buckstein et 
al., 2008; Conlon et al., 2016), this has not been studied in Mtb. In order to fully understand 
the biological reasoning behind the evolution of NTP promiscuity, investigation of NTP 
levels at varying stages of the complex Mtb lifestyle is required. This could be performed via 
quantitative measurement of NTP levels from Mtb whole cell lysates at differing stages of the 
lifecycle, and under certain stressors such as antibiotic treatment. Using this information in 
combination with the affinities determined in this thesis, the NTP most likely to be bound to 
MtDTBS at different stages of the lifecycle can be mathematically modelled. While it is 
possible that MtDTBS is required to use alternate sources of energy, it may be that a high 
affinity substrate such as dCTP is present a sufficient level to be ubiquitously utilized for 
catalysis. Such studies may reveal insight into whether or not MtDTBS has evolved NTP 
promiscuity as a biological requirement to maintain activity. 
 
5.3.4 The adenosine diphosphate binding mode 
  
Throughout this thesis, there have been several observations that invite further investigation 
into the intermolecular interactions between MtDTBS and adenosine diphosphate (ADP). In 
chapter 2 it was observed that ADP bound in a conformation distinct from that of CTP, with 
the adenosine moiety exhibiting two binding poses, one within and one adjacent to the DAPA 
pocket. Electron density distinguished the entirety of the ADP in this crystal structure, which 
was also distinct from that of adenosine triphosphate (ATP) in chapter 3, where electron 
density was only present for the triphosphate moiety. This comparison raised the possibility 
that the adenosine moiety of ATP may also be able to bind in the poses observed for ADP. 
However, it was modelled in a state that would allow for catalytic activity, an ability that was 
previously determined by enzyme activity assays (Salaemae et al., 2015). In chapter 3, it was 
also observed that ADP exhibited a higher affinity for MtDTBS than ATP (17.9 µM vs 75 
µM respectively). This was unusual, considering that the addition of a phosphate caused a 3-
fold increase in affinity between CDP and CTP. However, the structural data is consistent 
with the difference in affinity between ADP and ATP; electron density for the whole of ADP 
was present, indicating that it forms a more stable complex. Additionally, the alternate ADP 
binding modes exhibited new interactions that could have caused an increase in affinity. 
Adjacent to the DAPA pocket, extra hydrogen bonds were observed between the adenosine 
moiety and MtDTBS. Within the predominantly hydrophobic DAPA pocket, it is likely that 
several hydrophobic forces contributed to binding the adenosine moiety. In both modes, 
hydrogen bonds between the ribose ring and MtDTBS were also observed. As mentioned 
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previously, these interactions could be investigated and validated by alternate structural 
techniques, such as HSQC-NMR. Specifically, comparison of spectra performed in the 
presence of ADP or ATP would reveal whether or not these ligands interact with the same 
MtDTBS residues. Likewise, comparison between ADP and DAPA would reveal whether the 
adenosine moiety interacts with residues within the DAPA pocket. Confirming these 
interactions by an orthogonal method would bring additional validity to the binding mode 
observed by crystallography. 
 
Altogether, the presented data regarding the ADP binding mode are consistent, inviting 
speculation into the biological relevance of these findings. Naturally, after a certain number 
of catalytic cycles where ATP is used as the energy source, the concentration of ADP would 
increase. The higher affinity of ADP suggests that relatively few catalytic cycles would have 
to occur before ADP begins to outcompete ATP. However, MtDTBS is able to catalyze its 
reaction using ATP, with similar Km and kcat values observed for other NTPs (all NTPs Km = 
17 – 30 µM; Kcat = 10.2 – 15.2 s-1 × 10-3) (Salaemae et al., 2015). Although it is known that 
ADP is an inhibitor of MtDTBS, these Km and kcat values demonstrate that ADP does not 
cause product inhibition to the point where catalysis is prematurely prevented. A possible 
explanation for this is that when ADP binds in small amounts as a result of catalytic turnover, 
it is outcompeted by the simultaneous binding of both ATP and DAPA. Indeed, phosphoryl 
transfer between ATP and DAPA has been shown in EcDTBS to include additional residues, 
which would likely increase the affinity of the overall complex (Huang et al., 1995; Käck et 
al., 1998). Further investigation is required to determine the biological implications of the 
observed ADP binding modes; however, it is clear that ATP can be competently utilized by 
MtDTBS for catalysis. 
 
5.4  Fragment-based lead discovery and design against MtDTBS 
 
5.4.1 MtDTBS is an amenable drug discovery target  
 
MtDTBS is a promising target for the development of anti-tuberculosis drugs. Foremost, 
because the biotin biosynthesis pathway is essential to Mtb infection and survival (Dey et al., 
2010; Salaemae et al., 2011, 2016; Woong Park et al., 2011). Additional to this, there now 
exists an increasing body of knowledge regarding DTBS from multiple species, including 
MtDTBS (Salaemae et al., 2015), EcDTBS (Huang et al., 1995; Käck et al., 1998) and 
HpDTBS (Porebski et al., 2012). Comparison to DTBS from other species is not only useful 
for the investigation of natural ligand binding, it will also aid the development of molecules 
that bind specifically to MtDTBS and only inhibit Mtb. Indeed, focusing on the development 
of narrow-spectrum antibiotics has been suggested to be the future of infectious disease 
medicine, especially in regards to combating resistance (Brown and Wright, 2016). In 
addition to this, there are no human homologues to MtDTBS, indicating that off-target effects 
will be minimal. Finally, and importantly, MtDTBS is highly amenable to biochemical, 
biophysical and structural investigation. A consideration that can be overlooked, this has 
enabled the development of several robust protocols which constitute a pipeline for the 
accurate and rapid assaying of compounds or inhibitors. MtDTBS is readily immobilized to a 
streptavidin coated SPR chip, retaining activity for up to 3 weeks (chapter 3). Using this 
assay, it was possible to rapidly, accurately and precisely investigate the protein-ligand 
interactions with over 20 compounds, including nucleoside polyphosphates, fragments and 
analogues. It is clear that further SPR experiments, such as fragment screening, are possible 
with this enzyme. MtDTBS also meets all of the ‘fundamental crystal requirements’ for 
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protein amenability to crystallography in fragment-based projects (Öster et al., 2015). These 
requirements were: robustness, including reproducible crystal growth, high stability, adequate 
diffraction; an accessible binding site; and ‘soakability’. MtDTBS readily forms crystals in a 
range of conditions that contain cryo-protectants, taking roughly 3 days to begin growing and 
reaching a full size of 100 – 400 µM and consistently diffracting to sufficient resolution for 
atomic analysis. MtDTBS crystals are highly stable, and are able to withstand high 
concentration soaking experiments and physical manipulation, such as during precipitant-
ligand exchange. Generally, the maximum concentration of DMSO tolerated by MtDTBS 
crystals was 10% (v/v), corresponding to high concentrations of ligands. The ligand-bound 
structure of compound 2 in chapter 4 required a concentration of at least 30 mM; it is possible 
that this interaction would not have been observed had high concentrations not been possible. 
Additionally, NTPs were present at concentrations of ~300 mM during the structural 
investigations into promiscuity. The use of extremely high fragment concentrations during 
soaking (20 – 500 mM) has been demonstrated to be highly useful in FBLD projects 
(Bauman et al., 2016). Indeed, there is also evidence suggesting that high concentration 
crystallographic soaking results in the highest hit-rates, identifying many hits that other 
primary screening techniques would not (Schiebel et al., 2016). The amenability of MtDTBS 
to biophysical and structural investigation, especially high concentration crystallographic 
soaking, further exemplifies this enzyme as a promising target for drug discovery projects. 
Foremost, this highlights the feasibility of performing fragment screening by SPR and X-ray 
crystallography. These experiments were determined to be lower priority than the 
characterisation of MtDTBS natural ligand binding (Chapters 2, 3) and the identification and 
optimisation of the hits (Chapter 4) presented in this thesis, but should be higher priority for 
the continuation of this project. 
 
5.4.2 MtDTBS fragment screening by crystallography 
 
As discussed in chapter 4, further fragments need to be identified in order aid future drug 
discovery against MtDTBS. While some successful development was performed with the two 
cytidine analogues and one fragment that were identified to bind to MtDTBS, further probing 
of the active site would increase the capacity for growing, merging and linking of existing 
compounds. The Booker laboratory has access to a ChemBridge fragment library consisting 
of 1,135 compounds, which is rule of three compliant (MW ≤300, H-bond donors ≤3, H-bond 
acceptors ≤3, cLogP ≤3)(Carr et al., 2005). This library is stored at Compounds Australia. In 
order to aid the use of this library for fragment screening by crystallography, it would be 
preferable to have compounds solubilized to as high a concentration as possible. This is 
because, as discussed previously, high concentrations are preferable for fragment soaks, and 
the amount of compound that can be tolerated by crystals is generally limited by the 
concentration of DMSO (~10% for MtDTBS crystals). Considering this, there is a ‘High 
Solubility Set’ of fragments within the ChemBridge library that are soluble in 100% DMSO 
to at least 200 mM, which could result in soaking concentrations of at least 20 mM. Using the 
Art Robbins Phoenix crystallography drop setting robot, it would be possible to input up to 
288 independent sitting drop crystallization conditions per tray (Intelliplate). Compounds can 
then be soaked into each well that contains a crystal and incubated for a period of time. Given 
that the reported MtDTBS crystal conditions contain cryo-protectants, each crystal can be 
mounted and flash cooled in liquid nitrogen with minimal handling. Subsequently, the 
crystals can be subjected to X-ray diffraction at the Australian Synchrotron. Datasets are 
automatically autoprocessed using XDS (Kabsch, 2010) at the synchrotron, and each one 
should be subject to the following criteria before continuing: <3 Å, CC1/2 > 0.3 and 
completeness > 0.85. Following this, truncation and phasing can be automated using CCP4 
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(Winn et al., 2011) and in-house MtDTBS search models. Finally, PanDDA automatically 
identifies areas of electron density that may pertain to bound fragments (Pearce et al., 2017). 
By comparing multiple datasets, PanDDA is also able to enhance the electron density of 
weakly bound fragments or those that are obscured by water molecules. Following this, 
comparison to fragment screens using orthogonal techniques such as SPR should be 
performed. Overall, fragment screening by X-ray crystallography is feasible with MtDTBS as 
the target protein. 
 
There are several considerations for the use of MtDTBS in fragment screening. Firstly, the P-
loop is bound to the precipitant molecules SO42- or citrate in MtDTBS crystal structures. 
Given that these precipitants prevented the binding of NTPs, it is likely that they would also 
prevent the binding of fragments to this region. One option would be to perform precipitant-
ligand exchange with fragments, however this would require a large amount of potentially 
error prone manual crystal handling. Furthermore, fragments may not bind tightly enough to 
prevent crystal degradation. Another option would be to identify alternate crystallization 
conditions for MtDTBS that do not contain anionic precipitants. Nevertheless, despite the 
presence of SO42- or citrate, fragment screening would still be beneficial to discover new 
compounds that bind to the cytidine binding site, DAPA binding pocket or even other, hereto 
unknown MtDTBS binding sites. The next consideration is one of library design. X-ray 
crystallographic screening requires highly soluble hits, which can be determined 
computationally with cLogP, a value that has shown to have a weak correlation to hit success 
rates (Öster et al., 2015). By further filtering the fragment library based on a value such as 
this, the number of compounds required to screen would reduce. This would reduce the 
number of individual crystals required to mount, which is likely a major bottle-neck to 
throughput of screening by X-ray crystallography and one of the predominant reasons why 
this was not attempted in the current project. Indeed, X-ray fragment screening at Diamond 
Light Source uses robotic assistance for crystal harvesting (Oxford University, UK, 2018). 
Without such equipment, compounds can be soaked in pools, rather than in singleton. With 
careful consideration of the factors presented here, a fragment screen of MtDTBS using X-
ray crystallography would be a useful and feasible exercise to identify alternate compounds 
that may aid future development of inhibitors. 
 
5.4.3 Advances in the characterisation of the MtDTBS active site 
 
Throughout this thesis, the MtDTBS active site was probed by biophysical and structural 
methods, revealing key characteristics that must be taken into account when designing 
inhibitors. These will be discussed subsequently, starting with the cytidine binding site and 
followed by the P-loop and the DAPA pocket. 
 
Cytidine binds into a shallow, solvent exposed pocket on the surface of MtDTBS. The 
cytosine base in particular binds extremely efficiently to this pocket, forming 4 hydrogen 
bonds with the peptide backbone of residues in the region. Throughout this thesis, no 
alternate moieties were observed to bind into cytosine pocket, despite testing several alternate 
NTPs and cytidine analogues via crystallography. While this observation demonstrates the 
specificity of the interaction between cytosine and MtDTBS, it is still possible that alternate 
molecules are able to bind here. This is especially so when considering the possibility that the 
MtDTBS active site may differ in solution from what is observed by crystallography. Unlike 
the cytosine pocket, it appears that the ribose moiety of CTP does not exhibit hydrogen bonds 
to the enzyme. However, structural and biophysical evidence indicates that the 2ʹ-hydroxyl 
group of CTP interacts unfavourably with nearby hydrophobic residues, leading to slower 
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association and faster dissociation than the unsubstituted dCTP. This highlights that future 
development of compounds intended to bind in the CTP pocket may benefit from SAR of the 
ribose moiety, in order to determine the optimal substituents. It is possible that the entire 
ribose moiety could be replaced by a more efficient chemical structure. Finally, the cytidine 
binding pocket is likely crucial to the development of narrow-spectrum anti-tuberculosis 
drugs which, as mentioned previously, is an important consideration for future antibiotic 
development (Brown and Wright, 2016). As observed in chapter 3, this region is structurally 
distinct between DTBS from different species. Furthermore, it appears that the preference for 
CTP is unique to MtDTBS. Therefore, targeting the cytidine binding pocket may achieve 
specificity over DTBS from other species. 
 
Located between the cytidine binding site and the DAPA pocket, the P-loop is a short motif 
that binds to the triphosphates of NTPs with high affinity. The LRLR nest clearly has a high 
propensity for binding anionic species, and was identified as crucial to the mechanism by 
which MtDTBS elicits NTP promiscuity. No developed compounds were observed to bind to 
the LRLR nest in this thesis, but this must be a primary goal for the future of compound 
design against MtDTBS. Whether as an analogue from the 2-series or with a linked 
compound, performing chemical growth of a compound to interact with the P-loop would 
provide a significant boost to affinity. 
 
The DAPA pocket is a large hydrophobic cavity that forms at the homo-dimer interface 
between MtDTBS monomers. The natural substrate DAPA binds to this pocket with a 
moderate affinity (KD = 80 µM ± 20 µM; Chapter 3), which suggests that outcompeting this 
substrate with a high affinity compound is feasible. However, DAPA is a relatively simple 
alkyl chain compound, with a small molecular weight and heavy atom count, resulting in 
quite an efficient molecule (MW = 188 Da; Ligand efficiency = 0.43 vs 0.32 for compound 
5). Thus, DAPA itself may constitute a preferable moiety to include in future inhibitor 
design, particularly within a linked compound. Nonetheless, it appears that the DAPA pocket 
is able to accommodate a variety of different moieties, such as the 2-series compounds and 
ADP. These observations invite further probing of this region, particularly with a fragment 
screen.  
 
5.4.4 Future directions for the development of MtDTBS inhibitors 
 
There are currently two compound series that have been identified and developed: the 2-
series and the linked compound series. Each series will be discussed in the context of the 
development of inhibitors of the enzyme and the mycobacterium. Firstly, the location at 
which the compound binds within the active site will determine which substrate it competes 
with in vivo. Indeed, it appears that 2-series compounds bind to the same region of the 
MtDTBS active site as the ɣ-phosphate of CTP, indicating that the two would compete for 
binding. This was one hypothesis as to why 2-series compounds did not inhibit Mtb, and it 
was suggested that higher affinity for MtDTBS is required. Intended inhibitors should exhibit 
higher affinity than any competing natural substrates. Conversely, it may be beneficial to 
build 2-series compounds away from where CTP binds, such that they only compete with 
DAPA. However, the low affinity of 2-series compounds compared to CTP supports the 
development of a linked compound. Designing a molecule that binds optimally to the 
cytidine binding site, P-loop and DAPA pocket would likely exhibit extremely high affinity. 
However, care must be taken to ensure that linked compounds exhibit the appropriate drug-
like characteristics. Indeed, many anti-TB drugs are smaller and more hydrophilic molecules, 
expected to enter the mycobacterium through porin channels (Lambert, 2002). Rifampicin, on 
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the other hand, is more akin to the large linked compounds (9 MW = 524 Da; 10 MW = 628 
Da; rifampicin MW = 823 Da). However, the current linked compounds are less lipophilic 
than rifampicin, which is suggested to be one of the reasons it can passively traverse the 
mycobacterial cell wall (Lambert, 2002) (9 LogP = 0.51, 10 LogP = -2.32, rifampicin LogP = 
2.62; values determined using Molinspiration). Future development of linked compounds to 
become more lipophilic may aid cell penetration in the future. Nevertheless, the iterative 
compound development process will require continual testing against the mycobacterium, 
which is performed by collaborators at the Prof. James Triccas laboratory (University of 
Sydney, Australia). Indeed, bacterial cell penetration of drugs has been identified as one of 
the key challenges for the development of new antibiotics (Lamoree and Hubbard, 2018; 
Payne et al., 2007; Tommasi et al., 2015). In order to address this, there is on-going research 
into the mechanisms behind cell permeability and to monitor the accumulation of antibiotic 
compounds within bacteria (Masi et al., 2017). Along with structural, biophysical and 
biochemical assays, including techniques that observe the bacterial cell permeability of 
compounds during the iterative development of MtDTBS inhibitors would also greatly 
increase the chances of successful inhibition of Mtb.  
 
5.5  Concluding remarks 
 
The work presented in this thesis represents the progression of a project aiming to develop 
inhibitors for the promising anti-tuberculosis drug target MtDTBS. By using a fragment-
based approach, accompanied by careful consideration and investigation into the biophysical 
nature of the enzyme, a significant improvement in the binding characteristics of novel 
compounds was achieved. This highlights that FBLD is an enabling method, encouraging 
participation in drug discovery by researchers who were previously prohibited by 
infrastructural barriers. It is hypothesized that the iterative FBLD optimization process will 
suit the development of future antibiotic compounds. Using the techniques reported here, it 
will be possible to rapidly, accurately and precisely guide compound development using 
biochemical, biophysical and structural information. Regular inclusion of assays to test cell 
permeability and bacterial inhibition will likewise guide the development of new anti-
tubercular compounds. Such innovations in drug discovery will provide a strong and positive 









Appendix 1; Table 1.  Data collection and refinement statistics.
dCTN dCDP dCTP dFdC 2 Synthesized-2
Wavelength (Å) 0.9537 0.7108 0.9537 0.9537 0.9537 0.9537
Resolution range 49.01  - 2.23 (2.31  - 2.23) 46.18  - 2.0 (2.071  - 2.0) 45.83  - 2.125 (2.201  - 2.125) 38.35  - 1.991 (2.062  - 1.991) 46.29  - 1.9 (1.968  - 1.9) 38.55  - 2.4 (2.486  - 2.4)
Space group P 2₁2₁2₁ P 2₁2₁2₁ P 2₁2₁2₁ P 2₁2₁2₁ P 2₁2₁2₁ P 2₁2₁2₁
Unit cell (a b c (Å) α β Ɣ (°)) 55.2 106.2 152.9 90 90 90 54.8 105.2 154.2 90 90 90 54.4 104.1 153.1 90 90 90 55.5 106.1 152.0 90 90 90 54.6 105.7 154.5 90 90 90 56.1 106.2 152.8 90 90 90
Total reflections 89236 (8645) 651931 (62556) 30546 (2990) 123750 (11711) 1904288 (189745) 707995 (66092)
Unique reflections 44653 (4102) 57086 (4923) 25126 (2574) 62008 (5910) 71394 (6988) 36160 (3140)
Multiplicity 2.0 (2.0) 11.4 (10.7) 1.2 (1.2) 2.0 (2.0) 26.7 (26.9) 19.6 (19.4)
Completeness (%) 98.68 (87.57) 87.66 (81.06) 50.40 (52.50) 99.34 (96.51) 99.35 (96.96) 95.83 (88.08)
Mean I/sigma(I) 13.99 (3.62) 31.20 (4.05) 8.36 (1.69) 14.28 (2.14) 76.12 (3.92) 28.93 (2.09)
Wilson B-factor 25.54 22.18 42.84 32.58 22.73 48.3
R-merge 0.02848 (0.3063) 0.7795 (1.953) 0.01738 (0.1616) 0.02526 (0.2679) 0.756 (2.351) 0.8552 (2.964)
R-meas 0.04028 (0.4332) 0.8154 (2.055) 0.02458 (0.2286) 0.03573 (0.3788) 0.7709 (2.396) 0.8758 (3.039)
R-pim 0.02848 (0.3063) 0.235 (0.6278) 0.01738 (0.1616) 0.02526 (0.2679) 0.1491 (0.4608) 0.1852 (0.6556)
CC1/2 0.997 (0.772) 0.799 (0.708) 0.999 (0.938) 0.999 (0.913) 0.838 (0.845) 0.868 (0.543)
CC* 0.999 (0.933) 0.942 (0.91) 1 (0.984) 1 (0.977) 0.955 (0.957) 0.964 (0.839)
Reflections used in refinement 44138 (3875) 53601 (4879) 25125 (2575) 61885 (5910) 70939 (6837) 34984 (3140)
Reflections used for R-free 2185 (194) 2706 (251) 1218 (118) 3090 (305) 3490 (330) 1711 (155)
R-work 0.2012 (0.6390) 0.2039 (0.3351) 0.1762 (0.2905) 0.1979 (0.2844) 0.2285 (0.5854) 0.2054 (0.2900)
R-free 0.2486 (0.6796) 0.2716 (0.4490) 0.2373 (0.3722) 0.2505 (0.3270) 0.2761 (0.5861) 0.2855 (0.3640)
CC(work) 0.963 (0.117) 0.840 (0.601) 0.963 (0.574) 0.948 (0.591) 0.834 (0.413) 0.747 (0.553)
CC(free) 0.955 (0.001) 0.798 (0.271) 0.919 (0.302) 0.924 (0.464) 0.827 (0.407) 0.742 (0.461)
Number of non-hydrogen atoms 6938 7345 6724 7269 7207 7066
  macromolecules 6326 6293 6351 6382 6370 6719
  ligands 84 99 112 74 220 164
  solvent 528 953 261 813 617 183
Protein residues 908 907 908 908 909 908
RMS(bonds) 0.006 0.007 0.007 0.007 0.08 0.042
RMS(angles) 0.83 0.89 0.85 0.88 0.85 0.99
Ramachandran favored (%) 97.67 98.33 98.33 98.55 98.33 97.44
Ramachandran allowed (%) 1.78 1 1.33 1.11 1.34 1.78
Ramachandran outliers (%) 0.56 0.67 0.33 0.33 0.33 0.78
Rotamer outliers (%) 2.64 3.15 2.95 1.79 1.14 3.51
Clashscore 3.8 3.48 5.82 3.53 6.23 8.75
Average B-factor 37.03 24.39 45.85 37.02 39.47 60.3
  macromolecules 36.81 23.8 45.92 36.29 39.43 60.68
  ligands 43.13 23.44 40.62 47.03 36.39 58.85
  solvent 38.62 28.32 46.55 41.87 40.97 47.67
Statistics for the highest-resolution shell are shown in parentheses. Values are subject to change prior to PDB submission. 
Tables were made using Table 1 (PHENIX), with the most recently refined .pdb and .mtz files, as well as the relevant unmerged .mtz
Appendix 1; Table 2.  Data collection and refinement statistics continued.
2 & CTN 3a 4 5 6 7
Wavelength (Å) 1.54 0.9537 0.9537 0.9537 0.9537 0.9537
Resolution range 53.28  - 2.6 (2.693  - 2.6) 45.97  - 1.94 (2.009  - 1.939) 37.69  - 2.3 (2.382  - 2.3) 46.34  - 2.438 (2.525  - 2.438) 44.46  - 2.652 (2.747  - 2.652) 45.77  - 1.691 (1.751  - 1.691)
Space group P 2₁2₁2₁ P 2₁2₁2₁ P 2₁2₁2₁ P 2₁2₁2₁ P 2₁2₁2₁ P 2₁2₁2₁
Unit cell (a b c (Å) α β Ɣ (°)) 54.5 106.6 154.3 90 90 90 56.3 106.9 152.8 90 90 90 55.6 108.4 153.8 90 90 90 54.8 105.6 152.5 90 90 90 55.1 105.2 150.5 90 90 90 53.9 105.0 154.3 90 90 90
Total reflections 875992 (82802) 137720 (13152) 1414302 (127424) 66739 (5798) 52194 (5062) 195343 (18390)
Unique reflections 28191 (2632) 68914 (6618) 41902 (3779) 33416 (2935) 26106 (2538) 98148 (9363)
Multiplicity 31.1 (31.0) 2.0 (2.0) 33.8 (32.3) 2.0 (2.0) 2.0 (2.0) 2.0 (2.0)
Completeness (%) 98.10 (95.78) 99.57 (97.05) 90.45 (85.88) 98.53 (88.16) 99.84 (98.83) 99.44 (96.29)
Mean I/sigma(I) 59.82 (3.53) 18.31 (2.81) 76.96 (2.20) 21.16 (2.88) 11.71 (2.25) 11.79 (1.66)
Wilson B-factor 51.91 35.87 39.46 52.4 43.93 21.07
R-merge 0.7296 (1.811) 0.01317 (0.173) 0.6221 (9.689) 0.0163 (0.2101) 0.03916 (0.2362) 0.03214 (0.3269)
R-meas 0.7411 (1.841) 0.01862 (0.2446) 0.6313 (9.848) 0.02305 (0.2972) 0.05538 (0.3341) 0.04546 (0.4623)
R-pim 0.1281 (0.3225) 0.01317 (0.173) 0.1056 (1.704) 0.0163 (0.2101) 0.03916 (0.2362) 0.03214 (0.3269)
CC1/2 0.904 (0.677) 1 (0.953) 0.982 (0.709) 1 (0.951) 0.998 (0.854) 0.999 (0.839)
CC* 0.974 (0.898) 1 (0.988) 0.995 (0.911) 1 (0.987) 1 (0.96) 1 (0.955)
Reflections used in refinement 27878 (2631) 68899 (6618) 38125 (3546) 33364 (2935) 26105 (2538) 97991 (9363)
Reflections used for R-free 1385 (110) 3448 (309) 1893 (159) 1736 (137) 1377 (138) 4978 (463)
R-work 0.2010 (0.2771) 0.1991 (0.2676) 0.2456 (0.3336) 0.1987 (0.2768) 0.1839 (0.2173) 0.1973 (0.2598)
R-free 0.2880 (0.3502) 0.2388 (0.3234) 0.3015 (0.3636) 0.2629 (0.3610) 0.2574 (0.3380) 0.2298 (0.2955)
CC(work) 0.848 (0.527) 0.947 (0.651) 0.766 (0.687) 0.933 (0.572) 0.952 (0.788) 0.956 (0.693)
CC(free) 0.862 (0.614) 0.929 (0.619) 0.743 (0.678) 0.917 (0.326) 0.936 (0.691) 0.941 (0.643)
Number of non-hydrogen atoms 6618 7027 6912 6793 6848 7775
  macromolecules 6295 6364 6560 6549 6580 6580
  ligands 141 118 108 100 56 96
  solvent 182 545 244 144 212 1099
Protein residues 907 908 909 909 909 909
RMS(bonds) 0.043 0.007 0.045 0.033 0.007 0.039
RMS(angles) 0.98 0.85 1.02 0.91 0.9 0.86
Ramachandran favored (%) 95.55 98.56 98.44 97.11 97.55 98.44
Ramachandran allowed (%) 3.23 1.22 1.22 2.44 2 1.22
Ramachandran outliers (%) 1.22 0.22 0.33 0.44 0.45 0.33
Rotamer outliers (%) 5.46 1.96 3.14 2.83 2.97 1.72
Clashscore 8.73 6.04 8.27 6.65 6.77 4.75
Average B-factor 56.63 42.16 48.75 57.1 44.1 25.6
  macromolecules 56.94 41.81 49.08 57.41 44.23 24.42
  ligands 53.21 49.63 46.12 46.81 42.66 16.85
  solvent 48.46 44.67 40.99 49.99 40.25 33.44
Statistics for the highest-resolution shell are shown in parentheses. Values are subject to change prior to PDB submission. 
Tables were made using Table 1 (PHENIX), with the most recently refined .pdb and .mtz files, as well as the relevant unmerged .mtz
Appendix 1; Table 3.  Data collection and refinement statistics continued.
8 9 10
Wavelength (Å) 0.9537 0.9537 0.9537
Resolution range 46.13  - 1.99 (2.061  - 1.99) 45.51  - 2.44 (2.528  - 2.44) 45.99  - 2.005 (2.077  - 2.005)
Space group P 2₁2₁2₁ P 2₁2₁2₁ P 2₁2₁2₁
Unit cell (a b c (Å) α β Ɣ (°)) 54.4 104.3 154.3 90 90 90 56.8 106.0 151.2 90 90 90 54.7 104.6 153.6 90 90 90
Total reflections 122013 (11854) 69313 (6673) 119699 (11578)
Unique reflections 61101 (5975) 34674 (3354) 59871 (5806)
Multiplicity 2.0 (2.0) 2.0 (2.0) 2.0 (2.0)
Completeness (%) 99.57 (99.02) 99.80 (98.47) 99.75 (98.01)
Mean I/sigma(I) 13.57 (2.00) 17.45 (2.85) 17.55 (2.72)
Wilson B-factor 29.03 41.47 36.41
R-merge 0.03028 (0.2679) 0.02354 (0.1977) 0.01501 (0.1871)
R-meas 0.04282 (0.3789) 0.03329 (0.2796) 0.02123 (0.2646)
R-pim 0.03028 (0.2679) 0.02354 (0.1977) 0.01501 (0.1871)
CC1/2 0.999 (0.889) 0.999 (0.947) 1 (0.928)
CC* 1 (0.97) 1 (0.986) 1 (0.981)
Reflections used in refinement 60902 (5975) 34668 (3354) 59869 (5806)
Reflections used for R-free 3106 (304) 1737 (163) 3026 (312)
R-work 0.2108 (0.2742) 0.1883 (0.2602) 0.1922 (0.2777)
R-free 0.2499 (0.3222) 0.2510 (0.3409) 0.2277 (0.3286)
CC(work) 0.943 (0.676) 0.930 (0.578) 0.954 (0.681)
CC(free) 0.936 (0.582) 0.895 (0.493) 0.936 (0.628)
Number of non-hydrogen atoms 7255 6711 6907
  macromolecules 6580 6263 6351
  ligands 40 69 58
  solvent 635 379 498
Protein residues 909 905 908
RMS(bonds) 0.016 0.007 0.007
RMS(angles) 1.81 0.88 0.85
Ramachandran favored (%) 98.22 98.22 98.44
Ramachandran allowed (%) 1.34 1.45 1.22
Ramachandran outliers (%) 0.45 0.33 0.33
Rotamer outliers (%) 1.56 4.49 2.3
Clashscore 2.84 6.64 3.63
Average B-factor 32.33 41.81 40.12
  macromolecules 31.64 41.85 39.91
  ligands 27.87 46.92 34.8
  solvent 39.77 40.08 43.49
Statistics for the highest-resolution shell are shown in parentheses. Values are subject to change prior to PDB submission. 
Tables were made using Table 1 (PHENIX), with the most recently refined .pdb and .mtz files, as well as the relevant unmerged .mtz
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Appendix 2: Surface plasmon resonance data 
 
Contained in this appendix is the remaining SPR ligand binding data referred to in Chapter 4. 
Included are the kinetic parameters determined for dCDP and dCTP (Table 1). See Chapter 4, 
Figure 4.4 for example sensorgrams with these ligands. Subsequently, the steady state 
analysis parameters and example sensorgrams for compounds 2-10 are included (Table 2, 
Figure 1). 
 
Table 1: Kinetics parameters for dCDP and dCTP SPR data. Data is collated from three experiments. 
 










(RU) Chi² (RU²) Replicates 
dCDP 1.2e+6 4e+5 0.12 0.03 1.18e-7 30-50 0.02 – 0.1 3 
dCTP 7.13e+5 0.05e+5 0.0341 0.0002 4.76e-8 53 0.5 3 
 




Table 2: Steady state affinity analysis and averaged KD with standard error of the mean for compounds 2-10.  
 
Substrate KD (μM) Rmax (RU) Chi² (RU²) 
2 2700 48 1.05 
 2700 39 0.01 
 4100 39 0.52 
 4200 35 0.05 
Average 3400 ± 400   
3 2000 21 0.01 
 5000 26 0.01 
Average 4000 ± 1000   
3a 50 52 0.45 
 47 50 0.93 
 42 50 1.14 
Average 46 ± 2   
4 1000 16 0.14 
 6000 47 0.19 
 3000 28 0.01 
Average 4000 ± 1000   
5 28 40 3.56 
 14 36 1.19 
 14 37 1.19 
Average 19 ± 5   
6 16 32 0.39 
 19 34 1.16 
 13 33 0.22 
 19 36 0.90 
Average 17 ± 2   
7 42 38 0.96 
 32 39 5.95 
 40 39 0.55 
 40 35 2.51 
Average 38 ± 2   
8 72 43 0.45 
 50 36 0.22 
 47 49 1.89 
Average 56 ± 8   
9 400 36 0.09 
 800 49 0.01 
Average 600 ± 200   
10 800 39 0.29 
 800 64 0.55 
 300 53 0.61 








Figure 1: Examples of SPR sensorgrams for ligands 2-10 (left). Fast kinetics were observed and the ligands 




Appendix 3: Report on the MtDTBS linking project by Birgit Gaiser  
 
Enclosed within this appendix is select data that is relevant to the current thesis. This work 
was adapted from the MtDTBS Linking Project Report by Birgit Gaiser. Please note: 
Compounds 1 and 2 are referred to as per the notebook designations B9 and B9D respectively 
throughout this report. 
 
B9 degradation 
1) B9 under basic conditions 
B9 was treated with LiOH in THF/H2O at 45oC and the formation of B9D was confirmed by 
NMR and MS (Scheme 1). 
 
Scheme 1. Induced degradation of B9 to B9D. 
2) B9 under neutral aqueous conditions 
A sample of B9 in DMSO had been stored on the bench for several years. Presumably, the 
sample had become wet and the water has induced degradation. Over time the solvent had 
evaporated and the residue contained a crystal and an amorphous solid. The crystal was 
analysed by small molecule X-ray crystallography and was shown to be B9 (vida infra). The 
amorphous residue was analysed by NMR spectroscopy, showing that the sample consisted in 
large parts of B9, but that B9D was also present. The NMR spectrum indicated a ratio of ca. 
2:1 in favour of B9, but taken into consideration the B9 crystal that had been removed before 
the NMR analysis, the ratio was approximately 3:1. 
 
3) B9 under crystallization conditions 
As it was confirmed in the above described experiment that B9 was still the major component 
of the sample for binding assays and crystallization experiments, the question arose what had 
happened to B9 in the crystallization soak. Therefore, a sample of the crystallization buffer 
(1.4 M NH4SO4, 0.1 M Tris pH 8, 10% glycerol) containing B9 was analysed by TLC and it 
was shown that B9D formation had started after 2 days and no B9 was left after 6 days. 
However, the sample had not been checked on days 4 and 5. 
 
These experiments show that B9 only slowly degrades to B9D under neutral aqueous 
conditions, but that the degradation gets faster under increasing basic conditions. 
 
Characterization of B9 and B9D / Stereochemistry 
B9 
B9 was known to be racemic, but the supplier could not specify the stereochemistry of the 
compound. B9 was characterized in-house in order to shine light on its stereochemistry. NMR, 
HPLC and MS confirmed the structure of B9 and optical rotation confirmed that it is a racemic 
mixture ([α]D25 +0.800). 
 
NOE experiments could unfortunately not unravel the stereochemistry. However, the crystal 
mentioned above was analysed by small molecule X ray crystallography. B9 was shown to be 
the cis – cis – cis isomer (Figure 1). 
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Figure 1. B9 structure confirmed by small molecule X-ray crystallography. 
B9D 
B9D (Scheme 1) was analysed in the same means as B9, however not by X-ray crystallography. 
As for B9, the structure was confirmed, but NOE experiments could not unravel the 
stereochemistry of B9D. 
The relative stereochemistry of B9D and its analogues was finally determined with the aid of 
compound BGA-04 (Figure 2). This ethyl ester was synthesized by mistake (vida infra) and 
surprisingly consisted of two separable diastereoisomers. Both diastereoisomers were analysed 
by NMR. By comparison of their NOE spectra, peak 1 was identified as the trans isomer and 
peak 2 as the cis isomer. The trans isomer showed a correlation between the α-proton and the 
CH2 group, whereas the cis isomer showed a correlation between the two single protons on the 
cyclopentane ring (Figure 2). Notably, the α-proton undergoes a rather large downfield shift 
when switching from trans to cis (δcis ≈ 3.9 ppm; δtrans ≈ 3.5 ppm). Comparison of the 1H NMR 
spectra of the two BGA-04 peaks with the one of B9D led to the conclusion that B9D is in its 
trans conformation.  
 
Figure 2. Structure of the two BGA-04 diastereoisomers (left top: trans-BGA-04; left 
bottom: cis-BGA04) and structure of B9D (right). Red arrows indicate the correlations found 
in NOESY experiments. 
Having obtained this knowledge, the NMR spectrum of the B9/DMSO sample was compared 
to the NMR of BGA-21 and by this, it was revealed that the B9D contained in this sample was 
mostly trans-B9D (ca. 75 %), but cis-B9D was also present (ca. 25 %). 
 
In summary, the stereochemistry of B9D could not be determined until the B9D ethyl ester 
(BGA-04) was synthesized by mistake and luckily was obtained as a mixture of separable 
diastereoisomers. The fact that the B9/DMSO sample contained mostly trans-B9D indicates 
that the cis-isomer is poorly stable, even under neutral conditions. However, BGA-04 was 
synthesized under basic conditions, and yet the cis-isomer was obtained. 
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Appendix 4: Adelaide Proteomics Centre LC/MS compound analysis  
 
Data acquisition – Orbitrap – Liquid Chromatography ESI-MS (LC-ESI-MS). 
 
The compound was diluted 1:5 with water prior to LC-ESI-MS analysis. Nano-LC−ESI-
MS/MS was performed on an Ultimate 3000 RSLC system (Thermo-Fisher Scientific) 
coupled to a LTQ Orbitrap XL ETD MS instrument (both Thermo-Fisher Scientific). 20 µL 
of the sample was pre-concentrated onto a C18 trapping column (Acclaim PepMap100 C18 
75 µm × 20 mm, Thermo-Fisher Scientific) at a flow rate of 5 µL/min in 2% ACN 0.1% TFA 
for 5 minutes. Separation was performed using a 75 µm ID C18 column (Acclaim 
PepMap100 C18 75 µm × 15 cm, Thermo-Fisher Scientific) at a flow rate of 0.3 µL/min 
using a linear gradient from 5 to 90% B (A: 5% ACN 0.1% FA, B: 80% ACN 0.1% FA) over 
30 minutes, followed by a 10 minute wash with 95% B, and an 20 minute equilibration with 
5%. MS scans were acquired in the mass range of 50 m/z to 500 m/z at a resolution of 60,000.  
 
Data analysis  
 
Data analysis was performed using the XCalibur software (Version 2.0.7, Thermo Fisher 
Scientific). The acquired spectrum was compared with a theoretical spectrum using the 
elemental composition of the compounds utilizing the isotope simulation option of the 
XCalibur software.  
 






Figure 1: Total ion chromatography for the stock sample of compound 1. Four independent 
peaks are observed. 
  
RT: 0.00 - 64.99





















































Figure 2: MS spectrum for analysis of peak 1. M/Z pertaining to 1 (231), 2 (248) and an 
unidentified compound (213) were observed. 
  
ORB160706_16-042_B9_01 #1978-2056 RT: 28.76-29.87 AV: 79 NL: 5.35E8
T: FTMS + p NSI Full ms [50.00-500.00]



































C 14 H15 O3
213.08896
z=1
C 14 H13 O2
121.02747
z=1
C 7 H5 O2
248.12581
z=1
C 11 H20 O6 461.19186z=1
C 28 H29 O6
163.03766
z=1
C 9 H7 O3
185.09442
z=1






C 28 H25 O4
340.17273
z=1




Figure 3: MS spectrum for analysis of peak 2 (shoulder). M/Z pertaining to 1 (231), 2 (248), 
as well as an unidentified compound (189) were observed. 
 
  
ORB160706_16-042_B9_01 #2171-2199 RT: 31.51-31.91 AV: 29 NL: 3.86E8
T: FTMS + p NSI Full ms [50.00-500.00]
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Figure 4: MS spectrum for analysis of peak 3. M/Z pertaining to 1 (231) and 2 (249) were 
observed. The variation in the m/z of 2 was attributed to differing ionization states. 
  
ORB160706_16-042_B9_01 #2210-2276 RT: 32.07-33.00 AV: 67 NL: 8.44E8
T: FTMS + p NSI Full ms [50.00-500.00]
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Figure 5: MS spectrum for analysis of peak 4. M/Z pertaining to an unidentified compound 
(213) was observed. This compound corresponds to 1 with a loss of water. 
  
ORB160706_16-042_B9_01 #2496-2529 RT: 36.15-36.62 AV: 34 NL: 1.25E9
T: FTMS + p NSI Full ms [50.00-500.00]



































C 14 H13 O2
185.09463
z=?






C 11 H18 O5
425.17132
z=1
C 28 H25 O4
107.04840
z=1

















Adams, P.D., Afonine, P.V., Bunkóczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., 
Hung, L.-W., Kapral, G.J., Grosse-Kunstleve, R.W., McCoy, A. J., Moriarty, N. W., Oeffner, 
R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C. (2010). PHENIX: a 
comprehensive Python-based system for macromolecular structure solution. Acta Cryst D 66, 
213–221. 
Alvarellos, M.L., Lamba, J., Sangkuhl, K., Thorn, C.F., Wang, L., Klein, D.J., Altman, R.B., 
and Klein, T.E. (2014). PharmGKB summary: Gemcitabine Pathway. Pharmacogenet 
Genomics 24, 564–574. 
Andrews, P.R., Craik, D.J., and Martin, J.L. (1984). Functional group contributions to drug-
receptor interactions. J. Med. Chem. 27, 1648–1657. 
Baker, M. (2013). Fragment-based lead discovery grows up. Nat. Rev. Drug Discov. 12, 5–7. 
Battye, T.G.G., Kontogiannis, L., Johnson, O., Powell, H.R., and Leslie, A.G.W. (2011). 
iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta 
Cryst D 67, 271–281. 
Bauman, J.D., Harrison, J.J.E.K., and Arnold, E. (2016). Rapid experimental SAD phasing 
and hot-spot identification with halogenated fragments. IUCrJ 3, 51–60. 
Bergfors, T. (2007). Succeeding with seeding: some practical advice. In Evolving Methods 
for Macromolecular Crystallography, R.J. Read, and J.L. Sussman, eds. (Springer 
Netherlands), pp. 1–10. 
Brown, E.D., and Wright, G.D. (2016). Antibacterial drug discovery in the resistance era. 
Nature 529, 336–343. 
Buckstein, M.H., He, J., and Rubin, H. (2008). Characterization of Nucleotide Pools as a 
Function of Physiological State in Escherichia coli. J. Bacteriol. 190, 718–726. 
Carr, R.A.E., Congreve, M., Murray, C.W., and Rees, D.C. (2005). Fragment-based lead 
discovery: leads by design. Drug Discov. Today 10, 987–992. 
Chang, C.A., Chen, W., and Gilson, M.K. (2007). Ligand configurational entropy and protein 
binding. PNAS 104, 1534–1539. 
Chung, S., Parker, J.B., Bianchet, M., Amzel, L.M., and Stivers, J.T. (2009). Impact of linker 
strain and flexibility in the design of a fragment-based inhibitor. Nat Chem Biol 5, 407–413. 
Coimbra, J.R.M., Marques, D.F.F., Baptista, S.J., Pereira, C.M.F., Moreira, P.I., Dinis, 
T.C.P., Santos, A.E., and Salvador, J.A.R. (2018). Highlights in BACE1 Inhibitors for 
Alzheimer’s Disease Treatment. Front Chem 6. 
Conlon, B.P., Rowe, S.E., Gandt, A.B., Nuxoll, A.S., Donegan, N.P., Zalis, E.A., Clair, G., 
Adkins, J.N., Cheung, A.L., and Lewis, K. (2016). Persister formation in Staphylococcus 
aureus is associated with ATP depletion. Nat. Microbiol. 1, 16051. 
Davis, B.J., and Erlanson, D.A. (2013). Learning from our mistakes: The ‘unknown knowns’ 
in fragment screening. Bioorg. Med. Chem. Lett. 23, 2844–2852. 
 118 
Dey, S., Lane, J.M., Lee, R.E., Rubin, E.J., and Sacchettini, J.C. (2010). Structural 
Characterization of the Mycobacterium tuberculosis Biotin Biosynthesis Enzymes 7,8-
Diaminopelargonic Acid Synthase and Dethiobiotin Synthetase. Biochemistry 49, 6746–
6760. 
Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular graphics. Acta 
Cryst D 60, 2126–2132. 
Erlanson, D.A., Fesik, S.W., Hubbard, R.E., Jahnke, W., and Jhoti, H. (2016). Twenty years 
on: the impact of fragments on drug discovery. Nat. Rev. Drug Discov. 15, 605–619. 
Feng, J., Paparella, A.S., Tieu, W., Heim, D., Clark, S., Hayes, A., Booker, G.W., Polyak, 
S.W., and Abell, A.D. (2016). New Series of BPL Inhibitors To Probe the Ribose-Binding 
Pocket of Staphylococcus aureus Biotin Protein Ligase. ACS Med. Chem. Lett. 7, 1068–
1072. 
Greenhill, J.V., and Lue, P. (1993). 5 Amidines and Guanidines in Medicinal Chemistry. In 
Progress in Medicinal Chemistry, G.P. Ellis, and D.K. Luscombe, eds. (Elsevier), pp. 203–
326. 
Hopkins, A.L., Keserü, G.M., Leeson, P.D., Rees, D.C., and Reynolds, C.H. (2014). The role 
of ligand efficiency metrics in drug discovery. Nat. Rev. Drug Discov. 13, 105–121. 
Huang, W., Jia, J., Gibson, K.J., Taylor, W.S., Rendina, A.R., Schneider, G., and Lindqvist, 
Y. (1995). Mechanism of an ATP-dependent carboxylase, dethiobiotin synthetase, based on 
crystallographic studies of complexes with substrates and a reaction intermediate. 
Biochemistry 34, 10985–10995. 
Ichihara, O., Barker, J., Law, R.J., and Whittaker, M. (2011). Compound Design by 
Fragment-Linking. Mol. Inform. 30, 298–306. 
Jencks, W.P. (1981). On the attribution and additivity of binding energies. Proc. Natl. Acad. 
Sci. U.S.A. 78, 4046–4050. 
Joseph-McCarthy, D., Campbell, A.J., Kern, G., and Moustakas, D. (2014). Fragment-based 
lead discovery and design. J. Chem. Inf. and Model. 54, 693–704. 
Kabsch, W. (2010). XDS. Acta Cryst D 66, 125–132. 
Käck, H., Gibson, K.J., Lindqvist, Y., and Schneider, G. (1998). Snapshot of a 
phosphorylated substrate intermediate by kinetic crystallography. PNAS 95, 5495–5500. 
Karplus, P.A., and Diederichs, K. (2012). Linking Crystallographic Model and Data Quality. 
Science 336, 1030–1033. 
Karplus, P.A., and Diederichs, K. (2015). Assessing and maximizing data quality in 
macromolecular crystallography. Curr Opin Struct Biol 34, 60–68. 
Krug, U., Totzauer, R., Zebisch, M., and Sträter, N. (2013). The ATP/ADP Substrate 
Specificity Switch between Toxoplasma gondii NTPDase1 and NTPDase3 is Caused by an 
Altered Mode of Binding of the Substrate Base. ChemBioChem 14, 2292–2300. 
 119 
Lambert, P.A. (2002). Cellular impermeability and uptake of biocides and antibiotics in 
Gram-positive bacteria and mycobacteria. J. Appl. Microbiol. 92, 46S-54S. 
Lamoree, B., and Hubbard, R.E. (2018). Using Fragment-Based Approaches to Discover 
New Antibiotics. SLAS Discov 23, 495–510. 
Lockhart, S.R., Fothergill, A.W., Iqbal, N., Bolden, C.B., Grossman, N.T., Garvey, E.P., 
Brand, S.R., Hoekstra, W.J., Schotzinger, R.J., Ottinger, E., et al. (2016). The Investigational 
Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against 
Cryptococcus neoformans and Cryptococcus gattii. Antimicrob. Agents and Chemother. 60, 
2528–2531. 
Mashalidis, E.H., Śledź, P., Lang, S., and Abell, C. (2013). A three-stage biophysical 
screening cascade for fragment-based drug discovery. Nat. Protoc. 8, 2309–2324. 
Masi, M., Réfregiers, M., Pos, K.M., and Pagès, J.-M. (2017). Mechanisms of envelope 
permeability and antibiotic influx and efflux in Gram-negative bacteria. Nat. Microbiol. 2, 
17001. 
McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., and Read, 
R.J. (2007). Phaser crystallographic software. J Appl Crystallogr 40, 658–674. 
McPhillips, T.M., McPhillips, S.E., Chiu, H.-J., Cohen, A.E., Deacon, A.M., Ellis, P.J., 
Garman, E., Gonzalez, A., Sauter, N.K., Phizackerley, R.P., et al. (2002). Blu-Ice and the 
Distributed Control System: software for data acquisition and instrument control at 
macromolecular crystallography beamlines. J Synchrotron Radiat 9, 401–406. 
Myznikov, L.V., Hrabalek, A., and Koldobskii, G.I. (2007). Drugs in the tetrazole series. 
(Review). Chem Heterocycl Com 43, 1–9. 
Öster, L., Tapani, S., Xue, Y., and Käck, H. (2015). Successful generation of structural 
information for fragment-based drug discovery. Drug Discov. Today 20, 1104–1111. 
Paparella, A.S., Feng, J., Blanco-Rodriguez, B., Feng, Z., Phetsang, W., Blaskovich, M.A.T., 
Cooper, M.A., Booker, G.W., Polyak, S.W., and Abell, A.D. (2018a). A template guided 
approach to generating cell permeable inhibitors of Staphylococcus aureus biotin protein 
ligase. Tetrahedron 74, 1175–1183. 
Paparella, A.S., Lee, K.J., Hayes, A.J., Feng, J., Feng, Z., Cini, D., Deshmukh, S., Booker, 
G.W., Wilce, M.C.J., Polyak, S.W., et al. (2018b). Halogenation of Biotin Protein Ligase 
Inhibitors Improves Whole Cell Activity against Staphylococcus aureus. ACS Infect. Dis. 4, 
175–184. 
Payne, D.J., Gwynn, M.N., Holmes, D.J., and Pompliano, D.L. (2007). Drugs for bad bugs: 
confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29–40. 
Pearce, N.M., Krojer, T., Bradley, A.R., Collins, P., Nowak, R.P., Talon, R., Marsden, B.D., 
Kelm, S., Shi, J., Deane, C.M., et al. (2017). A multi-crystal method for extracting obscured 
crystallographic states from conventionally uninterpretable electron density. Nat. Comm. 8, 
15123. 
 120 
Porebski, P.J., Klimecka, M., Chruszcz, M., Nicholls, R.A., Murzyn, K., Cuff, M.E., Xu, X., 
Cymborowski, M., Murshudov, G.N., Savchenko, A., et al. (2012). Structural 
characterization of H. pylori dethiobiotin synthetase reveals differences between family 
members. FEBS J 279, 1093–1105. 
Rendina, A.R., Taylor, W.S., Gibson, K., Lorimer, G., Rayner, D., Lockett, B., Kranis, K., 
Wexler, B., Marcovici-Mizrahi, D., Nudelman, A., et al. (1999). The design and synthesis of 
inhibitors of dethiobiotin synthetase as potential herbicides. Pesticide Science 55, 236–247. 
Salaemae, W. (2015). Novel inhibitors for biotin biosynthesis pathway in Mycobacterium 
tuberculosis. Thesis. University of Adelaide. 
Salaemae, W., Azhar, A., Booker, G.W., and Polyak, S.W. (2011). Biotin biosynthesis in 
Mycobacterium tuberculosis: physiology, biochemistry and molecular intervention. Protein 
Cell 2, 691–695. 
Salaemae, W., Yap, M.Y., Wegener, K.L., Booker, G.W., Wilce, M.C.J., and Polyak, S.W. 
(2015). Nucleotide triphosphate promiscuity in Mycobacterium tuberculosis dethiobiotin 
synthetase. Tuberculosis 95, 259–266. 
Salaemae, W., Booker, G.W., and Polyak, S.W. (2016). The Role of Biotin in Bacterial 
Physiology and Virulence: a Novel Antibiotic Target for Mycobacterium tuberculosis. 
Microbiol Spectr 4. 
Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989). Molecular Cloning: a laboratory manual 
(Cold Spring Harbor Laboratory Press). 
Satapathy, A.K., Crampton, D.J., Beauchamp, B.B., and Richardson, C.C. (2009). 
Promiscuous Usage of Nucleotides by the DNA Helicase of Bacteriophage  T7. J Biol Chem 
284, 14286–14295. 
Sawaya, M.R., Guo, S., Tabor, S., Richardson, C.C., and Ellenberger, T. (1999). Crystal 
Structure of the Helicase Domain from the Replicative Helicase-Primase of Bacteriophage 
T7. Cell 99, 167–177. 
Schiebel, J., Radeva, N., Krimmer, S.G., Wang, X., Stieler, M., Ehrmann, F.R., Fu, K., Metz, 
A., Huschmann, F.U., Weiss, M.S., et al. (2016). Six Biophysical Screening Methods Miss a 
Large Proportion of Crystallographically Discovered Fragment Hits: A Case Study. ACS 
Chem. Biol. 11, 1693–1701. 
Schramm, V.L. (2018). Enzymatic Transition States and Drug Design. Chem. Rev. 118, 
11194–11258. 
Shah, P., and Westwell, A.D. (2007). The role of fluorine in medicinal chemistry. J Enzyme 
Inhib. Med. Chem. 22, 527–540. 
Shuker, S.B., Hajduk, P.J., Meadows, R.P., and Fesik, S.W. (1996). Discovering high-affinity 
ligands for proteins: SAR by NMR. Science 274, 1531–1534. 
Soares da Costa, T.P., Tieu, W., Yap, M.Y., Pendini, N.R., Polyak, S.W., Sejer Pedersen, D., 
Morona, R., Turnidge, J.D., Wallace, J.C., Wilce, M.C.J., et al. (2012). Selective inhibition of 
biotin protein ligase from Staphylococcus aureus. J. Biol. Chem. 287, 17823–17832. 
 121 
Sternicki, L.M., Wegener, K.L., Bruning, J.B., Booker, G.W., and Polyak, S.W. (2017). 
Mechanisms Governing Precise Protein Biotinylation. Trends Biochemical Sci. 42, 383–394. 
Takayama, K., Wang, C., and Besra, G.S. (2005). Pathway to synthesis and processing of 
mycolic acids in Mycobacterium tuberculosis. Clin. Microbiol. Rev. 18, 81–101. 
Thompson, A.P., Wegener, K.L., Booker, G.W., Polyak, S.W., and Bruning, J.B. (2018a). 
Precipitant–ligand exchange technique reveals the ADP binding mode in Mycobacterium 
tuberculosis dethiobiotin synthetase. Acta Cryst D 74, 965–972. 
Thompson, A.P., Salaemae, W., Pederick, J.P., Abell, A.D., Booker, G.W., Bruning, J.B., 
Wegener, K.L., and Polyak, S.W. (2018b). Mycobacterium tuberculosis dethiobiotin 
synthetase facilitates nucleoside triphosphate promiscuity through alternate binding modes. 
ACS Catalysis 8, 10774–10783. 
Tieu, W., Polyak, S.W., Paparella, A.S., Yap, M.Y., Soares da Costa, T.P., Ng, B., Wang, G., 
Lumb, R., Bell, J.M., Turnidge, J.D., et al. (2015). Improved Synthesis of Biotinol-5′-AMP: 
Implications for Antibacterial Discovery. ACS Med. Chem. Lett. 6, 216–220. 
Tommasi, R., Brown, D.G., and Walkup, G.K. (2015). ESKAPEing the labyrinth of 
antibacterial discovery. Nat. Rev. Drug Discov. 14, 529–542. 
Toroney, R., Hull, C.M., Sokoloski, J.E., and Bevilacqua, P.C. (2012). Mechanistic 
characterization of the 5′-triphosphate-dependent activation of PKR: Lack of 5′-end 
nucleobase specificity, evidence for a distinct triphosphate binding site, and a critical role for 
the dsRBD. RNA 18, 1862–1874. 
Warrilow, A.G.S., Hull, C.M., Parker, J.E., Garvey, E.P., Hoekstra, W.J., Moore, W.R., 
Schotzinger, R.J., Kelly, D.E., and Kelly, S.L. (2014). The Clinical Candidate VT-1161 Is a 
Highly Potent Inhibitor of Candida albicans CYP51 but Fails To Bind the Human Enzyme. 
Antimicrob. Agents and Chemother. 58, 7121–7127. 
Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans, P.R., Keegan, 
R.M., Krissinel, E.B., Leslie, A.G.W., McCoy, A., et al. (2011). Overview of the CCP4 suite 
and current developments. Acta Cryst D 67, 235–242. 
Woong Park, S., Klotzsche, M., Wilson, D.J., Boshoff, H.I., Eoh, H., Manjunatha, U., 
Blumenthal, A., Rhee, K., Barry, C.E., Aldrich, C.C., et al. (2011). Evaluating the Sensitivity 
of Mycobacterium tuberculosis to Biotin Deprivation Using Regulated Gene Expression. 
PLoS Pathogens 7, e1002264. 
Xu, Y.W., Moréra, S., Janin, J., and Cherfils, J. (1997). AlF3 mimics the transition state of 
protein phosphorylation in the crystal structure of nucleoside diphosphate kinase and 
MgADP. Proc. Natl. Acad. Sci. U.S.A. 94, 3579–3583. 
 
